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Abstract 
OCT1 is a polyspecific organic cation transporter belonging to the solute carrier gene 
family SLC22. Human OCT1 is mainly expressed on the sinusoidal membrane of 
hepatocytes and thus may play an important role in the hepatocellular uptake and 
metabolism of cationic drugs. Beside this OCT1 is highly polymorphic with 9% of 
Caucasians carrying functional amino acid substitutions in both their OCT1 alleles. 
These amino acid substitutions are known to decrease or abolish OCT1 activity. 
Therefore these variants may significantly affect pharmacokinetics and consequently 
efficacy and adverse effects of all those drugs, which are transported at typical 
therapeutic concentrations by OCT1.  On the other hand, drugs when enter into the 
hepatocytes are metabolized by metabolizing enzymes such as the cytochrome P450 
enzyme 2D6 (CYP2D6). CYP2D6 is one of the most important drug metabolizing 
enzymes in the liver and is also highly polymorphic. Since such intracellular 
metabolism changes the concentration gradient at the outer cell membrane and at 
intracellular compartments, a combined analysis of drug membrane transport and 
intracellular drug metabolism may give insights with general importance. 
The aims of this study were to investigate whether OCT1 mediates the cellular uptake 
of clinically relevant drugs, what is the effect of the common genetic polymorphisms in 
OCT1on the uptake and how the interaction between the OCT1 and CYP2D6 may 
affect drug transport and metabolism.  
To do this, stable transfection was used to generate HEK293 cells overexpressing 
OCT1alone, CYP2D6 with its helper enzyme POR, and a combination of OCT1 with 
CYP2D6 and POR. In addition to these 3 constructs reflecting transport, metabolism 
and transport+metabolism, I generated cells overexpressing variant OCT1s carrying the 
five common amino acid substitution polymorphisms known in Caucasians, Arg61Cys, 
Gly401Ser, and a single deletion of Met420, or combination of Met420 deletion with 
Cys88Arg or Gly465Arg. Drug uptake and metabolism were analyzed using high 
pressure liquid chromatography to quantify the intracellular concentration of the 
parental drugs and their metabolites. 
Our results demonstrated that OCT1 mediates the cellular uptake of different groups of 
drugs. The antiemetic tropisetron and O-desmethyltramadol, the active metabolite of the 
opioid tramadol, were shown to be inhibitors and substrates of OCT1. The uptake of 
tropisetron and O-desmethyltramadol was abolished if any of the five common 
polymorphic OCT1 variants was expressed. On the other hand, the antiemetic 
Abstract 
  viii 
 
ondansetron and the opioid tramadol itself were no substrates, but only inhibitors of 
OCT1. 
A prototypic substrate of the enzyme CYP2D6 is debrisoquine. It was unknown how 
debrisoquine enters into cells. I demonstrated  that it is an inhibitor and a substrate of 
OCT1 (IC50 of 6.2 ± 0.8 µM, KM of 5.9 ± 1.5 µM and Vmax of 41.9 ± 4.5 pmol/min/mg 
of protein). The uptake of debrisoquine was significantly reduced in the presence of the 
variants OCT1s.  
 In the cells overexpressing CYP2D6 and POR, the co-expression of OCT1 led to a 
significant increase in the production of the metabolite, 4-OH debrisoquine, in a time-
dependent manner. The increase was not observed when the variant OCT1 was co-
expressed. In addition, utilizing the OCT1 and CYP2D6-POR co-expressing cells we 
were able to measure drug-drug interactions separately by the uptake or by the 
metabolism of debrisoquine. Interestingly, paroxetine, known thus far as a CYP2D6 
inhibitor, showed much higher potency in inhibiting OCT1 uptake than in inhibiting 
CYP2D6 metabolism. Thus, the experiments performed here might shed a new light on 
known and medically relevant interactions between drugs in humans.  
It can be concluded that OCT1 may influence the pharmacokinetics of the drugs and 
may be substantially involved in drug-drug interactions. Therefore, as also supported by 
the human in vivo study data, OCT1 polymorphisms may affect the pharmacokinetics 
and efficacy of clinically relevant drugs like tropisetron and O-desmethyltramadol. This 
work show also that the cell models developed here are useful tool and may help in the 
future to better understand absorption, distribution and elimination of numerous other 
drugs and other endogenous and exogenous chemicals as well. 
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1 Introduction  
1.1 Importance of genetic polymorphisms in drug therapy 
Pharmacogenetics studies how inherited variants in specific genes may impact the 
reactions of human beings on drugs and other environmental factors and also how it can 
provide molecular diagnostic methods which improve drug therapy. Pharmacogenetics 
has changed the practices and requirements in preclinical and clinical drug research, so 
that nowadays, pharmacogenomic has become increasingly important in clinical trials.  
The field of pharmacogenetics not only focuses on drug metabolism (WEINSHILBOUM 
2003), but also encompasses the full spectrum of drug disposition also known as 
pharmacokinetics, including drug transporters that influence drug absorption, 
distribution, and excretion  (EVANS and MCLEOD 2003; EVANS and RELLING 1999; 
MEYER 2000). 
Although many nongenetic factors such as age, organ function and drug interactions 
influence the effects of medications, there are numerous examples of cases in which 
interindividual differences in drug response (also known as pharmacodynamics) are due 
to variants in genes encoding drug-metabolizing enzymes, drug transporters or drug 
targets (BROCKMOLLER and TZVETKOV 2008; EVANS and MCLEOD 2003; EVANS and 
RELLING 1999). In 1000 genomes project, the location, allele frequency and local 
haplotype structure of approximately 15 million single-nucleotide polymorphisms 
(SNPs) distributed throughout the human genome, one million short insertions and 
deletions and 20,000 structural variants were described. Some of these SNPs may 
involve genes controlling drug metabolism, drug transport, disease susceptibility, or 
drug targets, and some are now being used to predict clinical response (EVANS and 
MCLEOD 2003).  
Recently much attention has been focused on the pharmacogenetics of drug transporters. 
Genetic polymorphism in biotransformation and transmembrane transport represents a 
crucial factor in the pharmacokinetic variability of many drugs (HO and KIM 2005; 
INGELMAN-SUNDBERG 2004; KOEPSELL et al. 2007; LYNCH and PRICE 2007; SEITHEL et 
al. 2008; VORMFELDE et al. 2008). For instance, a wide range of drugs may be 
transported into the liver by the human organic cation transporter (hOCT1). Genetic 
variants in OCT1 have been shown to modulate the pharmacokinetics of metformin 
after oral administration and reduce the therapeutic response, presumably by decreasing 
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the hepatic uptake (SHIKATA et al. 2007; SHU et al. 2007) and increasing the renal 
elimination of the drug (TZVETKOV et al. 2009).  
On the other hand, individual variability in drug efficacy and toxicity is to a big extent 
determined by polymorphisms in drug metabolizing enzymes, in particular the 
cytochrome P450 enzymes (CYPs) (Johansson and Ingelman-Sundberg).  CYPs play 
important role in the phase I of drug metabolism. In the past 30 years, convincing data 
have emerged about the impact of polymorphisms in cytochrome P450 enzymes on the 
pharmacokinetics and clinical effects of many drugs (BROCKMOLLER et al. 2000; 
INGELMAN-SUNDBERG 2004). This variability influences metabolism of 20%–30% of 
clinically used drugs (EICHELBAUM et al. 2006; INGELMAN-SUNDBERG 2005). Genetic 
polymorphism of several phase II enzymes, including some relevant to cancer 
chemotherapy, are also causing variability in the drug metabolism (EICHELBAUM et al. 
2006). 
The polymorphic nature of the CYP2D6 locus and the functional inequalities associated 
with its variants are responsible for the variable responses to number of drugs 
(INGELMAN-SUNDBERG 2005; LYNCH and PRICE 2007).Variant alleles usually encode a 
CYP450 enzyme which result in decreased or no enzyme activity (WILKINSON 2005). 
Individuals with two copies of no activity alleles lack CYP2D6 activity and are called 
“poor” metabolizers, people with one active and one inactive allele have reduced 
enzyme activity and are called inactive metabolizers and people with two active or one 
active and one decrease activity alleles have average CYP2D6 activity and are called 
extensive metabolizers. Finally, some persons inherit multiple copies of active alleles, 
which results in excess enzyme activity. This phenotype is termed an “ultrarapid” 
metabolizer (JOHANSSON et al. 1993; ZANGER et al. 2004). Also Mutations in 
cytochrome P450 genes or deficiencies of the enzymes are responsible for several 
human diseases (NELSON, 2003).  
 
1.2 Drug transporter: Organic Cation Transporters OCTs 
Transporters are proteins that span cellular membranes and selectively transfer the 
molecules through the membranes.  The body is equipped with broad-specificity 
transporters that have an important role in regulating the absorption, distribution, and 
excretion of endogenous organic cations as well as cationic drugs and toxins (EVANS 
and MCLEOD 2003; KOEPSELL et al. 2007).   
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The SLC22A family of solute carrier (SLC) transporters contains three isoforms of 
passive diffusion organic cation transporters also called electrogenic. Those are OCT1 
(SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3). Additionally there are two cation 
and carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5) (KOEPSELL et 
al. 2007). The three organic cation transporters (OCTs) share common genomic 
structures. The genes encoding the three OCTs are localized within a cluster on human 
chromosome 6q26 and each of these three genes has 11 coding exons and 10 introns 
(Fig.1.1). This suggests that the three isoforms evolved through gene duplication from a 
single ancestral OCT gene (URBAN and GIACOMINI, 2007). 
          
 
Fig.1. 1 Schematic structure of the three OCT genes in humans. The three genes are located 
on long arm of the chromosome 6. All three genes share similar structure of 11 exons and 10 
introns, as can be seen for the OCT1 gene. 
 
Also OCTs proteins share a common secondary structure. The OCT proteins comprise 
12 transmembrane domains (TMDs) with intracellular amino and carboxy termini, a 
large glycosylated extracellular loop between TMDs 1 and 2, as well as a large 
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intracellular loop between TMDs 6 and 7 which includes predicted phosphorylation 
sites (Fig 1.2). The transmembrane domains (TMD4 and TMD10) have been shown to 
be important for substrate recognition by the OCTs (KOEPSELL et al. 2007). Site-
directed mutagenesis in rat OCT1 revealed the importance of transmembrane domain 
eleven in substrate translocation as substitution of aspartate at position 475 to glutamate 
largely reduced transport rates and increased the Michaelis Menten constant (Km) 
values for some substrates (GORBOULEV et al. 1999). Also mutations of the two residues 
in TMD4 (Trp218Tyr and Tyr222Leu) resulted in increased affinity for both 
tetraethylammonium (TEA) and 1-methyl-4- phenylpyridinium (MPP
+
), whereas a third 
mutant (Thr226Ala) is only involved in the binding of MPP
+
 but no change in affinity 
for TEA (POPP et al. 2005). This data suggests that OCT1, and presumably all of the 
OCTs, contain multiple overlapping but nonidentical recognition sites for the various 
structurally diverse substrates (KOEPSELL, 2011). Another study showed that the large 
extracellular loop located between TMDs 1 and 2 influences substrate affinity and this 
structure is required for oligomerization and membrane insertion of OCT1 (KELLER et 
al. 2011). Recent data indicated a substrate binding domain in the middle of TMD 11 
which appears to be important for substrate translocation (EGENBERGER et al. 2012). 
        
 
 
 
 
 
 
 
 
Fig.1. 2 Proposed secondary structure of the human organic cation transporter type 1 
(hOCT1). The secondary structure of OCT1 is shown as an example for the structure of all 
OCTs.  OCT1 contains 12 transmembrane domains (TMDs), a large extracellular loop between 
TMD1 and TMD2. TMD4 and TMD10 (highlighted here in blue) are suggested to contribute 
for substrate recognition by OCT1.  
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The organic cation transporter 1 (OCT1; SLC22A1), is an integral membrane protein 
that transports cationic drugs and is highly expressed in the sinusoidal membrane of the 
human liver (ZHANG et al. 1997; GORBOULEV et al. 1997; KOEPSELL et al. 2003; 
KOEPSELL et al. 2007; NIES et al. 2009). 
Organic cations and weak bases that are positively charged at physiological pH, can be 
transported into cells according to the electrochemical gradient. This transportation 
occurs by facilitated diffusion and is driven by the inside-negative membrane potential 
(URBAN and GIACOMINI, 2007). 
 
1.2.1 Tissue distribution and subcellular localization of the human 
OCT homologs  
Despite the similarities in structure and function in the three transporters OCT1, OCT2 
and OCT3, there are important differences in the tissue distribution (Table 1.1). In 
human OCT1 is strongly expressed in the liver with lower levels of expression in other 
tissues (GORBOULEV et al. 1997; ZHANG et al. 1997). OCT1 is localized on the 
sinusoidal membrane of the hepatocytes (KOEPSELL et al. 2007). Human OCT2 is 
specifically expressed in the kidney. Human OCT2 is localized to the basolateral 
membrane of epithelial cells in renal proximal tubules (KOEPSELL et al. 2007; 
TZVETKOV et al. 2009). In situ hybridization and preliminary immunohistochemical 
data revealed expression of hOCT2 in the luminal membrane of distal tubules 
suggesting that hOCT2 participates in cation reabsorption in the nephron segment 
(GORBOULEV et al. 1997).  The tissue expression pattern of the OCT3 is very broad. 
This transporter is thought to be important for extraneuronal clearance of monoamine 
neurotransmitters as well as uptake of monoamines into the heart and across the 
placenta (URBAN and GIACOMINI, 2007). 
 
Table 1. 1 Tissue Distribution of Human OCT Isoforms  
Human organs OCT1 OCT2 OCT3 
Liver +++ − + 
Kidney + +++ + 
Lung + − + 
Trachea − − − 
Heart + − ++ 
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Skeletal Muscle ++ − ++ 
Placenta + − ++ 
Pancreas − − − 
Brain − + + 
Spinal cord − − + 
Adrenal gland + − − 
Testis − − − 
Ovary + − + 
Fetal liver + − − 
Fetal lung + − − 
Fetal heart + − − 
Fetal brain + − − 
Data modified from Urban and Giacomini, 2007 
 
An expression gradient from central vein to the peripheral parts of the hepatic lobuli 
was observed in rats (MEYER-WENTRUP et al. 1998), but the information whether such 
gradient exist in human is missing. 
In other species,  OCTs act in different organs, for example in mouse small intestine, 
OCT1 was located to the basolateral membrane of enterocytes (CHEN et al. 2001). 
Confocal microscopy revealed that in rat kidney both rOCT1 and rOCT2 were localized 
to the basolateral membranes of epithelial cells in  proximal tubules (KARBACH et al. 
2000; SUGAWARA-YOKOO et al. 2000). Using immunohistochemistry in the trachea and 
bronchi of human, rat and mouse OCT1, OCT2, and OCT3 were localized to the 
luminal membrane of ciliated epithelial cells (LIPS et al. 2005; KUMMER et al. 2006).  
 
1.2.2 Substrate and Inhibitor Specificities of OCTs 
Common compounds that are translocated by OCT transporters include low-molecular-
weight relatively hydrophilic organic cations such as model cations 
tetraethylammonium (TEA), the neurotoxin MPP
+
, and the endogenous compounds 
such as amine neurotransmitters like dopamine, epinephrine, norepinephrine, histamine, 
serotonin, choline, acethylcoline, N-methylnicotinamide (NMN) and agmatine. A 
detailed list summarizing known OCTs substrates and inhibitors was recently published 
by (NIES et al. 2011). Several clinically important drugs have been shown to interact 
with all of the OCTs, including quinidine, quinine (ZHANG et al. 1998), the antiviral 
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agents, such as acyclovir and ganciclovir (TAKEDA et al. 2002), the antidiabetic drug 
metformin (Koepsell 2004; SHU et al. 2007; NIES et al. 2009; TZVETKOV et al. 2009) 
and the peptic ulcer drug famotidine (BOURDET et al. 2005). In general, OCTs may have 
a broad impact on drug disposition and drug action (AHLIN et al. 2008; BEDNARCZYK et 
al. 2003). Some of these drugs were used as typical OCT inhibitors. According to a 
comparison of the molecular structures of currently known OCT inhibitors, an inhibitor 
must have lipophilicity and hydrophobicity property with positively charge and low 
hydrogen bonding. Although most known substrates of the OCTs are cations, some 
OCT substrates are anionic or neutral compounds at physiological pH. Thus, a net 
positive charge does not appear to be an absolute requirement for interaction with the 
OCTs  (URBAN and GIACOMINI, 2007; KOEPSELL et al. 2007). 
Although the affinities of transported substrate and non-transported inhibitors for 
individual transporters of OCT1, OCT2 and OCT3 broadly overlap, it is difficult to find 
isoform specific substrates or inhibitors. Still recent studies identify a number of OCT2 
specific inhibitors (KIDO et al. 2011) and some examples of relatively isoform-specific 
substrates and inhibitors for other two isoforms were published (KOEPSELL et al. 2003).  
 
1.2.3 Functions of polyspecific OCTs in various organs 
OCT1 is by far the most abundant organic cation transporter in the human liver 
(Hilgendorf et al., 2007). In the liver, OCT1 and OCT3 are located in the sinusoidal 
(basolateral) membrane of the hepatocytes (MEYER-WENTRUP et al. 1998).  This 
suggests that these transporters act as sinusoidal uptake transporters in liver, aiding in 
presentation of substrate drugs from blood into the hepatocyte for elimination by 
metabolism or biliary excretion. The tissue distribution and subcellular localization of 
these transporters suggest that their primary role is in the elimination of toxic xenobiotic 
and endogenous organic cations. In addition, for drugs that target the liver for their 
pharmacological activity, OCT1 may be a limiting step in drug access to hepatocytes 
and may therefore influence drug action. 
 
1.2.4 Implication of OCTs in tumor cells 
Organic cation transporters are involved in drug uptake in cancer cells (GUPTA et al. 
2011). These transporters may be necessary to reach therapeutical cytostatic 
concentrations during treatment of tumors. Each cytostatic drug may be taken up by 
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several influx transporters expressed in a specific tumor cell and may be released by 
efflux pumps (KOEPSELL et al. 2007). For example, cisplatin is transported by hOCT2 
(CIARIMBOLI et al. 2005; ZHANG et al. 2006; YONEZAWA et al. 2006), or oxaliplatin is 
transported by hOCT2, hOCT3 and hOCT1 (ZHANG et al. 2006; YONEZAWA et al. 
2006). Ballestero et al. showed that hOCTs can be detected in various tumors 
(BALLESTERO et al. 2006). Shnitsar et al showed that OCT3 is expressed in kidney 
carcinoma cells and may increase chemosensitivity to melphalan, irinotecan and 
vincristin (SHNITSAR et al. 2009). Other studies showed that OCT1 and OCT2 are major 
determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor 
specificity (ZHANG et al. 2006). These examples indicate that hOCTs have a strong 
impact on the pharmaco- and toxicokinetics of many cationic cytostatic drugs and 
knowledge concerning the expression of drug transporters in tumor cells may help to 
develop cytostatic drugs that are targeted to specific tumors. Good candidates for 
targeting transporters are those that are highly expressed due to up regulation in tumors 
(KOEPSELL et al. 2007) Therefore we may in future be able to optimize cancer treatment 
in patients by knowing about specific cancer cell transporters and drugs that are 
substrates for these transporters, or using inhibitors that prevent uptake of the cytostatic 
drug into normal cells without any influence on uptake into tumor cells (CIARIMBOLI et 
al. 2010).  
    
1.2.5 Genetic variation in the SLC22A1 gene coding for OCT1 
Human OCT1 is highly genetically polymorphic. Many single-nucleotide 
polymorphisms (SNPs) with population dependent frequencies were identified by 
analyzing the SLC22A1, the gene that encodes for human OCT1. Some of these SNPs 
occur in coding region of the OCT1 gene and then result in single amino acid 
substitutions or the deletion of one amino acid. These SNPs may have different 
consequences in transporter activity, for example six mutations are known to reduce 
transporter activity (Arg61Cys, Cys88Arg, Gly220Val, Pro341Leu, Gly401Ser, 
Gly465Arg), whereas in one mutation (Ser14Phe) transport expression was increased 
(KERB et al. 2002; SHU et al. 2003). For polymorphisms Cys88Arg, Gly220Val, 
Gly401Ser, and Gly465Arg respective frequencies of 0.01%, 0.2%, 0.8%, 1.6%, were 
obtained and transport of MPP
+
 was reduced to <10% compared to wild-type (KERB et 
al. 2002; SHU et al. 2003). However, for mutants Cys88Arg and Gly401Ser substrate 
specific effects were observed (KERB et al. 2002). Several polymorphisms altering the 
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function have been described in the OCT1 gene. In a sample of 57 healthy Caucasians, 
25 genetic variants were identified, eight of which change the protein sequence (KERB 
et al. 2002).  Five of these (Arg61Cys, Cys88Arg, Phe160Leu, Gly401Ser, and 
Met420del) significantly reduce the transport efficiency. On the other hand, the 
Ser14Phe variant in the OCT1 gene showed a significant increase in activity (SHU et al. 
2003). Some of these SNPs exhibit a changed substrate selectivity that could affect the 
disposition of OCT1 substrates and as a consequence may alter the duration and 
intensity of effects of drugs which are substrates for OCT1 (KERB et al. 2002). It was 
noted that all of the variants with reduced function occurred at evolutionarily conserved 
amino acid residues, and that variants with reduced function tended to be amino acid 
substitutions that result in a large chemical change (URBAN and GIACOMINI, 2007). 
Takeuchi et al, 2003 assessed three coding single nucleotide polymorphisms (cSNPs) in 
OCT1 that resulted in the amino acid changes Pro283Leu, Arg287Gly and Pro341Leu. 
They showed that the reduction in activity of these variants was not explained by 
reduction in protein expression, as immunofluorescence indicated that these SNPs did 
not affect the membrane localization of hOCT1 (TAKEUCHI et al. 2003). These results 
suggested that the amino acid residues Pro283 and Arg287 have a substantial role in 
substrate recognition of hOCT1. 
Due to high frequency of this polymorphisms in the Caucasian population, nine percent 
of people are compound homozygous carriers of the five common coding 
polymorphisms resulting in reduced or absent function (Arg61Cys, Cys88Arg, 
Gly401Ser, Gly465Arg and deletion of Met420) and therefore have reduced ability to 
take up drugs such as metformin (SHU et al. 2007; TZVETKOV et al. 2009). These 
individuals have also impaired uptake into the liver of other hydrophobic cationic drugs. 
 
1.3 Drug metabolizing enzymes 
1.3.1 Drug Metabolism 
Drugs are most often eliminated by biotransformation and excretion into the urine or 
bile. The liver is the major site for drug metabolism, but specific drugs may undergo 
biotransformation in other tissues, such as the intestines. The process of metabolism 
mostly transforms lipophilic drugs into more polar products that are more readily 
excreatable in the urine or have less re-absorption when excreted via the bile. Therefore, 
lipid-soluble agents must first be metabolized in the liver using two general sets of 
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reactions, called Phase I and Phase II (Fig. 1.3). As it can be seen, typical Phase I 
reactions are oxidation, reduction and hydrolysis. This may increase, decrease, or leave 
unaltered the drugs pharmacologic activity. Phase II are conjugation reactions like 
sulfation, glucuronidation, methylation or acetylation which result in production of 
highly polar, most often therapeutically inactivate compounds. 
 
             
Fig.1. 3 Schematic diagram of drug metabolism in hepatocytes. 
 
1.3.2 Catalytic Mechanism 
There are more than 30 families of drug-metabolizing enzymes in humans (Evans and 
McLeod 2003). Among them, Cytochrome P450s (CYP450s) accounting for about 75% 
of the total number of different metabolic reactions (GUENGERICH, 2008). CYPs are a 
superfamily of monooxygenases that are predominantly expressed in the liver and are 
involved in phase I metabolism of many drugs. Different CYP isoforms catalyze the 
oxidative metabolism of drugs, other xenobiotics and different endogenous compounds.  
CYP450 enzymes are so named because they are bound to membranes within a cell 
(cyto) and contain a heme pigment (chrome, P) that absorbs light at a wavelength of 450 
nm when exposed to carbon monoxide. There are more than 50 CYP450 enzymes, but 
the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes 
metabolize 90 percent of drugs that undergo metabolism in the human body (LYNCH and 
PRICE 2007; WILKINSON 2005). 
Drugs interact with the CYP450 system in several ways. Drugs may be metabolized by 
only one CYP450 enzyme (e.g., metoprolol by CYP2D6) or by multiple enzymes (e.g., 
warfarin by CYP1A2, CYP2D6, and CYP3A4) (Daly and King 2003). Drugs may also 
inhibit the activity of CYP450s or down-regulate or induce the expression of CYP450s 
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and cause by that metabolic drug-drug interactions (Lynch and Price 2007). Inhibitors 
block the metabolic activity of one or more CYP450 enzymes like sertraline (Zoloft) 
which is considered a mild inhibitor of CYP2D6 (SPROULE et al. 1997), whereas 
inducers increase CYP450 enzyme activity by increasing transcription (e.g. rifampin 
which induces CYP2C9, (KANEBRATT et al. 2008) or by blocking degradation (e.g. 
ethanol prevents degradation of CYP2E1, (ROBERTS et al. 1995).  
 The catalytic cycle of CYP450 is shown in Figure 1.4. After the substrate is bound to 
the active site of the CYP450 an electron will be donated to the cytochrome’s heme 
group by a NADPH-P450 reductase. This results in the reduction of Fe
3+
 to Fe
2+
. This 
reduction allows the breaking of the oxygen-oxygen bond in a molecule of oxygen that 
is attached to the heme. The complex formed by the binding of oxygen is very unstable 
and can result in the production of superoxide anions (GUENGERICH 2008). A second 
electron donated by NADPH-P450-reductase causes reduction of the iron-oxygen 
complex, and this is followed by the addition of a proton and the cleavage of the 
oxygen-oxygen (O-O) bond and releasing water. Finally, the resulting electron-deficient 
complex abstracts either hydrogen or an electron from the substrate, and the resulting 
intermediate collapses, producing the oxidized substrate and regenerates the iron centre 
(Fig. 1.4). 
   
Fig.1. 4 Catalytic cycle for CYP450s.  NADPH-P450 reductase mediates an electron donation 
to the cytochrome heme group (Step 2).  This reduction allows for the breaking of the oxygen-
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oxygen bond in molecular oxygen (Steps 3-6). This allows for the hydroxylation of the 
compound to be metabolized (Step 8), which can then serve as a site for further hydroxylation 
(Step 10).  
 
1.3.3 Metabolizing enzyme CYP2D6 
A cytochrome P450 isoform CYP2D6 was originally cloned and characterized by Gon-
zales et al in 1988 (GONZALEZ et al. 1988). CYP2D6 is part of the extensive CYP2D 
family, which includes three members in humans, CYP2D6 and the pseudogenes 
CYP2D7P and CYP2D8P (Yasukochi and Satta, 2011). In human the three isoforms are 
located in tandem on chromosome 22 (KIMURA et al. 1989). However, CYP2D7P and 
CYP2D8P are so called pseudogenes and only CYP2D6 codes for an active protein. 
CYP2D6 is one of 57 cytochrome P450s, a class of metabolic enzymes found primarily 
in the human liver. Many of these enzymes, including CYP2D6, play an instrumental 
role in the breakdown and clearance of clinically prescribed drugs (Ingelman-Sundberg 
2004). Indeed, together with CYP2C9 and CYP2C19, CYP2D6 is responsible for 40% 
of hepatic drug metabolism and is thought to be active in the enzymatic breakdown of 
20-25% of all medicines now prescribed, a fraction that consists of approximately 100 
identified drugs (INGELMAN-SUNDBERG 2005; LEDESMA and AGUNDEZ 2005; 
SODERBACK et al. 2005), some of which are listed in table 1.2.  
 
 
Table 1. 2 List of drugs known to be CYP2D6 substrates (from Brockmöller and Tzvetkov, 2008) 
Protein                               Abbreviation                                     Substrates 
Cytochrome P450 
2D6 
CYP2D6                      Amitriptyline, clomipramine, debrisoquine, 
desipramine, doxepin, duloxetin, 
imipramine, nortriptyline, trimipramine, 
paroxetin, venlafaxin; haloperidol, 
perphenazine; chlorpromazine, perazine, 
promethazine,  thioridazine, 
zuclopenthixol; aripiprazole, olanzapine; 
amphetamine,  atomoxetin; carvedilol, 
metoprolol, nebivolol, propranolol, timolol; 
perhexiline; encainide, flecainide, 
mexilletine; ondansetron, tropisetron; 
codeine, tramadol; tamoxifen 
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The clinical impact of the CYP2D6 genotype depends on whether the drugs are 
bioactivated by CYP2D6 or inactivated. Most of the substrates of this enzyme are 
metabolized to inactive metabolites, whereas there are notable exceptions of drugs bio-
activated by CYP2D6. For example, tropisetrone convertes to inactive form by 
CYP2D6, while codeine, tramadol, tamoxifen and encainide convert to the 
pharmacologically active forms by this enzyme (BROCKMOLLER and TZVETKOV 2008).  
Phenotypic classification of CYP2D6 activity shows there is a wide range of enzyme 
activities ranging from a complete lack of enzyme activity to high activity. These 
phenotypes consist of: PMs, poor metabolizers, IMs, intermediate metabolizers, EMs, 
extensive metabolizers, and UMs, ultra metabolizers (MEYER 2004; ZANGER et al. 
2004).  For drugs that are inactivated by CYP2D6, PMs and, to a lesser extent, IMs are 
prone to exaggerated side effects from drugs metabolized by CYP2D6, whereas normal 
doses of the same drugs tend to be ineffective for UMs (INGELMAN-SUNDBERG 2005; 
MEYER 2004).  For drugs that are bioactivated by CYP2D6 these phenotypes have 
reverse effect so that normal doses of drugs is ineffective for PMs and IMs, whereas the 
same dosage of drugs accompany with the side effect in EMs or UMs. 
 
1.4 Drug-Drug Interaction 
The mechanistic basis of many drug–drug interactions is well established. They can 
occur as a result of changes in pharmacodynamics and/or pharmacokinetics. The latter 
can occur through effects on absorption, distribution, metabolism or excretion. One of 
the most clinically important causes of drug-drug interactions is the inhibition or 
induction of the activity of cytochrome P450 (DAVIES et al. 2004; MICHALETS 1998; 
TUCKER et al. 2001). Cytochrome P450 enzymes can be inhibited or induced by drugs 
either by directly inhibiting the activity of the CYP or by down-regulating or inducing 
the biosynthesis of an enzyme. This is a major source of adverse drug interactions, since 
changes in CYP enzyme activity may influence on the metabolism and clearance of 
various drugs and resulting in clinically significant drug-drug interactions that can cause 
unanticipated adverse reactions or therapeutic failures. For example, if one drug inhibits 
the CYP-mediated metabolism of another drug, the second drug may accumulate within 
the body to toxic levels. Some other drugs, such as tramadol, are not therapeutic until 
they are metabolized by CYP450 to their active compounds. These medications, known 
as prodrugs, may cause an exaggerated therapeutic effect or adverse effect when a 
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CYP450 inducer is added. Conversely, if a CYP450 inhibitor is combined with a 
prodrug, or a person is a CYP450 poor metabolizer, therapeutic failure is likely to result 
because of little or no production of the active drug (POULSEN et al. 1996). 
Hence, these drug interactions may necessitate dose adjustments or choosing drugs that 
do not interact with the CYP450 system. Knowledge of the most important drugs 
metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and 
inducing drugs, can help to minimize the risk of adverse drug reactions and interactions 
(LYNCH and PRICE 2007). Table 1.3 lists some examples of common drug-drug 
interactions and their potential clinical effects. 
 
Table 1. 3  Examples of drug-drug interactions involving the CYP450  
Drug(s)/ 
product 
Enzyme     
inhibitor 
 or inducer 
Drug(s) 
Metabolizing 
enzyme 
Possible clinical 
effect 
Amiodarone 
(Cordarone) 
CYP2C9 and 
CYP3A4 
inhibitor 
Warfarin 
(Coumadin) 
CYP2C9 
Increased risk of 
bleeding caused by 
Increased warfarin level 
Carbamazepine 
(Tegretol), 
phenobarbital, 
phenytoin 
(Dilantin) 
CYP3A4 
inducer 
Ethinyl 
estradiol- 
containing 
contraceptives 
CYP3A4 
Unplanned pregnancy 
caused by reduced 
estradiol level 
Clarithromycin 
(Biaxin), 
erythromycin, 
telithromycin 
(Ketek) 
CYP3A4 
inhibitor 
Simvastatin 
(Zocor), 
verapamil 
(Calan) 
CYP3A4 
Myopathy or 
rhabdomyolysis caused 
by 
increased simvastatin 
level21 
Hypotension and QT 
interval 
prolongation caused by 
increased 
verapamil level 
Diltiazem 
(Cardizem), 
verapamil 
 
CYP3A4 
inhibitor 
Prednisone CYP3A4 
Immunosuppression 
caused by increased 
prednisolone serum 
levels 
Fluoxetine 
(Prozac), 
paroxetine 
(Paxil), 
CYP2D6 
inhibitor 
Risperidone 
(Risperdal), 
tramadol 
(Ultram) 
CYP2D6 
Increased risk of 
extrapyramidal 
adverse effects caused 
by increased 
risperidone level24; 
decrease in 
analgesic effect caused 
by low level of active 
metabolite 
Grapefruit juice CYP3A4 Buspirone CYP3A4 Dizziness and serotonin 
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inhibitor (Buspar) syndrome 
caused by increased 
buspirone level 
Metronidazole 
(Flagyl) 
CYP2C9 
inhibitor 
Warfarin CYP2C9 
Increased risk of 
bleeding caused by 
increased warfarin level 
Terbinafine 
(Lamisil) 
CYP2D6 
inhibitor 
Amitriptyline CYP2D6 
Dry mouth, dizziness, 
and cardiac 
toxicity caused by 
prolonged increase 
in amitriptyline and 
nortriptyline 
(Pamelor) levels 
(from Lynch and Price, 2007) 
All these reactions take place within the cell and thus a prerequisite for all these 
reactions is that the drug can enter the cell. With some very hydrophobic drugs this 
entering may be via simple diffusion, but many typical CYP2D6 substrates have only 
moderate hydrophobicity and therefore influx transporters like OCT1 may be relevant 
for the risk of drug-drug interactions. 
 
1.5 Drugs that may be OCT1 substrates 
In this chapter a detailed overview is given about drugs that based on their chemical 
properties and structure were analyzed as potential substrates of OCT1. The focus is on 
drugs that are weak organic bases and were not known before the start of this work to be 
OCT1 substrates. 
 
1.5.1 5-HT3 receptor antagonists  
Vomiting is a clinically relevant side effect of chemotherapy treatment that substantially 
reduces the quality of life of the patients and may lead to therapy discontinuation. 
Vomiting is triggered by serotonin (5-HT) which is released from the enterochromaffine 
cells of the small intestine.  Under treatment with some chemotherapeutic agents, like 
cisplatin, an uncontrolled release of large amounts of serotonin occurs. The released 
serotonin activates sertotonin-type 3 (5-HT3) receptors that are located on the peripheral 
vagal nerve terminals in the intestine and that vagal stimulation results in triggering the 
vomiting reflex.  
Significant progress in the treatment of chemotherapy-induced vomiting and nausea 
(CINV) has been achieved in the 1990s with the advent of selective 5-HT3 receptor 
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antagonists (DE LEON 2006; HESKETH 2008). Nevertheless, approximately 15–30% of 
the patients do not respond sufficiently to the current antiemetic therapy (AAPRO 2005; 
HESKETH 2008). One reason for the substantial differences in response may be genetic 
variability in the uptake and elimination of 5-HT3 receptor antagonists.   
 
Ondansetrone and tropisetrone 
The 5-HT3 receptor antagonists ondansetron and tropisetron (Fig.1.5) have become first 
line therapy for the treatment of chemotherapy induced as well as postoperative nausea 
and vomiting (HESKETH 2008). The biotransformation of tropisetron and ondansetron is 
mediated by multiple cytochrome P-450 enzymes, among them the polymorphic 
CYP2D6 (FISCHER et al. 1994; DIXON et al. 1995) resulting in a high interindividual 
variability in plasma concentrations and effectiveness of both drugs. Tropisetron is 
mainly, and ondansetron is partially, metabolized by cytochrome P450 2D6 (CYP2D6). 
Genetic polymorphisms in CYP2D6 are known to affect the pharmacokinetics and the 
efficacy of these two 5-HT3 antagonists. Ultra rapid metabolizer (UM) for CYP2D6 
showed the highest, whereas poor metabolizer (PM) showed the lowest rates of 
vomiting and nausea, and significantly higher tropisetron blood concentrations (KAISER 
et al. 2002). 
Therefore, genotyping for CYP2D6 before the start of the chemotherapy or the use of 
antiemetic drugs that are not metabolized by CYP2D6 may further reduce nausea and 
vomiting.  
 
Palonosetrone 
Palonosetron is the newest agent in the group of 5-HT antagonists. Polanosetron has a 
strong binding affinity to 5-HT3 receptors and thus selectively blocks serotonin from 
binding to these receptors peripherally and centrally. It has little or no affinity for other 
receptors. Palonosetron is indicated for the prevention of acute and delayed nausea and 
vomiting associated with initial and repeat courses of moderate to highly emetogenic 
cancer chemotherapy (DE LEON 2006). Due to its long half-life of about 40 hours and 
thus prolonged action, palonosetron is now the preferred antiemetic drug used in 
oncology. 
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Fig.1. 5 Structures of the 5-HT3 antagonists ondansetrone (A), palonosetrone (B) and 
tropisetrone (C). Tropisetrone is metabolized in hepatocytes by CYP2D6 to its metabolite 6-
hydroxy tropisetrone. 
 
All these drug metabolism reactions take place within the cell and thus a prerequisite for 
all these reactions is that the drug can enter the cell. Since the 3-HT3 antagonists are 
only moderately hydrophobic influx transporters like OCT1 may be relevant for the 
pharmacokinetics and consequently for the efficacy. 
 
1.5.2 The analgesic drugs tramadol and O-desmethyl tramadol 
Tramadol is an analgesic and antitussive drug belonging to the class of synthetic 
opioids. Tramadol is a prodrug that is metabolized to its active form O-
desmethyltramadol. O-desmethyltramadol exerts its action through complex interactions 
between opiate, adrenergic, and serotonin receptors (POULSEN et al. 1996; STAMER et 
al. 2003) but it may be argued that activation of the µ-opioid receptors is the main 
mechanism of analgesic action. Tramadol is administered as a racemic mixture of (+) 
and (−) tramadol, and both diastereomers are O-demethylated. In vitro receptor binding 
studies have indicated that opioidergic tramadol analgesia is mediated mostly by (+) O-
desmethyltramadol (LAI et al. 1996). The (+) O-desmethyltramadol is more potent 
agonist of the µ-opioid receptor than (-) O-desmethyltramadol or tramadol.  However, 
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both (+) and (−) tramadol may contribute to analgesic effects by inhibiting serotonin 
and norepinephrine reuptake (DRIESSEN and REIMANN 1992; HALFPENNY et al. 1999). 
Tramadol is metabolized to O-desmethyltramadol by CYP2D6 (PAAR et al. 1992; PAAR 
et al. 1997; POULSEN et al. 1996) (Fig.1.6). Polymorphic cytochrome P450 (CYP) 2D6 
activity has been shown to be a determinant of the pharmacokinetics and 
pharmacodynamics of tramadol (PEDERSEN et al. 2005). Therefore, CYP2D6 genotype 
can determine concentrations of O-desmethyltramadol enantiomers and thereby can 
influence efficacy of tramadol treatment (KIRCHHEINER et al. 2008; STAMER et al. 
2007).           
 
Fig.1. 6 Metabolism of tramadol to O-desmethyl-tramadol catalyzed by CYP2D6. 
 
All these drug metabolism reactions take place within the cell and thus a prerequisite for 
all these reactions is that the drug can enter the cell. Since tramadol and particularly 
desmethyltramadol are only moderately hydrophobic influx transporters like OCT1 may 
be relevant for the pharmacokinetics and consequently for the efficacy. 
 
1.5.3 The CYP2D6 model drug debrisoquine  
Debrisoquine, an antihypertensive drug metabolized to 4-hydroxydebrisoquine by 
CYP2D6, is commonly used as an in vivo probe of CYP2D6 activity and can be used to 
phenotype individuals as either extensive (EMs) or poor metabolizers (PMs). 
Debrisoquine is predominantly eliminated after metabolism via CYP2D6. The major 
metabolic pathway for debrisoquine is a hydroxylation at position 4, catalyzed by 
CYP2D6 (Fig.1.7). The results metabolite 4-hydroxydebrisoquine is then directly 
excreted into urine (CERQUEIRA et al. 2000; GONZALEZ et al. 1988).  
In the 1970s and early 1980s, pioneer works by Robert Smith and colleagues described 
variations in debrisoquine metabolism as one of the first monogenetic autosomal 
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recessive traits in pharmacology (MAHGOUB et al. 1977; Smith, 1986). Debrisoquine is 
weak base with a pKa value of 11.95. More than 99.99% of this molecule is positively 
charged at the physiological pH of 7.4. Besides, debrisoquine is hydrophilic compound 
with logD7.4 partition coefficient of -1.58. Taken together, debrisoquine may probably 
only poorly penetrate cell membranes by passive diffusion and will likely require 
carrier-mediated membrane transport for its cellular uptake. 
          
 
 
Fig.1. 7 Debrisoquine and its CYP2D6 catalyzed metabolite 4-hydroxydebrisoquine. 
 
1.5.4 Cytostatic drugs 
Irinotecan and its metabolite SN-38 
Irinotecan is used to treat several human cancers, including colon and lung cancer in 
adults and pediatric solid tumors such as rhabdomyosarcoma and neuroblastoma 
(EICHELBAUM et al. 2006). Irinotecan is a prodrug that is activated by hydrolysis to its 
active metabolite SN-38 (Fig.1.8). SN-38 is a potent inhibitor of topoisomerase I. The 
inhibition of topoisomerase I prevents DNA from unwinding and eventually leads to 
inhibition of both DNA replication and transcription. The mechanisms of action of these 
topoisomerase inhibitors is different, namely they inhibit relegation of the DNA after 
initial single strand break (topoisomerase I inhibitors) or double strand break 
(topoisomerase II inhibitors). This inhibition of relegation means DNA strand breaks 
and these strand breaks then result in apoptosis.SN-38 is inactivated by glucuronidation 
by uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1). The conjugated 
metabolite is relatively inactive and readily eliminated in bile and urine (ANDO et al. 
2000). 
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Fig.1. 8 The structures of irinotecan and its metabolite, SN38. Irinotecan is weak base with pKa 
8.48 whereas SN38 is weak acid. But both have the same lipophilicity (logD7.4). 
Inter-individual differences in irinotecan metabolism are caused by polymorphisms in 
the UGT1A1 enzyme. Homozygous carriers of two UTG1A1 allele 28 have lower 
expression of UGT1A1, have higher plasma concentrations of SN-38 and are at higher 
risk of neutropenia, the major adverse effect of irinotecan (INNOCENTI et al. 2004). 
 
 Doxorubicin 
Doxorubicin is an anthracycline antibiotic used as cancer chemotherapeutic. Like all 
anthracyclines, doxorubicine works by intercalating DNA. Additional cytotoxic 
mechanisms of doxorubicine are inhibition of  topisomerase II and increase in the the 
production of reactive oxygen species (RAVID et al. 1999). Doxorubicine is commonly 
used to treat breast cancer, non-Hogkin Lymphoma and other cancers. Doxorubicine is a 
weak organic base with pKa of 8.3 (Fig.1.9) and therefore may require carrier mediated 
uptake to enter cancer cells. 
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Fig.1. 9 Structure of doxorubicin. Doxorubicin is weak base with pKa 8.3 and positively 
charged compound in physiological pH. According to logD value, this compound has lipophylic 
property. 
 
1.6 Interaction between drug transporters and drug 
metabolizing enzymes 
The liver is the major drug metabolizing organ in the human body. However, all me-
tabolizing enzymes are localized intracellulary in the liver hepatocytes. Therefore to 
face liver metabolism drugs has to penetrate through the sinusoidal membrane from the 
systemic circulation into the hepatocytes. This may take place by passive diffusion or 
with the help of carrier mediated uptake transport. A number of drug uptake transporters 
are located on the sinusoidal membrane of the hepatocytes. These include the organic 
anion transporting polypeptides (OATPs), sodium-dependent taurocholate–
cotransporting polypeptide (NTCP), monocarboxylic acid transporter 2 (MCT2) and 
organic cation transporters (OCTs) (PANG et al., 2007; ZAMEK-GLISZCZYNSKI et al. 
2006) (Fig.1.10). After a xenobiotic has been taken up into the hepatocytes, it may 
undergo biotransformation and this biotransformation typically changes the biological 
activity of the substance. After all the products of metabolism are excreted into bile via 
the efflux transporters like organic cation-H
+
 exchanger MATE1, or MDR1 and MDR3 
(multidrug resistance protein 1and 3), MRP2 (multidrug resistance–associated protein 
2), BSEP (bile salt export pump), BCRP (breast cancer resistance protein) located on 
the canalicular membrane in hepatocytes or back into the blood by MRP3, MRP4 and 
MRP6 at the basolateral membrane. 
         Introduction 
22 
 
 
Fig.1. 10 Cellular localization of hepatic drug metabolizing enzymes, influx and efflux 
transporters.  Influx transporters such as OATP, NTCP, OAT2, OCT1, and MCT2 at the 
sinusoidal membrane; and efflux transporters such as Pgp or MDR1, MDR3, MRP2, BSEP, and 
BCRP at the canalicular membrane are shown. The enzymes such as CYP, UGT, SULT and GST 
are present to mediate intracellular metabolism. 
 
It is also recognized that rate-limit metabolism and excretion in the liver may correlate 
to hepatic uptake transporters (TIRONA and PANG 1999).  Zonal heterogeneities of 
transporters and metabolic enzymes further modulate drug disposition in the liver (ABU-
ZAHRA and PANG 2000). The rate-limiting effect of genetic polymorphisms in OCT1 on 
the uptake and metabolism of organic cationic drugs has thus for only infrequently been 
studied in relation to OCT1 and CYP2D6 genetic polymorphisms. But it may 
correspond to the well-studied effects of genetic polymorphisms in organic anion 
transporting polypeptide 1B1 (OATP1B1) on the metabolism of some organic anionic 
drugs (LINK et al. 2008; ROMAINE et al.; VORMFELDE et al. 2008). Concerning 
OATP1B1, Vormfelde et al., 2008 showed there was a combination effect between the 
Val174Ala polymorphism and the Asp130Val174 haplotype with CYP2C9*3 on the 
extrarenal torsemide clearance. The OATP1B1 haplotypes explained 25.6% variation in 
renal torsemide excretion whereas the variation reached to 43.8% when CYP2C9, 
OAT1, and OAT4 polymorphisms have also been counted. This suggests that beside 
OATP1B1 polymorphisms, variation in other genes may also play a role to explain high 
interindividual variation in response to torsemide. 
Until recently, the role of transporters during absorption and excretion of drugs received 
only minor attention. Even there is less information when we consider the combined 
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effect of drug membrane transporters and drug metabolizing enzymes. On the other 
hand, it is also important to understand how genetic variants in different genes (those 
coding for drug transport and those coding for drug metabolism) are acting in a 
combined fashion.  
 
1.7. The aim of this work 
The aim of this work was to identify drugs depending on OCT1 for their hepatocellular 
uptake and investigate combined effect of OCT1 transporter and CYP2D6 metabolizing 
enzyme on drug metabolism. 
Since OCT1 typically catalyses the influx transport of organic cations and CYP2D6 
typically metabolizes such organic cations, epistatic effects between OCT1 and 
CYP2D6 may become an important focus of molecular and clinical pharmacological 
research. For this reason, we hypothesized that the organic cation transporter OCT1 is 
involved in the uptake of tropisetrone, ondansetrone, palonosetrone, debrisoquine, 
tramadol, O-desmethyltramadol, irrinotecan, its metabolite SN38 or doxorubicine into 
the liver, and that genetic polymorphisms in OCT1 may contribute to the high inter- 
individual variability in uptake of these drugs. In this study we tested: 1) whether these 
drugs are substrates of OCT1, 2) whether drug–drug interactions or genetic 
polymorphisms in the OCT1 gene may affect cellular uptake of these drugs, 3) whether 
there is any combination effect between OCT1 and CYP2D6 metabolizing enzyme
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Chemicals, Kits and Medium                    Manufacturer 
1 kb Standard Ladder for Agarosegel  Rapidozym, Berlin  
100 bp Standard Ladder for Agarosegel  Rapidozym, Berlin  
2-Mercaptoethanol ≥ 99%  Sigma-Aldrich, Deisenhofen  
40% (w/v) Acrylamide:Bisacrylamide/ Mix 37,5:1  Biomol, Hamburg  
4326322E (TBP,VIC-MGB) Applied Biosystem, Darmstadt 
40 micron cell strainer BD Falcon (352340) 
Acetic acid 100%, pro analysis Merck, Darmstadt 
Acetonitril Merck, Germany 
Agar (for  Bacteriology)  AppliChem, Darmstadt  
Agarose Ultra Pure  Invitrogen, Karlsruhe  
AMMC Gentest 
Ammonium persulfate ≥ 98%  Sigma-Aldrich, Deisenhofen  
Ammonium sulfate ≥ 99,5%  Sigma-Aldrich, Deisenhofen  
Ampicillin  99%  AppliChem, Darmstadt  
Bicinchoninic acid   Sigma-Aldrich, Deisenhofen  
BigDye® Sequencing Kit Applied Biosystems, Darmstadt  
Boric Acid 100%  Merck, Darmstadt  
Bovine serum albumin (BSA)  Sigma-Aldrich, Deisenhofen  
Bromphenolblue Na-Salt (for Electrophoresis)  Roth, Karlsruhe  
Chloroform ≥ 99,8%  J.T. Baker, Phillipsburg, USA  
Collagen A  Biochrom, Berlin  
Coomassie Brilliant Blue R 250 BioRad, München 
Copper sulfate pentahydrate  Sigma-Aldrich, Deisenhofen  
Debrisoquine  Sigma-Aldrich, Deisenhofen 
Dimethyl sulfoxide (DMSO)  AppliChem, Darmstadt  
Disodium hydrogen phosphate ≥ 99,9%  Merck, Darmstadt  
Dithiothreitol ≥ 99,5% (for Molecular biology)  AppliChem, Darmstadt  
DNeasy Blood & Tissue Kit  Qiagen, Hilden  
dNTP Set  ABgene, Hamburg  
Doxorubicin hydrochloride Sigma-Aldrich, Deisenhofen 
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Dulbecco´s Modified Eagle Medium  Gibco/Invitrogen, Karlsruhe  
EDTA 0,5M in water solution  Sigma-Aldrich, Deisenhofen  
EDTA pure Merck, Darmstadt 
Ethanol 96%  Merck, Darmstadt  
Ethanol denatured 99% (Desinfection agent)  Chemie-Vertrieb Hannover  
Ethidiumbromide 1% in H2O (for electrophorese)  Merck, Darmstadt  
Exonuclease I E.coli (20u/μl)  Fermentas, St. Leon-Roth 
Fluoromount-G SouthernBiotech, Birmingham, USA 
FuGene 6  Roche, Mannheim  
GeneScanLIZ120 standard ladder for SNaPshot
TM
 Applied Biosystems, Darmstadt  
Glycerol 85 % 
Central Pharmacy, Clinic Hospital 
Göttingen  
HBSS medium Gibco/Invitrogen 
Goat anti mouse Alexa 488 Invitrogen 
Goat anti rabbit Alexa 546 Invitrogen 
Helipur
®
 H plus N desinfection agent  Braun, Melsungen  
Roti
®
-Histofix 4% Carl Roth, Gmbh, Karlsruhe 
HotStarTaq Master Mix Kit (250 units)  Qiagen, Hilden  
Hs00287016_A1 (POR) Applied Biosystem, Darmstadt 
Hs00427550_A1 (OCT1) Applied Biosystem, Darmstadt 
Hs02576158_g1 (CYP2D6) Applied Biosystem, Darmstadt 
Hydrogen chloride Merck, Darmstadt, Germany 
Hygromycin B (50mg/ml)  Invitrogen, Karlsruhe  
Irinotecan hydrochloride Sigma-Aldrich, Deisenhofen 
Isoamylalcohol 98%  Schuchardt, Hohenbrunn  
Isopropanol ≥ 99,9%  Merck, Darmstadt   
Kanamycin ≥ 750U/mg  AppliChem, Darmstadt  
KOD HotStart DNA Polymerase  Novagen Merck, Darmstadt  
Ligate-IT
TM
 Rapid Ligation Kit  usb, Staufen  
Lipofectamine
TM 
2000  Invitrogen, Karlsruhe  
LongRange PCR Kit (100) Qiagen, Hilden 
Magnesium chloride ≥ 99%  Riedel-De Haën AG, Seelze  
Magnesium sulfate ≥ 99,5%  Merck, Darmstadt  
Methanol for analysis Merck, Darmstadt 
Mini Quick Spin Oligo Columns  Roche, Mannheim  
Neodisher® A 8, cleaning powder  Chem. Fabrik Dr. Weigert, 
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Mühlenhagen  
Nonidet®P40 Substitute (Nonylphenylethylenglycol)  Sigma-Aldrich, Deisenhofen  
OCT1 rabbit polyclonal antibody (sc-133866)  Santa cruz Biotechnology, Heidelberg  
O-desmethyl-tramadol Sigma-Aldrich, Deisenhofen 
Ondansetron hydrochloride dihydrate Sigma-Aldrich, Deisenhofen 
Palonosetron Sigma-Aldrich, Deisenhofen 
Paroxetine hydrochloride hemihydrate Sigma-Aldrich, Deisenhofen 
PBS  Invitrogen, Karlsruhe 
Pre-Coated PAMPA Plate System Gentest, BD Biosciences 
PBS Powder (Dulbeccos 10-fold)  AppliChem, Darmstadt  
Penicillin/Streptomycin-Solution  Invitrogen, Karlsruhe 
Phenylmethansulfonyl fluoride (PMSF)  Sigma-Aldrich, Deisenhofen  
Polylysin-D-hydrobromide  Sigma-Aldrich, Deisenhofen  
Polymer POP6 und POP7 for sequencer Applied Biosystems, Darmstadt  
PureYield™ Midiprep Kit  Promega, Mannheim  
Puromycin Invitrogen, Karlsruhe 
QIAquick Gel Extraction Kit  Qiagen, Hilden  
QIAquick PCR Purification Kit  Qiagen, Hilden  
qPCR® Core Kit (RT-QP73-05)  Eurogentec, Köln  
qPCR® Core Kit for SYBR® Green (RT-SN10-15)  Eurogentec, Köln  
Random hexanucleotide primers dN6  Roche, Mannheim  
RNAse A ~70%  AppliChem, Darmstadt  
RNeasy Mini Kit  Qiagen, Hilden  
RNeasy Plus Mini Kit  Qiagen, Hilden  
Roti-Aqua® phenol/chloroform/ isoamyl alcohol  
pH = 4,5-5  
Roth, Karlsruhe  
Roti-Aqua® phenol/chloroform/ isoamyl alcohol   
pH = 7-8  
Roth, Karlsruhe  
Sephadex™ G-50 Superfine Amersham Bioscience, Freiburg 
Shrimp Alkaline Phosphatase (1u/μl)  usb, Staufen  
Skim milk powder  Real, Göttingen  
SnapShot
TM
 Multiplex Kit  Applied Biosystems, Darmstadt  
Sodium acetate Merck, Darmstadt 
Sodium chloride  Merck, Darmstadt  
Sodium dihydrogen phosphate monohydrate Merck, Darmstadt 
Sodium dodecyl sulfate  BioRad, Hercules, USA  
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Sodium hydrogen phosphate monohydrate Merck, Darmstadt 
Sodium hydroxide pellets pure Merck, Darmstadt  
Super Script II reverse transcriptase  Invitrogen, Karlsruhe  
Supersignal West Pico (Kit/100ml)  Thermo Scientific  
T4 DNA Ligase  MBI Fermentas, St. Leon-Roth  
Taq DNA polymerase  Qiagen, Hilden  
TaqMan
® 
genexpression assays (Assay on Demand) Applied Biosystem, Darmstadt 
TEMED ≥ 99%  Sigma-Aldrich, Deisenhofen  
Thiazolyl blue tetrazolium bromide Sigma, Steinheim, Germany 
TOPO® XL PCR Cloning Kit  Invitrogen, Karlsruhe  
Tramadol Sigma-Aldrich, Deisenhofen 
Tris 100%  Roth, Karlsruhe  
Triton X-100 Roth, Karlsruhe 
Tropisetron Sigma-Aldrich, Deisenhofen 
Trypan blue -solution (0,4 %)  Sigma-Aldrich, Deisenhofen  
TrypLE™ Express  Gibco/Invitrogen, Karlsruhe 
Tryptone AppliChem, Darmstadt  
Tween 20 (Polyoxyethylen-Sorbit-Monolaurat)  BioRad, München  
Venor
® 
GeM-Kit  Minerva Biolabs, Berlin  
X-ray film developer G150  AGFA, Leverkusen  
X-ray film fixer G354  AGFA, Leverkusen  
Xylene cyanol FF (for molecular biology)  AppliChem, Darmstadt  
Zeocin  Invitrogen, Karlsruhe  
 
2.1.2 Used Materials  
Used Materials   Manufacturer 
50 ml Centrifuge tube  Beckman, München  
96 Millipore MAHV N45 Plate  Millipore, Bedford, USA  
96 Millipore MANU 030 PCR-Plate  Millipore, Bedford, USA  
96 White Plate for luminescence measurement  Greiner, Frickenhausen  
96er PCR-Plate  ABgene, Epsom  
Absolute QPCR Seal (Optical Folie for Taqman)  Thermo Scientific  
Adhesive PCR Foil Seals  ABgene, Epsom  
Amersham Hyperfilm ECL for Western Blot  
(24 × 30 cm)  
GE Healthcare  
Culture flask 25 cm²  and 75 cm²  Sarstedt, Nümbrecht  
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Cuvette (UVetten) 50-1000 μl  Eppendorf, Hamburg  
Cuvette 10x4x45 mm  Sarstedt, Hamburg  
Dialyse filter VSWP01300  Millipore, Bedford, USA  
Electroporation cuvette 2 mm  PeqLab, Erlangen  
FBS Gibco/Invitrogen 
Filter paper Nr. 2668  Schleicher und Schuell  
Filter paper Nr. 2CHR  Schleicher und Schuell  
Flat cap strips, 12er  ABgene, Epsom  
Flat cap strips, 8er  ABgene, Epsom  
FrameStar® 384  4titude, Wotton  
Glass Pasteur pipette 230 mm  WU, Mainz  
Minisart 2000 0,2 μm  Sartorius, Göttingen  
Minisart–plus 0,2 μm  Sartorius, Göttingen  
Nunclon™ Multidishes 6 und 12 Wells  Nunc, Wiesbaden  
Parafilm®  Brand, Wertheim  
Petri Dish  Sarstedt, Hamburg  
Petri Dish for Cell culture, Falcon 353003  Schütt, Göttingen  
Pipette Tip (10 μl, 100 μl, 1000 μl)  Sarstedt, Hamburg  
Plate loader for Sephadex  Millipore, Schwalbach  
Plate Retainer for Sequencing  Applied Biosystems, Darmstadt  
Quali-Filterpipett tip sterile  Kisker, Steinfurt  
Reactions vessel 0,2 ml (RNase-free)  Biozym, Hessisch Oldendorf  
Reactions vessel 1,5 ml und 2 ml  Sarstedt, Hamburg  
Sterile Pipette (5 ml, 10 ml, 25 ml)  Sarstedt, Hamburg  
Sterile Polypropylen-tube 15 ml  Greiner, Frickenhausen  
Sterile Polypropylen-tube 50 ml  Sarstedt, Hamburg  
Thermo-Fast 384er Plate (PCR-Plates for Taqman)  ABgene Epsom  
Thermo-Fast 96er Plate  ABgene, Epsom  
 
2.1.3 Equipment and software 
Equipment and software Manufacturer  
3100 Data Collection Software  Applied Biosystems , Darmstadt 
3130xl Genetic Analyser  Applied Biosystems, Darmstadt  
Adobe Photoshop  Adobe Systems GmbH, München  
Bacteria Incubator-Incudrive  Schütt, Göttingen  
Biofuge fresco  Heraeus, Hanau  
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Biofuge pico  Heraeus, Hanau  
BioPhotometer  Eppendorf, Hamburg  
BioRobot
®
 EZ1  Qiagen, Hilden  
Centrifuge 5810 R  Eppendorf, Hamburg  
Centrifuge JA-20 Rotor  Beckman, München  
Clone Manager Suite  SECentral  
CO2-Incubator BBD 6220  Heraeus, Hanau  
ComPhor L Mini Gel-chamber  Biozym, Hessisch Oldendorf  
Concentrator 5301  Eppendorf; Hamburg  
Confocal laser scanning Microscope Carl Zeiss, Jena 
CorelDRAW X3  Corel Corporation  
DNA Sequencing Analysis  Applied Biosystems  
Electroporator Gene Pulser II  BioRad, Hercules USA  
Fine weight mashine  Sartorius, Göttingen  
Flow cytometer BD Bioscience 
Fluor-S™ MultiImager  BioRad, Hercules, USA  
Gel chamber Ruby SE600  Hoefer, San Francisco, USA  
HPLC Analysing System Merck Hitachi, Darmstadt, Germany 
Labofuge 400R  Heraeus, Hanau  
Magnetic stirrer  IKAMAG  
Mastercycler gradient  Eppendorf, Hamburg  
Membran-Vacuum pumpe  Vacuubrand, Wertheim  
Microscope Axiovert 40 CFL  Zeiss, Jena  
MS 2 Mini shaker-Vortexer  IKA, Staufen  
Nanodrop cuvette  Implen  
Neubauer-Cell chamber  Schütt, Göttingen  
PTC-200 Peltier Thermal Gradient Cycler  MJ Research/BioRad, Hercules, USA  
QiaCube  Qiagen, Hilden  
Scintillation instrument LS1801  Beckman, München  
Shaker for Bacteria K2 260 basic  IKA, Staufen  
Stereomicroscope Stemi 1000  Zeiss, Jena  
Sterile Bench-Clean Air type DFL/REC4 KL2A  Mahl, Trendelburg  
TaqMan 7900HT  Applied Biosystems, Darmstadt  
Thermomixer 5436  Eppendorf, Hamburg  
Transilluminator TI 2  Biometra  
Vertical-Autoclave KSG 40/60  KSG, Olching  
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Vertical-Autoclave: FV  Tecnorama, Fernwald  
Water bath GFL 1083  Schütt, Göttingen * 
 
2.1.4 Enzymes 
Restriction Enzyme    Manufacturer 
BamHI Fermentas, St. Leon-Roth  
BglII Fermentas, St. Leon-Roth  
DpnI New England Biolabs, Beverly, USA  
EcoRI Fermentas, St. Leon-Roth  
EcoRV Fermentas, St. Leon-Roth  
HindIII Fermentas, St. Leon-Roth  
NotI New England Biolabs, Beverly, USA  
PstI Fermentas, St. Leon-Roth  
PvuII Fermentas, St. Leon-Roth  
SacI Fermentas, St. Leon-Roth  
SalI Fermentas, St. Leon-Roth  
XhoI Fermentas, St. Leon-Roth  
XmaI  New England Biolabs, Beverly, USA  
 
2.1.5 Plasmid vectors used 
Clone-Nr.  Vector  Resistance  Delivery  
pcDNA3  Ampicillin Invitrogen, Karlsruhe 
pOG44  Ampicillin Invitrogen, Karlsruhe 
pcDNA5:FRT  Expression vector    Ampicillin Invitrogen, Karlsruhe  
pCR®-XL-TOPO  cloning vector kanamycin Invitrogen, Karlsruhe  
pCR4-TOPO  cloning vector kanamycin ImaGenes, Berlin  
pIRES  Ampicillin Invitrogen, Karlsruhe 
pCMV-SPORT6  Ampicillin Invitrogen, Karlsruhe 
pIRES2-EGFP  Neomycin 
Addgene, Cambridge, 
MA 
pSilencer 4.1- CMV  Ampicillin Invitrogen, Karlsruhe 
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 2.1.6 Cell lines 
Cell line Origin Characteristics Delivery 
HEK Flp-In
TM
 
TREx 293 
Human 
Embryonic kidney cell 
line (contain Flp 
Recombination  
Target (FRT)-
manipulate stable in 
Genom integrate) 
Invitrogen,  
Karlsruhe 
CHO Flp-In
TM
 
Chinese Hamster 
Ovary 
 
Invitrogen, 
Karlsruhe 
 
2.1.7 Strains of bacteria 
Strain of Bacteria  
Application  
for Transfection 
Delivery 
Top10 
(One shot TOP10  
Electro-comp. E.coli) 
Escherichia 
coli 
Electro-competent 
Invitrogen,  
Karlsruhe 
 
 
2.2 Methods 
2.2.1 DNA manipulations 
2.2.1.1 Polymerase chain reaction (PCR) 
PCR is a process of DNA amplification under cell-free conditions. In PCR, double-
stranded DNA (dsDNA) is heated to separate the two strands. Then the reaction is 
cooled to enable the primer annealing and heated again to a temperature of optimal 
function of the used thermostable DNA polymerase. The primers are chosen to flank the 
region of interest that should be selectively amplified. The three steps were repeated for 
a number of 18 to 35 cycles depending on the aim of the PCR amplification. A final 
step of elongation for 7 to 10 min at the optimal temperature for the thermostable DNA 
polymerase was performed. In this work KOD hot start DNA polymerase (Novagen, 
Darmstadt, Germany) and Long Range polymerase (Qiagen, Germany) were used. The 
reaction was carried out in thermal gradient cycler (BioRad, Hercules, USA) or thermal 
mastercycler machines (Eppendorf, Germany). 
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2.2.1.2 Agarose gel electrophoresis 
 
          TBE–buffer (pH 8,3) 
Substance Final concentration 
Tris 0,1 M 
Boric Acid 0,1 M 
EDTA 3,0 mM 
      
          5x Loading buffer 
Substance Final concentration 
Glycerol 30% (v/v) 
EDTA 50 mM 
Bromphenol blue 0,25% (v/v) 
Xylene cyanol 0,25% (v/v) 
                           
Agarose gel electrophoresis was used to separate DNA fragments according their size 
for both analytical and preparative purpose. To separate different sizes of DNA, agarose 
gel was used in different concentrations (ranging from 0.8- 1%). For this reason, 
corresponding amount of agarose was solved in TBE buffer and heated in microwave 
until agarose was completely dissolved. After the gel was cooled down to about 55°C, 
0.5 μg/ml Ethidiumbromid (Merck, Darmstadt) was added and distributed using magnet 
stirrer. Meanwhile gel casting tray was prepared and sealed ends of gel chamber using 
appropriate casting system and appropriate number of combs was placed in gel tray. 
Then, the gel was poured into gel tray and allowed it to cool for 15-30 min at room 
temperature. For loading the samples on the gel, loading buffer was added to a final 
concentration of 1x to each sample. For analytical electrophoresis 10 µl DNA sample 
mixed with 2 µl loading buffer. For preparative purposes usually 50 µl DNA samples 
were mixed with 10 µl loading buffer and run in a wells obtained by sticking together 
two teeth the comb. The electrophoresis was conducted by 120 V using for 30 min 
using ComPhor L Mini Gel chamber (Biozym). A 100 bp. and 1 kb. Ladder (ABgene, 
Fermentas) were used as size standard. Fluor-S™ MultiImager (BioRad, Hercules, 
USA)  was used to visualize DNA bands, and signals were analyzed using Quantity 
One® S Version 4.3.1 (BioRad) Software. 
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2.2.1.3 Photometric quantification of nucleic acids 
The principle for quantification of nucleic acid samples is based on absorbance at 
260nm. The concentration of DNA and RNA was measured by photometry on 
maximum absorption of 260 nm. For this reason, 3µl of nucleic acid solution was 
placed on Implen-Nanodropcuvett (Implen) and measured in BioPhotometer 
(Eppendorf, Hamburg, Germany). The DNA and RNA concentrations were determined 
using the Beer-Lambert law as expressed:  
                                                         A= αcl, 
where A is the absorbance, the constant α is the absorption coefficient (cm2/µg), c is the 
solute concentration (µg/ml), and l is the length of the light path (cm) (Gallagher, 1989). 
Additional measurements at 280 nm were performed and absorbance ratio 260/280 nm 
was calculated to evaluate the purity of the DNA. DNA samples with 260/280 nm ratio 
above 1.6 and RNA samples with ratio above 1.9 were regarded pure enough for further 
analyses.  
 
2.2.1.4 Isolation of total genomic DNA  
For rapid isolation of total DNA (genomic DNA) from fresh or frozen cells, DNeasy 
Blood & Tissue Kit (Qiagen) was used according to the manufacturer's instructions. 
Automatic extraction was performed using QIACube robot (Qiagen) with 1x10
6
 cells as 
starting material and genomic DNA was eluted in 50µl elution buffer.  
 
2.2.1.4.1 DNA extraction from agarose gel 
After a preparative agarose gel electrophoresis DNA fragments with the required size 
were cut out from the gel under UV-light using transilluminator TI2 (Biometra). The 
obtained gel fragment was applied to purify the DNA using QIAquick Gel Extraction 
Kit (Qiagen). The procedure was fully automatically on QiaCube robot (Qiagen) 
according to manufacturer’s instructions. DNA was eluted in 50µl elution buffer 
 
2.2.1.4.2  Enzymatic purification of DNA  
An enzyme digestion was used to purify PCR-product from excess primers and 
nucleotides. Shrimp alkalin phosphatase (SAP, Fermentas, Thermo Scientific) was used 
to remove excess nucleotides (dNTPs), while Exonuclease I from E.coli (Fermentas, 
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Thermo Scientific) degradates the primers. The following reaction mixture was 
prepared: 
 
Reagent Volume 
rSAP (1 U/µl) 5µl 
ExoI (10 U/µl) 0,2 µl 
10 X rSAP buffer 2 µl 
PCR product 13 µl 
Total volume 20 µl 
 
The reaction mix was incubated for 1 h at 37
o
C and then the enzymes were inactivated 
by incubation at 80
o
C for 15 min using thermal cycler (BioRad, Hercules, USA).  
 
 2.2.1.5 Restriction digestion 
This enzymatic reaction using restriction endonucleases can be performed for cleaving 
DNA molecules at specific sites. This step was used both for analytical and preparative 
purposes during the DNA-recombination procedures. 
 
2.2.1.5.1 Analytical digestion 
 Analytical digestion was performed using restriction enzymes to determine the 
fragment length pattern of a particular piece of DNA. The following reaction mixture 
was prepared: 
 
 
 
 
 
 
 
 
 
Analytical reaction: Volume  
10 x Restriction buffer      1 μl  
BSA (optional)  0,1 μl  
DNA  1μl (~1 μg)  
Enzyme  1 μl  
ddH2O  Up to 10 μl  
Total volume                                 10 µl  
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This reaction mix was incubated for 1 hour at optimal temperature for the enzyme 
activity (in most of the cases 37°C). The results of the restriction reaction were directly 
analyzed by agarose gel electrophoresis. 
 
2.2.1.5.2 Preparative digestion 
This restriction reaction was used to prepare the plasmid and genomic DNA for cloning. 
The following reaction mixture was prepared: 
 
Preparative reaction: Volume 
10 x Restriction buffer 5 μl 
BSA (optional) 0,5 μl 
DNA max. 10 μg 
Enzyme 5 μl 
ddH2O Up to 50 μl 
Total volume 50 µl 
 
In this case, the digestion was performed for 2 hours at the optimal temperature and 
then after adding 1 µl additional enzyme, the incubation was continued for another 1 
hour. When DNA is cleaved with two or more restriction enzymes, the digestions can 
be carried out simultaneously if both enzymes work in the same buffer using universal 
buffer (Tango; Fermentas, St. Leon-Roth), or it can be done consequently for each 
enzyme with a gel extraction reaction and using the special buffer for each enzyme.                                       
 
2.2.1.6 Ligation 
This process is used to introduce a foreign DNA fragment (insert) into the linearized 
plasmid vector. This reaction is usually catalyzed by a DNA ligase enzyme. This 
enzyme will ligate DNA fragments having ‘blunt’ end or overhanging complementary, 
‘sticky’ end. The ligation mixtures were made using Ligate-ITTM Rapid Ligation Kit 
(USB, Staufen, Germany). For this purpose, an insert: vector ratio of 13:2 (v/v) was 
used. The following reaction mixture was prepared:  
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Ligation reaction: Volume 
5x ligase buffer  4 μl 
Plasmid vector  2 μl 
Insert fragment  13 μl 
Ligase  1 μl 
Total volume  20µl 
 
The mixture was incubated for 5-10 min at RT. In order to estimate the number self-
ligate plasmid as negative control reaction was performed by using ddH2O instead of 
insert fragment. In order to enhance efficiency of transformation, ligation mixture was 
concentrated using vacuum concentrator. For this reason, an open lid Eppendorf
® 
microcentrifuge tube containing ligation mixture was placed in  SpeedVac Plus
®
 
SC110A vacuum centrifuge (Schütt, Göttingen) and with highest temperature was 
centrifuged under vacuum (200 mbar, Membran-Vacuumpumpe, Vacuubrand, 
Wertheim) for 10 min to achieve about 60 % of primary reaction volume. Afterwards 
remaining DNA attached on the eppi wall was detached by pipetting the residual liquid.   
                     
 2.2.1.7 TOPO cloning  
To ligate one DNA fragment into the TOPO vector, the TOPO® XL PCR Cloning Kit 
(Invitrogen) was used. This kit allows PCR inserts to ligate efficiently with a vector 
covalently bound to a Topoisomerase enzyme originated from Vaccinia virus. The 
linearized plasmid in this kit has been also supplied with single 3´-thymidine (T) 
overhangs for TA Cloning. 
The TOPO reaction requires the PCR product to have A-overhangs that are naturally 
produced by some thermostable polymerases like Taq-polymerase, but not by others 
like KOD- or Pfu-polymerases. For this reason, an additional incubation with Taq- 
polymerase was used to generate 3'-Adenosin-overhang on the flank of insert fragment 
when the PCR product was generated with KOD or Pfu-polymerases. Taq-Polymerase 
has transferase activity that adds a single deoxyadenosine (A) to the 3´ ends of PCR 
products. The following reaction mixture was prepared: 
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Reaction for generation  
of 3’-A-overhangs 
Volume 
dATPs (10mM)  1 μl 
10 x buffer  5 μl 
Taq-Polymerase (5 U/μl)  1 μl 
DNA-Fragment  43 μl 
Total volume 50µl 
 
The reaction mixture was incubated for 15 min at 72°C in thermocycler. Then the 
ligation reaction was followed by adding 0.5µl TOPO-vector mix to 4.5 µl of the 
reaction above: 
 
Reaction mix                                           Volume 
DNA-Fragment solution 4.5 μl 
TOPO XL® PCR Cloning Vector 0.5 μl 
 
After 5 min incubation at room temperature, 1 μl 6X TOPO Cloning Stop Solution (0.3 
M NaCl, 0.06 M MgCl2) was added and ligation mix was placed on ice for 10 min. 
After all the mixture was dialyzed and transformed in E.coli by electroporation as 
described in chapter 2.2.4.3. 
 
2.2.1.8 Site-directed mutagenesis 
The pcDNA3::hOCT1 plasmid was amplified by PCR using the KOD Hot Start DNA 
Polymerase Kit (Novagen Merck, Darmstadt) and site-directed mutagenesis primers 
(Table 3.1).  
 
Table 2. 1 Site-directed mutagenesis primer list. The mutated bases are bolded and the genetic codons 
were underlined. 
Amino acid variant Primer sequence 
Arg61Cys    5’-GGCTGAGCTGAGCCAGTGCTGTGGCTGGAGCCC-3’ 
5’-GGGCTCCAGCCACAGCACTGGCTCAGCTCAGCC-3’ 
Cys88Arg 5’-GGCCTTCCTTGGCCAGCGCAGGCGCTATGAAGT-3’ 
5’-ACTTCATAGCGCCTGCGCTGGCCAAGGAAGGCC-3’ 
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Gly401Ser 5’-CACCATTGACCGCGTGAGCCGCATCTACCCCAT-3’ 
5’-ATGGGGTAGATGCGGCTCACGCGGTCAATGGTG-3’ 
Deletion of Met420 5’-GGGCAGCCTGCCTCGTCATTTTTATCTCACCTGA-3’   
5’-TCAGGTGAGATAAAAATGACGAGGCAGGCTGCCC-3’  
Gly465Arg 5’- ATTCGTCAGGAACCTCAGAGTGATGGTGTGTTC-3’             
5’-GAACACACCATCACTCTGAGGTTCCTGACGAAT-3’ 
 
 
In order to find the optimum annealing temperature for each primer, the gradient-PCR 
was performed according to the following conditions:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR-Condition 
 
 
 
 
 
 
 
 
Standard-PCR-Reaction Mixture Volume 
10 x buffer  2.5 μl 
 dNTPs (2 mM)                   2.5 μl 
 MgSO4 (25 mM)  1 μl 
 Q-Solution   5 μl 
 Forward-Primer (10 nM)  0.65 μl 
 Reverse-Primer (10 nM)  0.65 μl 
 Template DNA (50 ng/µl)  1 μl 
 KOD HotStart Polymerase (1.0 U/μl)  0.5 μl 
 ddH20  11.2 μl 
Total Volume                                                         25 µl 
Phase  Duration Temperature 
Initial Denaturation  3  min 95°C 
Denaturation 30 sec 95°C 
Annealing  30 sec 50-70°C 
Elongation  3 min 30 sec 72°C 
 Cool down for ever 8°C 
19
x 
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For this purpose, DNA template was amplified in five different annealing temperatures 
(50-70°C) in gradient-cycler and optimum annealing temperature was identified by 
analyze the PCR product on the agarose gel.  
Following temperature cycling, the product is treated with 2µl digestive enzyme Dpn I 
(NEBiolabs, Frankfurt am Main, Germany) for 1 hour at 37°C and again with 1 µl of 
this enzyme for one hour more. The Dpn I endonuclease (target sequence: 5´-Gm6ATC-
3´) which is specific for methylated and hemimethylated DNA is used to digest the 
parental DNA template and to select for mutation-containing synthesized DNA. 
Afterwards, the PCR products were dialyzed for 30 min and then transformed in E. coli 
TOP10 strain. The pcDNA3::OCT1 plasmids carrying the required mutations were then 
isolated and the correctness of OCT1 wild type and variants were validated by 
sequencing of the entire OCT1 reading frame. 
 
 
2.2.1.9 PCR for analyzing the chromosomal integration of pcDNA5 
constructs 
Total DNA was extracted from the stably transfected cells using automatic DNA 
extraction with the DNeasy® blood and tissue kit and the QIACube robot (Qiagen, 
Hilden, Germany).  Two independent PCR reactions were conducted to check 
integration of the OCT1 gene in to the genome using two pairs of primers 
complementary to the hygromycin resistance gene and the OCT1 gene. First, an 
integration-specific PCR was performed with the forward primer PSV40 located in the 
SV40 promoter of the pFRT/lacZeo plasmid (which is pre-integrated in the genome of 
the T-REx HEK293 cells and is the target of the integration) and the reverse primer Hyg 
(Table 3.2) located in the hygromycin B resistance gene of the pcDNA5.1 plasmid 
(which should be integrated within the Flp recombination target (FRT) sites of the 
pFRT/lacZeo plasmid) according to following procedure: 
 
 
  
 
 
 
                                                                                                        Materials and Methods 
40 
 
Table 2. 2 List of primer and corresponding sequences to test for chromosomal integration of 
pcDNA5.1  
Primer                                                   Sequence 
PSV40-f 5’- AGCTGTGGAATGTGTGTCAGTTAGG-3’ 
Hyg-r 5’-ACGCCCTCCTACATCGAAGCTGAAA-3’ 
PCMV 5’-CCATGGTGATGCGGTTTTGGCAGTA-3’ 
Lac 5’-CCTTCCTGTAGCCAGCTTTCATCAA-3’ 
 
 
      
Integration-PCR-Reaction Mixture for Hyg                                              
 
Volume
 
 10 x buffer  2.5 μl 
 dNTPs (2 mM)                   2.5 μl 
MgSO4 (25 mM)  1 μl 
Q-Solution   5 μl 
Forward-Primer  PSV40 (10 nM)  0.65 μl 
Reverse-Primer Hyg (10 nM)  0.65 μl 
Templat DNA (300 ng/µl)  1 μl 
KOD HotStart Polymerase (1.0 U/μl)  0.5 μl 
ddH20  11.2 μl 
           Total Volume                                                                   25 µl 
 
 
PCR-Condition 
 
 Phase               Duration Temperature 
Initial Denaturation  2 min 95°C 
Denaturation 30 sec 95°C 
Annealing  30 sec 68°C 
Elongation  1 min30 sec 72°C 
Final elongation                 10 min 72°C 
  for ever 8°C 
 
35
x 
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Second, the OCT1 open reading frame was amplified using the primers PCMV and Lac 
and the KOD Hot Start DNA Polymerase Kit under the following conditions: 
 
      
Integration-PCR-Reaction Mixture for OCT1                                              
 
Volume
 
 10 x buffer  2.5 μl 
 dNTPs (2 mM)                   2.5 μl 
MgSO4 (25 mM)  1 μl 
Q-Solution   5 μl 
Forward-Primer  PCMV (10 nM)  0.65 μl 
Reverse-Primer Lac (10 nM)  0.65 μl 
Template DNA (300 ng/µl)  1 μl 
KOD HotStart Polymerase (1.0 U/μl)  0.5 μl 
ddH20  11.2 μl 
Total volume 25 µl 
 
PCR-Condition 
 
 
 
 
 
 
2.2.1.10 DNA assembling 
In order to assemble two or more different DNA regions together, assembly PCR was 
used according to procedure described by Stemmer et al., 1995. In this particular work I 
used assembly PCR technique to prepare a fused transcript of CYP2D6 and POR genes. 
An Internal Ribosomal Entry Site (IRES) was inserted between these two genes in order 
to increase translational efficiency of the second gene, in this case POR. Used IRES was 
Phase  Duration Temperature  
Initial Denaturation  2 min  95°C  
Denaturation 30 sec  95°C  
Annealing  30 sec  68°C  
Elongation  2 min   72°C  
Final elongation                 10 min 72°C 
  for ever  8°C  
 
35
x 
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a 650 bp fragment originated from encephalomyocarditis virus (EMCV) which allows 
to recruit ribosome to start translation process in an independent manner to promoter 
(BOCHKOV and PALMENBERG 2006). 
The assembly PCR protocol consists of three stages. In the first stage, two 
corresponding fragments are amplified separately using two pair primers which have 
homology in reverse primer of one fragment with forward primer of another fragment, 
in the second stage, both amplified products were mixed together and added to PCR 
master mix without any primers. Since single-stranded ends of complementary DNA 
fragments are filled-in during the gene assembly process, cycling with DNA polymerase 
results in the formation of increasingly larger DNA fragments until the full-length 
fragment is obtained. In the third stage, the full-length fragment was amplified using the 
forward primer of the first fragment along with the reverse primer of the second 
fragment (Fig.2.1).   
 
 
 
Fig.2. 1 Scheme of fusion of CYP2D6 and POR genes using IRES fragment. All these 
fragments were bond together by DNA assembling method. 
 
For this purpose, each single fragment was amplified by PCR (first PCR) using specific 
primers designed for each one to have complementary part in reverse primer for first 
gene with forward primer of the second gene to cause two fragments bind together. The 
following reaction mixture and amplification conditions were used: 
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First-PCR 
 
Standart PCR-reaction mixture Volume 
10 x buffer  2.5 μl 
dNTPs (2 mM)                   2.5 μl 
MgSO4 (25 mM)  1 μl 
 Q-Solution   5 μl 
Forward-Primer (10 nM)  0.65 μl 
Reverse-Primer (10 nM)  0.65 μl 
Template DNA (300 ng/µl)  1 μl 
KOD HotStart Polymerase (1.0 U/μl)  0.5 μl 
ddH20  11.2 μl 
Total Volume   25 µl 
                                                                 
PCR-Condition 
 
 
Phase  Duration Temperature 
Initial Denaturation  2 min 95°C 
Denaturation 30 sec 95°C 
Annealing  30 sec 68°C 
Elongation  2 min 72°C 
Final Elongation 10 min 72°C 
  for ever 8°C 
 
 
Then the PCR products were run on 1% agarose gel, and the fragments were cut and 
eluted from the gel as described in chapter 2.2.1.5.1. Afterwards the eluted products 
which have complementary ends were mixed together to assemble a larger fragment 
containing both two genes and then amplified by PCR (second PCR). 
The following reaction mixture and amplification conditions were used: 
 
 
 
 
 
 
35
x 
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Second PCR 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
PCR-Condition 
 
 
Phase  Duration Temperature 
Initial Denaturation  2 min 95°C 
Denaturation 30 sec 95°C 
Annealing  30 sec 60°C 
Elongation  2 min 72°C 
Final Elongation 7 min 72°C 
  for ever 8°C 
 
 
After running the second PCR, immediately proceed to the third PCR. For this purpose, 
1 µl from the second PCR reaction was added to PCR reaction mixture and amplified by 
PCR (third PCR).  
The following reaction mixture and amplification conditions were used: 
 
 
 
 
Assembly-PCR-Reaction Mixture Volume 
10 x buffer 5 μl 
dNTPs (2 mM) 5 μl 
MgSO4 (25 mM) 2 μl 
Q-Solution 10 μl 
PCR-product gene 1 5 μl 
PCR-product gene 2 5 μl 
KOD HotStart Polymerase (1.0 U/μl) 1 μl 
ddH20 17 μl 
Total volume 50ml 
 35
x 
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Third-PCR 
 
Standart PCR-reaction mixture Volume 
10 x buffer 2.5 μl 
dNTPs (2 mM) 2.5 μl 
MgSO4 (25 mM) 1 μl 
Q-Solution 5 μl 
Forward-Primer for first gene(10 nM) 0.65 μl 
Reverse-Primer for second gene (10 nM) 0.65 μl 
Assembled DNA (300 ng/µl) 1 μl 
KOD HotStart Polymerase (1.0 U/μl) 0.5 μl 
ddH20 11.2 μl 
Total Volume 25ml 
                               
PCR-Condition 
 
 
 
 
 
The obtained products were purified through agarose gel, cloned and the correct 
assembly was verified by sequencing. 
 
2.2.1.11 DNA sequencing 
A capillary end-terminal sequencing was performed using BigDye® terminator v1.1 
Sequencing Kits (Applied Biosystems, Darmstadt). The end-terminal sequencing 
method, which was originally described by Frederick Senger and coworkers (Sanger 
and Coulson 1975) is based on pre-mature termination of DNA synthesis by using a 
mixture of desoxy (dNTPs) and di-deosoxiy nucleotide triphosphates (ddNTPs).  
Phase Duration Temperature 
Initial Denaturation  2 min 95°C 
Denaturation 30 sec 95°C 
Annealing  30 sec 60°C 
Elongation  3 min 72°C 
Final Elongation 7 min 72°C 
  for ever 8°C 
 
35
x 
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Different bases in the ddNTP are marked with different fluorescence dye. These 
nucleotides are integrated randomly in the growing DNA-strand and terminate chain 
extension based on missing 3’-OH-Group. This will result in product with different size 
that terminates at different positions in the sequence. In the capillary sequencer, the 
different size is separated through a capillar-gel electrophoresis and a laser-based 
detection was performed at the end of the capillary. The different fluorescence dye will 
give different emission expected corresponding to different bases in the DNA 
sequencing. 
 The sequencing reaction was performed using the following reaction mixture under the 
following condition: 
 
 
 
 
 
 
     
Reaction conditions 
 
Phase  Duration Temperature 
Initial Denaturation  2 min 94°C 
Denaturation 15 sec 96°C 
Annealing  15 sec 56,5°C 
Elongation  4 min 60°C 
Final Elongation  7 min 72°C 
  for ever 8°C 
 
 
The different sequencing primers used in this work are listed in table 2.3. 
 
 
 
Sequencing reaction mix Volume 
DMSO  0,25 μl 
Primer (10 μM)  0,5 μl 
BigDye®  1 μl 
ddH2O  2,25 μl 
DNA (~300 μg/ml)  1 μl 
Total volume 5 µl 
 25
x 
                                                                                                        Materials and Methods 
47 
 
Table 2. 3 Primers and corresponding sequences for OCT1 wild type and its variants. 
Primer Primer sequence 
OCT1-ORF (f) 5’-CATGAGCAAGCTTAGCCATCATGCCCACCGTGGA-3’ 
OCT1-Cys88Arg (f)                          5’-GGCCTTCCTTGGCCAGCGCAGGCGCTATGAAGT_3’ 
OCT1-Cys88Arg (r)                          5’-ACTTCATAGCGCCTGCGCTGGCCAAGGAAGGCC-3’ 
OCT1-Gly401Ser (f)                         5’-CACCATTGACCGCGTGAGCCGCATCTACCCCAT-3’ 
OCT1-Gly465Arg  (r)                       5’-GAACACACCATCACTCTGAGGTTCCTGACGAAT-3’ 
                                  
 
The sequencing reactions were purified prior to injection into the sequencer in order to 
remove both the unincorporated dideoxynucleotides as well as salts from the reaction 
buffers. For this reason, first 35 mg Sephadex G50 superfine (Amersham, Freiburg) was 
poured on plate loader (Millipore, Schwalbach) to fill all holes, and then this plate was 
turned upside down on 96-well filter plate (MAHV-N45, Millipore). Afterwards, 300 μl 
ddH2O was added to each well and allowed them to swell for 3 hours at RT. Then the 
filter plate was spined in centrifuge (650 g, 5 min, RT) to remove the surplus water. The 
sephadex gel was washed by adding 150 μl ddH2O in each well and incubation for 30 
min at RT. Again the surplus water was removed by centrifugation (Centrifuge 5810 R, 
Eppendorf, 650 g, 5 min, RT) and then 35 μl ddH2O was added to 5 µl sequencing 
reaction and pipetted on Sephadex-containing filter plate and centrifuged (650 g, 5 min, 
RT). Finally filtered Sequencing product was collected in one clean 96-Well-Plate. This 
Plate was used directly for sequencing in 3130xl Genetic Analyser (Applied 
Biosystems).  
The sequencing data was analyzed using Sequencing Analysis Version 5.2 (Applied 
Biosystems) and afterwards with Staden Package Version 4.0 (SourceForge.net) or 
Clone Manager (SECentral).  
 
2.2.1.12 Genotyping using single base primer extension method 
(SNaPshot®) 
The single base primer extension (SNaPshot
 TM
) is a method for genotyping Single 
Nucleotide Polymorphism (SNPs) or small deletions and insertions. The principle of 
this method is based on the dideoxy single-base extension of an unlabeled 
oligonucleotide primer. Each primer binds with his 3’-end located directly upstream of 
the polymorphic position in the DNA. The DNA synthesis is performed in the presence 
of fluorescently labeled ddNTPs but in the absence of dNTPs. Therefore, the 
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polymerase extends the primer by only one nucleotide, adding a single ddNTP to its 3’ 
end on the SNP position. This ddNTP does not carry OH- group in 3’ end which cause 
to stop DNA extension.  In multiloci analysis using Multiplex Kit (ABI PRISM
®
 
SNaPshot 
TM
), mixture of primers with different lengths are used to analyze a wide 
range of SNPs in DNA template. To analyze the final products successfully and 
robustly, a fluorescent marked internal standard (Gene Scan
TM
 120LIZ
TM
 Size Standard, 
Applied Biosystems) was added to each sample. 
 
In this study, the single-base primer extension reaction was performed using the 
SNaPshot
® 
kit (Applied Biosystems). Therefore, 2µl purified PCR-product or plasmid 
was mixed with 3 µl of following master mix: 
 
Reagents Volume 
2x SNaPshot reaction mix 2.5 μl 
10x  pooled primer mix 0,5 μl 
Total volume                                         3 µl 
 
The pooled primer mix contains polymorphism specific primers as given in the table 2.4 
and then the reaction was done under following condition: 
  
   Table 2. 4 Primers and corresponding sequences for CYP2D6. 
Name Sequence 
Length 
[bp] 
Con-
centration in 
Primer-Mix 
2850C>T 5 '-  (A) 7 CAGGTCAGCCACCACTATGC -3 '  27 250 nM 
1846G>A 5 '-  (A) 1 6TACCCGCATCTCCCACCCCCA -3 '  37 250 nM 
1707T>del 5 ' -  (A) 2 1 GGCAAGAAGTCGCTGGAGCAG -3 '  42 500 nM 
2613-15 
AGA>del 
5 ' -  (A) 2 6 GCCTTCCTGGCAGAGATGGAG -3 '  47 500 nM 
100C>T 5 '-  (A) 3 1 CAACGCTGGGCTGCACGCTAC -3 '  52 1,5 µM 
4180G>C 5 '-  (A) 3 7 CAAAGCTCATAGGGGGATGGG -3 '  58 1,5 µM 
1023C>T 5 '-  (A) 4 2 CCGCCCGCCTGTGCCCATCA-3 '  62 1,5 µM 
2988G>A 5 '-  (A) 4 5 AACAGTGCAGGGGCCGAGGGAG -3 '  67 1 µM 
31G>A 5 '-  (A) 4 3 CCAGGAGCAGGAAGATGGCCACTATCA -3 '  70 2,5 µM 
2549 
A>del_var3  
5 ' -  (A) 5 4 GGGCTGGGTCCCAGGTCATCC -3 '  75 5 µM 
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SNaPshot reaction conditions 
 
Phase   Duration Temperature 
Initial Denaturation  1 min 96°C 
Denaturation  30 sec                96°C 
Primer annealing  5 sec                50°C 
Elongation             30 sec                60°C  
Cool down         for ever                 8°C  
 
To prevent the unincorporated fluorescent ddNTPs from comigrating with the fragments 
of interest, the SNaPshot reaction was purified to remove non-integrated ddNTPs from 
reaction. To do this, 0.5 µl fast alkaline phosphatase (Fermentas, St. Leon-Rot, 
Germany) with the same volume of FastAP-buffer were added to reaction and incubated 
for 1 h at 37
o
C. Afterwards, alkaline phosphatase was inactivated by incubation at 75
o
C 
for 15 min. Finally, 1 μl of the SNaPshot reaction was added to 10 μL of the following 
mixture:  
 
Sequencing mix  Volume 
Formamid (Hi-Di
 TM
  Formamid, Applied Biosystems) 10 μl 
Gene Scan
TM
 120LIZ
TM
 Size 0,5 μl 
 
The reaction was denatured for 5 Min at 95°C, and then immediately placed on ice. The 
products were analyzed in 3130xl Genetic Analyser using Gene mapper v3.7 software
®
 
(Applied Biosystems). 
 
 
 
 
 
 
 25
x 
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2.2.2 RNA  
2.2.2.1 RNA Isolation 
 
PBS-buffer, pH 7,4  Volume 
NaCl  140,0 mM 
KCl  2,5 mM 
Na2HPO4  8,1 mM 
KH2PO4  1,5 mM 
ddH2O Up to 1 lit 
                       (Sterilized by autoclaiving for 20 min at 120oC) 
 
Before RNA extraction to avoid contamination and reduce RNase in the bench, anti-
RNase spray (RNaseZap; Sigma-Aldrich) was used for cleaning the working surfaces 
and pipettes. Also during the experiments RNase free plastic ware was used. Total RNA 
was extracted as follows: 
1 x 10
6
 cells were harvested by centrifugation (3500 rpm, 3 min, RT), the medium was 
discarded and the pellet was washed with 500 µl PBS. To lyse the cells, 300µl RTL 
buffer (Qiagen) supplemented with 10µl/ml 2-Mercaptoethanol (Sigma-Aldrich) were 
added to each sample. The RNA was extrcated using RNeasy Mini Kit or RNeasy Plus 
Mini Kit (Qiagen) in combination with QiaCube (Qiagen) robot according 
manufacturer’s instruction. RNA concentration was measured by absorbance at 260 nm 
using biophotometer as described in chapter 2.2.1.3. 
 
2.2.2.2 RT-PCR 
In order to evaluate expression rate of the genes of interest, total RNA was reversed 
transcribed to complementary DNA (cDNA) using SuperScript™ II reverse 
transcriptase (Invitrogen) as follows:  
One microlittre of random hexanucleotide primers (dN6, Roche, Mannheim) was added 
to 1µg mRNA, the samples were incubated at 70°C for 10 min and left to cool down at 
room temperature for 10 min. Afterwards, 11,25 µl of the following RT-mastermix were 
added to each RNA-primer reaction mix. 
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RT-Mastermix (per Reaction) Volume 
5 x Superscript RT buffer 6 μl 
DTT (0,1 M)  3,5 μl 
dNTPs (10 mM)  1 μl 
RNase Inhib P/N (40un/μl)  0,5 μl 
Super Script™ II (200 U/μl)  0,25 μl 
Total volume 11,25ml 
 
 
The cDNA was synthesized by incubation at 42°C for 60 min. Each sample was filled 
up with 70 μl ddH2O to reach to the final cDNA-concentration of estimated 10 ng/μl. 
 
2.2.2.3 Quantitative PCR 
Quantitative PCR (qPCR or also called real-time PCR) is based on monitoring the 
amount of PCR-product throughout the PCR amplification process rather than at the 
end, thereby allowing PCR reactions to be monitored in real time. Quantitative PCR 
reactions are characterized by the time point during cycling when amplification of a 
target is first detected rather than measuring the amount of target after a fixed number of 
reaction cycles. Therefore, the higher the starting copy number of the target, the sooner 
a significant increase in the fluorescent signal is detected (HIGUCHI et al. 1993) .  
In this work the expression of the genes of interest was determined in relation to the 
expression of an endogenous normalization gene and the ratio was related to the 
expression of both genes in a control sample, the so called relative expression or ∆∆CT 
method. In order to measure the expression rate of the gene of interest, below equation 
was used. 
 
Relative expression = 2
-[(Ct – Ct NGen) – (Ct controll – Ct NGen controll)]
 = 2
-[ΔΔCt]
 
 
According to the equation, the threshold cycle (CT) value is the cycle number at which 
the fluorescence emission exceeds the fixed threshold level. The CT values are inversely 
proportional to the expression level of the target gene. The expression level for the gene 
of interest was normalized to the expression level of an endogenous normalization gene 
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with known constant expression (so called housekeeping gene). Housekeeping genes are 
genes which are commonly expressed in most cell types and are present at consistent 
levels which can be used to normalize target cDNA across experiments and cell types. 
In this work TATA-Box Binding Protein (TBP) was used as such endogenous control. 
The expression of OCT1, CYP2D6 and POR genes was quantified by real-time RT-PCR 
using ready-to-use TaqMan
®
based gene expression assays (Table 2.5) and eurogentec 
Master Mix (Köln, Germany).  
 
 
             Table 2. 5 Primers and corresponding sequences for CYP2D6. 
TaqMan assay Manufacturer 
Hs00427550_A1 Applied Biosystems, Darmstadt, Germany 
Hs02576158_g1 Applied Biosystems, Darmstadt, Germany 
Hs00287016_A1 Applied Biosystems, Darmstadt, Germany 
 
 
The following reaction mix was prepared: 
 
Mastermix for qPCR  Volume 
2 x Mastermix (Eurogentec)  9 μl 
20 x AssayMix  0,9 μl 
cDNA (10 ng/μl)  3 μl 
ddH2O  5,1 μl 
Total volume 18 µl 
 
Where the 2xMastermix (Eurogentec) was prepared as follows:  
  
2 x Mastermix (Eurogentec) Volume 
10 x Buffer  1,8 μl 
MgCl2 (50 mM)  1,26 μl 
dNTPs (5 mM)  0,72 μl 
Hot Goldstar Polymerase (5 U/μl)  0,09 μl 
ddH2O  11,13 μl 
Total volume                                                    15 µl 
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The qPCR reaction was run in a Sequence Detection System 7900HT (Applied 
Biosystems) under the following conditions: 
 
PCR-condition:  
Phase  Duration Temperature 
Taq Polymerase activation 2 min 95°C 
Denaturation 15 sec 95°C 
Primer annealing  30 sec 60°C 
Elongation  1 min 72°C 
Cool down  for ever 8°C 
 
The gene expression was normalized on the expression of TATA-box binding protein 
(TBP, Applied Biosystem TaqMan assay # 4326322E). Relative expression of OCT1, 
CYP2D6 and POR was calculated using the 2
−ΔΔ Ct
 method according to the above 
equation. 
 
 
2.2.3 Protein analyses 
2.2.3.1 Quantification of total protein using bicinchoninic acid (BCA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
RIPA buffer (50 ml)                                     Volume 
Tris-HCl 50 mM 
NaCl 150 mM 
EDTA 1 mM 
NP-40 1% (v/v) 
Na-deoxycholate 0.25 % (w/v) 
PMSF (optional) 1 mM 
BSA Stock solutions (1mg/ml) Volume 
BSA 50 mg 
1x RIPA buffer 50 ml 
 
40
x 
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Cupric sulfate pentahydrate solution  
(CuSO4 x 5 H2O) 
Volume 
Cupric sulfate 4%  2 mg  
 ddH2O  50 ml  
 
 
The BCA assay, originally described by Smith et al. in 1985 (Smith et al., 1985), 
measures the formation of Cu
1+
 from Cu
2+
 by the Biuret complex in alkalic conditions. 
The detection is based on complexing the Cu
1+
 ion with BCA that give a colour 
complex with absorption maximum at 562 nm. By this assay the total protein 
concentration is exhibited by a color change of the sample solution from green to purple 
in proportion to protein concentration, which can then be measured using colorimetric 
techniques. The BCA assay was performed as follows: 
10µl of diluted protein samples (dilution 1:3 in RIPA buffer) were pipette in a single 
well of a transparent 96-well plate (Sarstedt). The samples were analyzed in duplicate. 
Then BCA-cupric sulfate solution was added. To prepare this solution, 50 portion of 
BCA solution with one portion of cupric sulfate 4% solution were mixed (green colour), 
and 200µl of this solution was added to each well. After that the plate was incubated at 
37
o
C for 30 min and then protein absorption was measured at 570 nm wave length in 
Tecan Ultra Microplate device (Tecan, Crailsheim) and finally the protein concentration 
was calculated from the standard curve. The standard curve was prepared using bovine 
serum albumin (BSA). The range of BSA concentrations for the standard curve was 
selected (0, 1, 5, 10, 15, 20, 25 and 30 mg/ml). For this reason, the amounts of 0, 1, 5, 
10, 15, 20, 25 and 30 µl of BSA stock solution (1mg/ml) were pipette in duplicate. The 
BSA was treated with put into the same 96-well plate, treated and measured in the same 
way as the samples of interest. 
 
2.2.3.2 Western Blot 
2.2.3.2.1 SDS-Polyacrylamid Gel Electrophoresis (SDS-PAGE) 
By using SDS-PAGE, denatured negative charged proteins can be separated according 
to their molecular weight. First the proteins were denatured by heating them at 95
o
C for 
5 min and in the presence of β-Mercaptoethanol or DTT to break down disulfide bonds 
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in the structure of protein. Second the denatured proteins are run on a polyacrylamide 
gel. In this step, first the samples run through a low concentration gel (stacking gel) and 
then were separated on higher concentration polyacrylamide gel (separation gel). First 
the separating gel was prepared. To prepare the separating gel, the compounds were 
mixed together in concentrations given in table 2.6. The mixture was degassed for 10 
min using water jet pump for 10 min and ammonium peroxydisulfate (APS) and 
N,N,N’,N’-Tetramethylethylendiamine (TEMED) were added to start gel 
polymerization. A gel chamber Mighty Small SE Dual Gel Caster (Hoeffer, Holliston, 
MA) was filled until the level reached approximately 1.5 cm before the top end. The 
rest part was filled up with water to make smooth and even the top side edge of the gel. 
Then the gel was left for 30 min at RT to polymerize. Meanwhile the stacking gel was 
prepared. The water was removed from top and degassed stacking gel was added on the 
top of the separation gel and incubated for 30 min at RT to polymerize. Then the gel 
was fixed in the electrophoresis chamber Mighty Small II (Hoeffer, Holliston, MA) and 
the chamber was filled with 1x Running buffer. 
 
Table 2. 6 Reagent required for preparation of Stacking gel and Separating gel  
Reagent 4% Stacking gel 12%  Separating gel 
ddH2O 1625 μl 2180 μl 
1,5 M Tris-HCl (pH 8,8) -  1250 μl 
0,5 M Tris-HCl (pH 6,8) 625 µl -   
10% (w/v) SDS 25 μl 50 μl 
40% (w/v) Acrylamid/Mix 37:5:1 250 μl 1500 μl 
10% APS 12.5 μl 25 μl 
TEMED 2.5 μl 2.5 μl 
 
2.2.3.2.2 Electrophoresis 
 
1x Running buffer  Volume 
Tris-HCl (pH 8.4) 3.03 g 
Glycin  14.41 g 
SDS  1.00 g 
ddH2O  Add 1 L 
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4x Loading buffer   Volume 
0,5 M Tris-HCl (pH 6,8) 6,6 ml  
Glycerin  7,5 ml  
10% (w/v) SDS  12,0 ml  
2% (w/v) Brome phenole blue   0,5 ml  
ddH2O   ad 25 ml  
                                    Stored at -20°C in 100 μl Aliquots 
 
The gel was pre-run at 12 mA for about 30 min. Meanwhile 15 µl of the protein samples 
were denatured at 95°C for 5 min in the presence of 5 µl of 4x loading buffer 
(Thermomixer 5436, Eppendorf) and then were placed on ice. Then 5 μl molecular 
weight marker (SeeBlue®Plus2 Prestained Standard, Invitrogen) and 100 µg of each 
sample were loaded onto the gel. The samples were run on the collection gel at 12 mA 
(per gel) for about 10-20 min till reached to the border of separation gel and then raised 
the current up to 25 mA (per gel) on the separation gel until loading buffer run out of 
the gel. During the electrophoresis, the gel chamber was cooled down using tap water 
stream. After electrophoresis was completed, the gel was removed from the assembly 
and processed for blotting. 
 
2.2.3.2.3 Protein blotting using a semidry method 
 
Transfer buffer (pH 9) Volume 
Tris-HCl 48 mM 
Glycin 39 mM 
SDS     0.0374% (w/v) 
Methanol 15% 
ddH2O Add to 1 L 
 
Protein blotting involves the transfer of proteins to an immobilizing membrane. In this 
study a semidry transfer method originally described by Kyhse-Andersen, 1984 was 
used. Electrophoretic transfer of resolved proteins from a polyacrylamide gel to a 
polyvinylidene difluoride (PVDF) membrane was used. The PAGE-separated proteins 
were transferred on the PVDF membrane. Therefore, first of all, the PVDF membrane 
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(Imobilon-P Transfer Membrane No. IPVH00010 Pore diameter 0.45 µm, Millipore) 
was activated by incubation with methanol for 30 sec. The activated membrane was 
washed with ddH2O and equilibrated in transfer buffer for 10 min. Meanwhile 6 thick 
(Whatman®, No. 2668) and 2 thin (Whatman®, No. 2CHR) filter papers (5.2 x 8.3 cm) 
were soaked in transfer buffer for 10 min. The gel sandwich consisting of filter paper, 
SDS-PAGE gel, PVDF membrane and filter paper was prepared and arranged on the 
electroblotting apparatus (Biometra) (Fig.2.2). The air bubbles were eliminated between 
layers using glass rolling tube. Protein transfer was done at 45 mA (per gel) for 1.5 hour 
at room temperature (90 mA if two gels were blotted simultaneously). 
 
                                                 
 
                      
Fig.2. 2 Assembly of a horizontal electroblotting apparatus. 
        
                      
2.2.3.2.4 Staining 
 
Coomasse blue staining solution Volume 
Coomassie® Brilliant Blue R250 1% (w/v) 
Methanol 5% (v/v) 
Acetic acid 7% 
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In order to examine the efficiency and uniformity of the transfer, the polyacrylamid gel 
was stained after the transfer. The polycrylamide gel was incubated with Coomassie 
Blue staining solution for 5 min at room temperature and then destained by washing for 
overnight with water.   
 
2.2.3.2.5 Blocking 
 
Buffer C (pH 7.5) Volume 
Tris-HCl 25 mM 
NaCl 150 mM 
Tween 20 0.01 % 
ddH2O Add 1 L 
 
 
After blotting, the membrane was washed with ddH2O and incubated for one hour in 20 
ml buffer C supplemented with 5% milk powder (1 g) to block the protein bands on the 
membrane. 
 
 
2.2.3.2.6 Incubation with primary antibody 
The primary antibody was diluted (between 1:500 to 1:1500) in 5 ml buffer C 
supplemented with 5% milk powder (250 mg). The primary and secondary antibodies 
used in this work are given in table 2.5. Then the membrane was placed in a plastic foil 
sealed the edges with the sealing apparatus. Afterwards the plastic foil was filled with 
the antibody-containing buffer C and fixed on the overhead shaker and incubated 
overnight at 4
o
C. 
 
 
2.2.3.2.7 Incubation secondary antibody 
After incubation with primary antibody, the membrane was washed 3 times for 5 min 
with the buffer A. Then a horse radisch peroxidase conjugated IgG was added as a 
secondary antibody. The secondary antibody was diluted 1:10000 in 10 ml buffer A 
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supplemented with 0.5% (w/w) milk powder. The membrane was put in a 50 ml falcon 
tube containing the secondary antibody solution and incubated for one hour on the roll 
shaker. Then the membrane was washed 3 times for 5 min with the buffer A. 
 
 
Buffer A (pH 7.5) Volume 
Tris-HCl 25 mM 
NaCl 150 mM 
ddH2O Add 1 L 
 
 
          Table 2. 7 Primary and secondary antibodies used in this study. 
             
 
 
 
 
 
 
 
 
2.2.3.2.8 Chemiluminescent detection  
Chemiluminescence detection was used to specifically detect the antibody-targeted 
proteins of interest. Chemiluminescence detection uses light produced by the perox-
idase catalyzed reaction of luminol with hydrogen peroxide. The peroxidase enzyme is 
conjugated on the secondary antibody.  The chemiluminiscence detection was 
performed as follows: the membrane was incubated for 5 minutes with 1 ml 
Luminol/Enhancer and 1 ml Peroxide Solution (SuperSignal® West Pico Trial Kit, 
Perbio Science, Bonn). Then the membrane was dried on paper towel and put in 
transparent plastic foil and fixed in the developer cassette. Treated membranes were 
Antibody Dilution Manufacturer 
Primary Antibody               
OCT1 1:500 Novus Biologicals (#NBP1-51684) 
CYP2D6    1:1500 BD Gentest (#458246) 
GAPDH 1:2500 Serotec (#AHP996) 
Secondary Antibody   
Anti Mouse IgG-HRP          
Peroxidase (for OCT1,  
CYP2D6 and GAPDG) 
1:10000 Biomol (#111-035-003) 
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exposed to the ECL film (HyperfilmTM MP, Amersham) for 1-5 minutes in the 
autoradiographic cassette (FUJIX Cassette 2040) in darkness to detect the light emitted 
by the reaction. Then the film was developed using developer solution (Entwickler 
G150 AGFA) and the colour was fixed in fixer solution (Fixierer G354 AGFA). The 
presence of the protein of interest was determined by the appearance of a band at the 
appropriate molecular weight when compared to the molecular size standard. 
Alternatively, after treating the membrane with peroxide/luminol enhancer solutions, 
the membrane was placed in VersaDoc equipment (BioRad, Hercules USA) to visualize 
the signal using Quantity One software. 
 
 2.2.4 Work with Bacteria 
2.2.4.1 Growth media and growth conditions 
 
LB-media Volume 
Trypton   10 g 
Yeast extract  5 g 
NaCl  5 g 
ddH2O Up to 1000 ml 
 
 
Luria-Bertani (LB) complex medium was used for propagation of the E.coli strains top 
10 (Invitrogen). The LB medium was autoclaved at 120
o
C for 20 min. To prepare solid 
LB medium, 14 g/l Agar (AppliChem, Darmstadt) was added to 1 L liquid LB medium 
before autoclaving. The medium was left to cool down to 60
o
C or below and antibiotic 
were added to reach to the final concentration of 100µg/ml for Ampicillin, or 20µg/ml 
for Kanamycin. The solid media was poured into 92 mm disposable plastic plates.  The 
antibiotics were dissolved in ddH2O, and after passing through sterile filter (Minisart 
0.2 µm, Sartorius, Göttingen), aliquot and stored at -20°C until used. The prepared 
liquid and solid LB media were stored at 4°C. 
Bacterial strains were cultured both in liquid and solid media. Liquid cultures with 
appropriate antibiotic were either 100 ml in 500ml glass bottles (used for Midi Prep 
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plasmid extraction, see chapter 2.2.4.5) or 5 ml in 15 ml falcon tubes (for Mini Prep 
plasmid extraction, see chapter 2.2.4.4).  
 
2.2.4.2 Long-term Storage of bacterial strains  
The bacterial clones were stored for long time in 25% glycerol at -80°C. For this reason 
600 μl of fresh over night culture of the bacteria was mixed with an equal volume of 
sterile 50% glycerol solution in one 1.5 ml eppi and immediately store at -80°C. 
 
2.2.4.3 Transformation through electroporation 
Bacterial transformation is the process to introduce a foreign plasmid into bacteria and 
to use that bacteria to amplify the plasmid in order to make large quantities of it. 
Two major methods of bacterial transformation are known, the chemical (or heat) 
transformation and electroporation. For chemical transformation, cells are treated with 
divalent cations such as CaCl2. Cells treated in such a way called competent cells. To 
chemically transform cells, competent cells are mixed with the DNA on ice, followed 
by a brief heat shock. Then, cells are incubated with rich medium. For electroporation, 
cells are washed extensively with water to eliminate all salts. To electroporate DNA into 
cells, washed cells are mixed with the DNA to be transformed and then pipette into a 
plastic cuvette containing electrodes. A short electric pulse, about 2400 volts/cm, is 
applied to the cells causing smalls holes in the membrane through which the DNA 
enters.  
In this work electroporation was used to transform bacteria with genetically recombi-
nant plasmids as follows. First the amount of salt in electroporation mixture was 
reduced as much as possible by dialyzing the plasmid solution before electoporation. To 
do this, a 0.025 µm dialyze filter from type VSWP01300 (Millipore, Schwalbach) was 
put on petri dish filled with ddH2O from brighter side upward of water surface. The 
plasmid solution (usually 15 to 20 µl) was carefully pipette in the middle of the filter 
preventing direct contact with the ddH2O below. After 30 min, dialyzed plasmid 
solution was carefully transferred from filter to a new 1.5 ml eppi. 
A 50 μl Aliquot of one shot TOP10 electrocompetent E.coli (Invitrogen, Karlsruhe) was 
thawed and put on the ice. Then 10 μl of bacteria was diluted with 40 μl ddH2O and 
transferred in a pre-cooled 2 mm electroporation cuvette (PeqLab, Erlangen). After that 
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1-3 μl of Plasmid solution was added in the bacterial mix in the cuvette. The 
electroporation was carried out in Gene Pulser II (BioRad, Hercules USA) under 
following condition: power of 2.5 kV, capacitance of 25μF and resistance of 200 Ω. The 
high excitation puls should be between 4.5 and 5 milisec. Right after the electroporation 
800 μl LB-Medium pre-warmed at 37°C was added and then bacterial mix was 
incubated for 1 hour at 37°C to allow the expression of the antibiotic resistance genes 
encoded in the plasmid. After all 50 – 200 μl of the transformed bacteria were spread on 
LB-agar plates supplemented with corresponding antibiotic. 
 
2.2.4.4 Isolation of plasmid DNA by chloroform extraction (plasmid 
mini-prep) 
 
Resuspension buffer B1 Volume 
Tris-HCl (pH 8.0) l50 mM 
EDTA 10 mM 
RNase A 100 µg/ml 
                            add this after autoclave above mixture and store at 4°C 
 
 
Lysis buffer B2    Volume 
NaOH 200 mM 
SDS 1% (w/v) 
                           store at room temperature 
 
Neutralization buffer B3 Volume 
Potassium  acetate (pH 5.5) 3 M 
                            store at room temperature 
 
After transformation, sub-population of the clones appeared on the agar plate were 
picked up using sterile pipette tips, resuspended in 5 ml LB-medium supplemented with 
the corresponding antibiotics and incubated at 37°C for overnight. After that the 
growing cells were pelleted by centrifugation (4000 rpm, 10 min, RT; Centrifuge 5810 
R; Eppendorf). The supernatant was discarded and the pellet was resuspended in 250µl 
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resuspension buffer (B1) and transferred in a 1.5 ml Eppendorf reaction tube. The cells 
were lysed, 250 µl Lysis buffer (B2) was added and shaked strongly. The reaction was 
neutralized by adding 350 µl neutralization buffer (B3) and mixed through invertion. In 
this step denatured proteins and genomic DNA will be appeared as white flakes. To 
remove the debris and purify the plasmid following steps were performed. Samples 
were centrifuged at 13000 rpm for 10 min at RT (Biofuge pico, Heraeus, Hanau). The 
supernatant was transferred in a new 1.5 ml eppendorf reaction tube and 500 µl mixture 
of chloroform/isoamylalchohol (24:1 v/v) was added and vortexed under the fume hood. 
The samples were centrifuged again at 13000 rpm (Biofuge pico) for 5 min at RT 
(Biofuge pico) and the upper phase was transferred to the new 1.5 ml Eppendorf 
reaction tube. The plasmid DNA was pelleted by adding 650 µl iso-propanol (pre-
cooled at -20°C). The samples were centrifugated at 13000 rpm for 15 min at 4°C 
(Biofuge fresco, Heraeus, Hanau). The supernatant was discarded and the pellet was 
washed once with 1000 µl of 70% ethanol (pre-cooled at -20°C). After the 
centrifugation (13000 rpm, 10 min, 4°C) the supernatant was removed, the pellet was 
dried at 37°C until it became transparent. The pellet containing the plasmid DNA was 
resuspended in 50 µl TE-buffer and quantified and qualified photometricaly (as 
described in chapter 2.2.1.3).                              
                                                                              
2.2.4.5 Isolation of plasmid DNA by solid extraction (plasmid midi 
prep) 
In order to isolate large quantities of high-quality plasmid DNA for transfection of 
eukaryotic cells a midiprep plasmid extraction was made using PureYieldTM Plasmid 
Midiprep System (Promega, Mannheim) according to manufacturer’s instruction. 
Briefly, the bacteria were pre-cultured for 5 hours at 37°C in 5 ml LB medium 
supplemented with corresponding antibiotic. Afterwards 10 µl of the pre-culture was 
transferred to a 500ml glass flask containing 100 ml LB medium with the corresponding 
antibiotic (dilution 1:10000). This “main” culture was incubated overnight at 37°C. On 
the next day, the culture was transferred into two 50 ml falcon tube, the cells were 
pelleted using centrifugation (5000 g, 10 min, RT, Centrifuge 5810 R, Eppendorf) and 
the supernatant was discarded. The cell pellet was resuspended in 3ml cell resuspension 
solution and transferred to 50 ml Beckman centrifuge tube (Beckman, München). Then 
3 ml cell lysis solution was added and mixed by gently inverting the tube 3–5 times. 
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Following 3 min incubation, 5 ml neutralization solution was added, mixed the tube 5–
10 times by gently inverting and incubated for 2-3 min at room temperature. The 
cellular debris was pelleted by centrifugation (15000g, 10 min, RT, J2-21 M/E 
Centrifuge, JA-20 Rotor, Beckman). 
Meanwhile the PureYield™ clearing column (blue) was assembled on the top of a 
PureYield™ binding column (white), and the assembled columns were stacked into the 
vacuum manifold was placed. Then the supernatant after the centrifugation was 
decanted into the PureYield™ clearing column. By applying vacuum the lysate was 
passed through the clearing membrane in the PureYield™ clearing column, and the 
DNA was bound to the binding membrane in the PureYield™ binding column. 
Afterwards 5 ml of Endotoxin Removal Wash solution was added to the column, and 
the vacuum was allowed to pull the solution through the column. Then 20ml of Column 
Wash Solution was added to the column, and again the vacuum was used to draw the 
solution through. The membrane was dried by applying the vacuum for 1 min without 
adding any solution on the column. The PureYield™ binding column was removed 
from the vacuum manifold and placed into a new 50ml disposable plastic tube. The 
plasmid DNA was eluted by adding 400–600μl of nuclease-free water (pre-warmed to 
70°C) to the DNA binding column and centrifugation (1800g, 5 min, RT). Finally the 
eluted plasmids were transferred into a 1.5 ml eppi and quantified photometricaly and 
analyzed using agarose gel electrophoresis (as described in chapters 2.2.1.3 and 2.2.1.2 , 
respectively). 
        
2.2.5 Mammalian cell culturing 
2.2.5.1 Used cell lines and culturing conditions 
Flp-In
TM
 T-REx
TM
 293 cell line is a derivate of the human embryonic kidney cell line 
HEK 293, that contains Flp Recombination Target (FRT) integrated into genome. The 
presence of FRT enables stable transfection using the Flp-In
TM
 system (Invitrogen). 
Chinese Hamster Ovary (CHO) cell line (Invitrogen) was also used in this study. This 
cell line is the most widely used mammalian cells for transfection, expression, and 
large-scale recombinant protein production. 
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Flp-In
TM
 TREx
TM
 293 cells were cultured in DMEM medium supplemented by 10% 
FBS and 1% Penicillin/Streptomycin and 0,1% Zeocin. The cells were cultured at 37
o
C 
under 5% CO2 and 95% humidity.  
Upon reaching approximately 80% confluency, the cells were subcultured at a ratio of 
1:5. Thereto, the old culture medium was removed. Cells were detached from the flasks 
by adding 5 ml fresh medium and pipetting up and down. Then 1 ml of the cells were 
transferred into a new 75 cm
2
 culture flask and placed in the 5% CO2 incubator. Media 
was changed every 3-4 days. 
If the cells were prepared for a transport experiment a tripsination was performed to 
assure homogenous distribution of single cells for the experiments. Therefore, the cells 
were treated with 5 ml of trypsin (TrypLE™ Express, Gibco/Invitrogen) for 
approximately 4 min at 37°C. The trypsin was neutralized by addition of an equal 
volume of serum-containing growth media. The cells were collected in 15 ml falcon 
tubes and centrifuged at 300 x g for 3 min. The trypsin and media were removed and the 
cell pellet was resuspended in fresh media and used to determine the cell count for 
plating. 
 
2.2.5.2 Freezing cell lines 
Cells were periodically frozen to maintain a stock of the cell line for future use. 
For this reason, the cells were grown in 75 cm² culture flask. After reaching 80% 
confluency, the cells were transferred to 50 ml falcon tube and pelleted by 
centrifugation (300 g, 3 min at room temperature; Heraeus Laborfuge 400R). The 
supernatant was removed and the cell pellet was resuspended in 6.8 ml of ice-cold 
freezing medium (90% FBS with 10% DMSO). Aliquots of 1.6 ml resuspended cells 
were transferred into 2ml cryovials (Nunc, Thermo Scientific, Denmark) and placed on 
ice pack (ice + NaCl + water) for 1 hour. Then the cells transferred to -80
o
C 
approximately for one week and afterwards stored in liquid nitrogen (-170
o
C).  
 
 
2.2.5.3 Defreezing cell lines 
DMEM medium (with 10% FBS and 1% P/S) was prewarmed at 37
o
C. An aliquot of 
cells was removed from the liquid nitrogen (-170
o
C) tank and rapidly thawed by holding 
in a hand or using the 37
o
C water bath. The cells were rapidly transferred to 15 ml 
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falcon tube containing 10 ml of pre-warmed DMEM medium (with 10% FBS and 1% 
P/S). The cells were pelleted by centrifugation (300 g, 3 min, RT; Heraeus Laborfuge 
400R). Then supernatant was discarded. The cells were resuspended in 5 ml DMEM 
medium (with 10% FBS and 1% P/S), transferred to 25 cm
2
 culture flask and cultured 
under standard condition. These cells can be used for experiment after 2-3 times passage 
to assure they reach to stable vital condition. 
 
2.2.5.4 Transfection 
Transfection is the process of introducing exogenous nucleic acids into eukaryotic cells. 
There are various methods of introducing foreign DNA into a eukaryotic cell like 
electroporation, lipofection and other chemical-based transfection such as calcium 
phosphate.  The technique used for transfection in this study was lipofection. In this 
technique the DNA to be transfected is coated by a lipid, which either interacts directly 
with the plasma membrane of the cell or is taken into the cell by nonreceptor-mediated 
endocytosis (Sambrook and Russell, 2007). 
 
2.2.5.4.1 Transient transfection 
The following procedure was used for transiently expression of the gene of interest in 
HEK293_TRex cells: 500 µl of poly-D-lysine (poly-D-lysine hydrobromide Sigma, 
100mg dissolved in 50 ml H2O) was added to each well of a 12-well plate and 
incubated for 15 min at 37
o
C. The poly-D-lysine was recollected (the same poly-D-
lysine solution may be reused up to 20 times) and the plates were let dried for 10 min 
with open lids in sterile bench. In each well 6x10
5
 cells were plated and incubated for 
overnight. A master-mix with 100µl of DMEM pure medium and 12µl FuGene 6 
transfection reagent (Roche, Mannheim) was prepared in 1.5 ml Eppendorf reaction 
tube and incubated for 5 min at room temperature. Four µg plasmid DNA was added 
and incubated for additional 15 min at RT. In the meantime, the cells grown in the 12-
well plate were washed with 1 ml of DMEM medium supplemented with 10% FCS 
serum. After that 1 ml of the same medium was added to each well and DNA/FuGene6 
mix was added. After 4-6 hours of incubation, the medium was changed with DMEM 
medium supplemented by 10% FBS serum and 1% Penicillin/Streptomycin antibiotics. 
The transfected cells were used 24 to 48 hours later for further experiments. 
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2.2.5.4.2 Stable transfection using Flp recombinase 
Unlike transient transfection, in which introduced DNA persists in cells for few days 
only, stable transfection results in chromosomal integration of the transfected DNA. 
And the stably transfected cells pass the introduced DNA to their progeny. This enables 
long-therm analyses of the transfected cells.  In this work, HEK Flp-In
TM
 TREx 293 cell 
line was used which is stably transfected with the plasmid pFRT/lacZeo. This plasmid 
contains Flp-Recombination Target (FRT), which is a target site for Flp recombinase 
and Zeocin resistance region for selection of the recombinant cells. In order to stably 
transfect the gene of interest in this cell line, an expression vector (pcDNA5.1) 
containing the gene of interest (GOI) was used. The pcDNA5.1 vector contains a FRT 
site linked to the hygromycin resistance gene and the gene of interest may be cloned 
under the control of the human cytomegalovirus (CMV) promoter (Fig. 2.3). The FRT 
site is necessary for Flp recombinase-mediated integration. Hygromycine is used for 
selection of a cell line stably integrated the pcDNA5.1 vector in their genomes. Another 
plasmid, the pOG44, is cotransfected with the pcDNA5 vector. The pOG44 plasmid 
enables the transient expression of the Flp recombinase under the control of the human 
CMV promoter.  
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Fig.2. 3 Major features of the stable transfection using the Flp-In system for targeted chromosomal 
integration. 
 
Following procedure was used for stable transfection using Flp-in system in this work: a 
6-well plate was coated with poly-D-lysine for 15 min and was let to dry with open lid 
under the sterile bench for 15 min.  9 x 10
5
   to 1 x 10
6
 cells were plated in each well of 
the 6-well plate and incubated overnight to reach to 80% confluence. 
For the co-transfection, a master mix containing 100µl of DMEM medium without 
additives and 12µl FuGene 6 transfection reagent (Roche, Mannheim) per transfection 
well was prepared. The mix was incubated for 5 min at room temperature. The master 
mix was distributed to Eppendorf reaction tubes (112µl per well) and 4 µg DNA was 
added to each mixture and incubated for 15 min at room temperature. The DNA 
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represents a mixture of the pOG44 plasmid and pcDNA5.1 plasmid carrying the gene of 
interest in a ratio of 9:1. All plasmids were isolated from bacteria using the midi prep 
extraction method (chapter 2.2.4.5). Meantime the cells plated in 6-well plate were 
washed with 2 ml of DMEM medium supplemented with 10% FCS serum and 1.9 ml of 
the same medium was added to each well. Following the 15 min of incubation the 
DNA-FuGene 6 mix was added to each well and incubated for maximum 72 hours. 
48 hours after the cotransfection, the cells were transferred to the 92 mm Petri dishes 
(Falcon, Schütt, Goettingen) and cultured overnight in 9 ml of DMEM medium 
supplemented with 10% FBS serum and 1% Penicillin/Streptomycin antibiotics. On the 
day after, the medium was removed and DMEM medium containing 10% FBS serum 
and 1% Penicillin/Streptomycin and the screening antibiotic (either hygromycine or 
puromycin) was added and incubated until single colonies appeared. Each colony was 
picked up and transferred into a single well of a 12-well plate and then to 6-well plate 
with same medium used for selection. Finally the cells were passaged to a 25 cm
2
 
culture flask and then to the 75 cm
2
 culture flask. Stable transfection was confirmed by 
the means of DNA, RNA, protein and activity analyses.  
 
2.2.5.4.3 Determination of optimal screening antibiotic concentration 
An essential role in successfully generation of stably transfected cell lines is 
determination of the minimum concentration of antibiotics which is required to kill 
untransfected host cell line. For this purpose, preliminary experiment was performed 
using HEK TRex cells exposed for 1-2 weeks to DMEM culture medium containing 
10% FBS serum, 1% Penicillin/Streptomycin and varying concentrations of hygromycin 
B (Invitrogen, Karlsruhe). Concentrations of 0, 10, 100, 200, 300, 400 and 600 µg/ml 
were used. The concentration of 300 µg/ml hygromycin was chosen as a minimum 
concentration and was used to screen for successfully transfected cell lines. 
Additionally, the appropriate concentration of puromycin (Invitrogen, Karlsruhe) 
necessary to screen CYP2D6_IRES_POR transfected cells from untransfected cells was 
determined. To do this, the HEK-TRex cells were cultured for 5-10 days in DMEM 
culture medium containing 10% FBS serum, 1% Penicillin/Streptomycin and varying 
concentrations of puromycin (0, 5, 10, 20, 50, 100 and 200 ng/ml). The concentration of 
5 ng/ml puromycin was chosen as a minimal concentration and was used to screen for 
successfully transfected cell lines. 
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The cells overexpressing CYP2D6 under puromycine selection required different 
hygromycine concentration to select for Flp-In-mediated stable transfection. To 
determine the optimal hygromycine concentration in this case, CYP2D6_IRES_POR 
overexpressing HEK cells were cultured for 1-2 weeks in DMEM medium containing 
10% FBS serum, 1% Penicillin/Streptomycin and varying concentrations of hygromycin 
B. Concentrations of 0, 10, 20, 50, 100, 200 and 400 µg/ml were used. The 
concentration of 10 µg/ml of hygromycin was selected as a minimum concentration for 
screening double transfected cells. 
 
2.2.6 Flow Cytometry 
 
Blocking buffer: (pH 7,2- 7,4)   Volume 
PBS 45 ml 
FBS 5 % (v/v) 
 
 
Permeabilization buffer Volume 
PBS  45 ml 
FBS 5 % (v/v) 
Triton X-100   0.5 % (v/v) 
 
 
Flow cytometry is a technique that simultaneously measures multiple physical 
characteristics of single particles, usually cells, as they flow in a fluid stream through a 
beam of light. The properties measured include a particle’s relative size, relative 
granularity or internal complexity, and relative fluorescence intensity (e.g. resulting for 
antigen-specific labeling). These characteristics are determined using an optical-to-
electronic coupling system that records how the cell or particle scatters incident laser 
light and emits fluorescence. A single cell analyzes for four parameters (FSC, SSC, 
FITC, and PE fluorescence). Forward-scattered light (FSC) is proportional to cell-
surface area or size, whereas side-scattered light (SSC) is proportional to cell 
granularity or internal complexity. Two other parameters reflect fluorescence 
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characteristics of the cells using fluorochromes like fluorescein isothiocyanate (FITC) 
and phycoerythrin (PE). One of the fluorochromes used in flow cytometry is FITC. In 
the absorption spectrum of FITC, the 488-nm line is close to the FITC absorption 
maximum. Excitation with this wavelength will result in a high FITC emission. Using 
secondary antibody conjugated to this fluorochrome we can identify protein of interest 
in a mixed sample. Because the amount of fluorescent signal detected is proportional to 
the number of fluorochrome molecules on the particle. 
In this work following flow cytometry protocol was used. First the 10 x 10
6
 cells were 
trypsinized with 4 ml TrypLE™ Express (Gibco/Invitrogen) for 4 min in incubator. The 
trypsin was inactivated by adding 4 ml DMEM medium and the cells were passed 
through the 40 micron cell strainer (Falcon) and collected in 50 ml falcon tube. The 
cells were pelleted by centrifugation (1400 rpm, 3 min, Room Temperature), washed 
once with PBS buffer, resuspended in 200 µl blocking buffer and transferred into 2 ml 
Eppendorf reaction tubes (2.5 x 10
5
 cells/tube). Next the cells were fixed with 500 µl 
Histofix 4% (Carl Roth, Gmbh, Karlsruhe) for 5 min at RT and pelleted by 
centrifugation (300 g, 4 min, 4
o
C). The supernatant was discarded; the pellet was 
washed with 1 ml PBS buffer and again centrifuged (300 g, 4 min, 4
o
C). After removing 
the supernatant, 1 ml permeabilization buffer was added to each sample and incubated 
for 10 min on ice and then centrifugation (300 g, 4 min , 4
o
C). The supernatant was 
discarded, the cells were resuspended in 100 µl primary antibody in blocking buffer 
(1:400 dilution) and the samples were incubated on ice for 30 min. The cells were 
washed twice in 1 ml blocking buffer and centrifuged (300 g, 4 min, 4
o
C). A hundred µl 
secondary antibody labeled with fluorochrome (1:1000 dilution in blocking buffer) was 
added to each sample and incubated on ice for 30 min. Used primary and secondary 
antibodies are listed in table 2.6. After the incubation, 1 ml blocking buffer was added 
and the cells were pelleted by centrifugation (300 g, 4 min, 4
o
C). The supernatant was 
removed and the pellet was washed again with 500µl blocking buffer, resuspended in 
450 µl PBS and transferred in 10 ml FACS tubes (Falcon). The measurements were 
performed using flow cytometer BD LSR II (BD Bioscience) and the data was analyzed 
using BD FACSDiva software. 
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               Table 2. 8 List of antibodies used for flow cytometry and immunocyto staining 
 
 
 
 
 
 
 
 
2.2.7 Immunocytochemical staining 
 
Blocking buffer: (pH 7,2- 7,4)   Volume 
PBS 45 ml 
FBS 5 % (v/v) 
Triton X-100   0.5 % (v/v) 
BSA 1% (v/v) 
 
In order to investigate the expression and localization of OCT1 transporter and 
CYP2D6 metabolizing enzyme in HEK cells overexpressing OCT1 alone, 
CYP2D6::IRES::POR or combination of OCT1::CYP2D6::IRES::POR, specific 
primary antibodies for OCT1 and CYP2D6 proteins were used and visualized by 
fluorescence and confocal microscopies using secondary antibody conjugated with 
fluorochrome. The described above transgenic cells were trypsinized using TrypLE™ 
Express medium (Gibco/Invitrogen) for 4 min in a 5% CO2 incubator. The cells were 
harvested and passed through a 40 micron cell strainer (BD falcon) and collected in 50 
ml falcon tube. Then the cells were centrifuged (1400 rpm, 3 min), the supernatant was 
removed and the cells were washed one time with PBS buffer. Next the cells were 
plated on the sterile cover-slip in 12 well-plate that previously coated with poly-D-
lysine. After reaching the cells to 80% or full confluency, the culture medium was 
removed, 500 µl Histofix 4% (Carl Roth, Gmbh, Karlsruhe) was added to each eppis as 
a fixative agent and incubated for 20 min at RT. Then the wells were washed with 1 ml 
Antibody Dilution     Manufacturer 
Primary Antibody               
OCT1 1:400 Novus Biologicals (#NBP1-51684) 
CYP2D6    1:1000 BD Gentest (#458246) 
Secondary Antibody   
Goat anti mouse 
Alexa 488 
1:400 Invitrogen (# A-11001) 
Goat anti rabbit 
Alexa 546 
1:400 Invitrogen (# A11010) 
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PBS buffer and 1 ml blocking buffer was added to each well and incubated for 90-120 
min at RT. After that 500 µl blocking buffer containing the primary antibody (in a 
dilution 1:400) was added to each well and the samples were incubated for 60 min at 
RT or overnight at 4
o
C for extremely packed cells. Afterwards 1 ml blocking buffer was 
added to each well and incubated for 3 min and subsequently washed once with1 ml 
blocking buffer and then 500 µl/well secondary antibody labeled with fluorochrome 
(1:400 dilution in blocking buffer) was added and incubated at RT for 60 min. After 
incubation time, 1 ml blocking buffer was added to each well and incubated for 3 min 
and this step repeated again and finally the wells were washed with 500µl PBS buffer. 
The primary antibodies used here are the same listed in table 2.8 chapter 2.2.6. To 
prepare the slide for fluorescence or confocal microscopy, one drop of Fluoromount-G 
(Southern Biotech) was added to slide and the cover-slip invertly transferred on slide. 
For this purpose the slide must be covered with this buffer cover with no air bubbles 
and after drying the slides, they were used for imaging by confocal laser scanning 
microscopy (Carl Zeiss, Jena). 
 
2.2.8 MTT assay 
 
Stock solution for MTT (5mg/ml) Volume 
Thiazolyl Blue Tetrazolium Bromid            100 mg 
 PBS 20 ml 
                      (and then filtrated and aliqouted and stored in 1-2 ml at -20
o
C) 
 
 
Lysis buffer  Volume 
Sodiumdodecylsulfate (SDS) 20 g 
HCl 1M                                               2 ml 
ddH2O   98 ml 
 
 
This colorimetric assay is used for measuring the activity of enzymes that reduce the 
yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to 
formazan, giving a purple colour. It is used to determine cell cytotoxicity on application 
of different substances, which would disrupt metabolic functions. Since the reduction of 
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MTT to formazan takes places only by active reductase enzymes, the test is a measure 
of active and viable (living) cells.  
The 6-well plates were pre-coated with poly-D-lysine for 15 min and 8 x 10
5
  cells per 
well were grown in 1mL DMEM medium supplemented with 10% fetal bovine serum 
(FBS, Gibco/Invitrogen) and 1% penicillin/streptomycin antibiotics. After 24 hours 50-
70% confluency was reached.  
The experiment was started by adding 1mL of F12 medium (Gibco, Invitrogen) 
with/without desired concentration of the test substrate (100µM irinotecan) to each well 
and the cells were incubated for 15 min at 37
o
C. Following this incubation, cells were 
washed and incubated in 1mL of the F12 medium overnight. On the next morning, the 
medium was removed and cell viability was determined by adding 1 ml MTT (750 
µg/ml ) to each well and incubated for 2 hours at 37
o
C. The cells were lysed by 1mL of 
lysis buffer and the plates were covered by foil and placed on shaker incubator for over-
night. After that purple formazan crystals were diluted in acidified isopropanol (96% 
isopropanol + 4% 1 N HCl) and the absorbance was measured at 570 nm. 
                        
2.2.9 Measurments of OCT1 activity  
2.2.9.1 ASP
+
 uptake assay 
The method described here is used to quantify the activity of organic cation transporter 
OCT1 using the model substrate ASP
+
 (4-(4-(dimethylamino) styryl)-N-
methylpyridinium. ASP
+
 is a fluorescent organic cationic mitochondrial dye that 
possesses strong fluorescence after uptake into the cells (excitation 475 nm and 
emission 605 nm), but has negligible fluorescence in the extracellular medium. 
The stock solution of ASP
+
 (50mM, Invitrogen) in Dimethylformamid (DMFA) was 
prepared and stored it in the fridge. The cells were cultured in DMEM medium 
supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 µg/ml) and 
Hygromycine B (100 µg/ml). The ASP
+
 uptake experiments were performed using 
Hank’s buffered salt solution medium (HBSS, Invitrogen). HBSS was supplemented 
with varying concentrations of ASP
+
: 0, 1, 5, 10, 20, 50, 100, 200 and 400 µM.  
The ASP
+
 uptake assay was performed as follows: 800 000 cells per well were plated in 
a 12 well plate pre-coated with 1 ml poly-D-lysine and incubated for 48 h to reach full 
confluence. On the day of measurement, the cells were washed two times with 1 ml pre-
warmed HBSS medium. Uptake measurements were performed at room temperature. 
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The uptake measurement was started by adding 0.5 ml pre-warmed HBSS medium 
containing ASP
+
. The uptake was stopped after 3 min by adding 2ml ice-cold HBSS. 
The medium was discarded and the cells were lysed in 0.5 ml RIPA buffer (see section 
2.2.3.1). Duplicates 200 µl each of the cell lysates were transferred into a black 96-wells 
plate with a transparent bottom (Nunce, Wiesbaden) for fluorescence measurement.  
The amount of intracellular ASP
+
 was determined using plate photometer (TECAN-
Ultra, TECAN, Crailsheim, Germany) with excitation and emission wavelengths of 485 
and 612 nm respectively. The rest of the cell lysates were transferred to another 
Eppendorf reaction tubes to measure the protein concentration for each sample for 
further data normalization (See section 2.2.3.1). 
Alternatively, the ASP
+
 uptake was evaluated using fluorescence microscopy. For this 
purpose, the uptake experiment was carried out as described above. The uptake was 
stopped after 3 min by adding 2ml ice-cold HBSS, the medium was discarded and 1ml 
ice-cold HBSS was added. The ASP
+
 uptake was visualized using fluorescence 
microscopy (Carl Zeiss, Jena). 
In experiments performed to measure the functional activity of OCT1 at different pH an 
HBSS medium with different pH (5.4, 6, 6.4, 7, 7.4, 8, 8.4 and 9) containing 1 µM 
ASP
+
 was used. The pH adjustment was performed using NaH2PO4 (1M) and Na2HPO4 
(1M). 
 
2.2.9.2 Inhibition of ASP
+
 uptake assay 
For this assay, the cells were plated in 12 well plates according to the method described 
in the previous section. After reaching full confluence, the cells were washed twice with 
1 ml pre-warmed HBSS medium and then 0.5 ml warm (37
o
C) HBSS medium 
containing 1 µM ASP
+ 
and varying concentrations (0, 1, 10, 50, 100, 500, 1000 and 
5000 µM) of the respective inhibitory substance was added. The uptake was stopped 
after 3 min by adding 2ml ice-cold HBSS to each well. The medium was discarded, the 
cells were lysed and intracellular ASP
+
 and total protein were quantified as described in 
the previous chapter. 
Graphical representations and regression analyses were performed using Sigma Plot1 
version 11.0 (Systat Software Inc., Chicago, IL, USA). The half-maximal inhibitory 
concentration (IC50) was calculated by regression analyses of the equation:  
 
                                                                                                        Materials and Methods 
76 
 
Y(C) = Ymin + (Ymax _ Ymin) /1 + (C/IC50) 
-H
 
 
where C is the drug concentration, Y(C) is the ASP
+
 or MPP
+
 uptake as inhibitor at a 
drug concentration of C, Ymin and Ymax are the maximal and minimal ASP
+
 or MPP
+
 
uptakes, respectively, and H is the Hill slope. 
 
2.2.9.3 Direct measurements of drug uptake  
 
 Lysis buffer Volume 
Acetonitril 80 ml 
Sodium acetate buffer (pH 5.0) (0.05 mol/l) 20 ml 
 
 
Runing buffer Volume 
Acetonitril 20 ml 
Sodium acetate buffer (pH 5.0)  
(0.05 mol/l) 
80 ml 
 
 
The measurement of the direct uptake of substances by cells was performed as de-
scribed elsewhere (SAADATMAND et al.; TZVETKOV et al.). Briefly, the 100 mm plates 
(BD Falcon, Heidelberg, Germany) were coated with 2 ml poly-D-lysine (P0296, 
Sigma-Aldrich) and incubate for 15-30 min in the CO2 incubator. The poly-D-lysine 
was recollected and the plates were kept open lid under the sterile bench to dry. Then 
4x10
6
 cells were plated and incubated for 48 hours at 37
o
C to reach full confluence. On 
the day of the measurements, the cells were washed with 10 ml pre-warmed HBSS (pH 
7.4). The experiment was started by adding 5 ml pre-warmed HBSS medium (pH 7.4) 
supplemented with the analyzed drug at concentration of 1μM. The cells were incubated 
for 1 min and the reaction was stopped with 20 ml ice cold HBSS (pH 7.4). The cells 
were rapidly washed twice with the ice cold HBSS, resuspended in 2 ml ice cold HBSS 
(pH 7.4) and transferred in 2 ml Eppendorf reaction tube and immediately placed on ice. 
An aliquot of 500µl of the cell suspension was transferred to another tube and was used 
to measure the protein concentration needed for normalization. That remaining cells 
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were pelleted by centrifugation (3000 rpm, 10 min, 4
o
C) and supernatant was discarded. 
The cells were lysed by adding 1 ml lysis buffer and 10µl of 10µg/ml internal standard 
was added. All drugs used and the corresponding internal standards are listed in table 
2.7. The sample was centrifugated (13000 rpm, 10 min, 4
o
C) to remove the cell debris. 
The supernatant was transferred to the glass tube, evaporated by incubating at 37
o
C 
under a nitrogen stream for 60 min. The residue was reconstituted in 200 µl running 
buffer and mixed by vortexing. Then 100 µl of the solution was transferred to HPLC 
tube immediately prior to analysis and thereof 50 µl aliquots were injected on the 
column. The protocols for drug quantification by HPLC are described in chapter 2.2.11. 
 
                                 Table 2.9. Drugs measured by HPLC in this study  
Drug Internal standard 
Tropisetron Ondansetron 
Ondansetron Tropisetron 
Tramadol O-desmethyl-tramadol 
O-desmethyltramadol Tramadol 
Debrisoquine Venlafaxin 
 
 
 
For measuring the concentration dependence of the drug uptake, the cells were 
incubated for 1 min with 5 ml pre-warmed HBSS medium (pH 7.4) containing 
increasing concentrations of substances. The concentrations varied from 1 to 40 μM for 
debrisoquine and from 0 to 200 µM for ASP
+
. The KM and Vmax values were estimated 
by regression analyses based on the Michaelis–Menten equation using Sigma Plot 
software version 11.0 (Systat Software Inc., Chicago, IL, USA). 
For measuring the time-dependence of drug uptake, the cells were incubated with 5 ml 
pre-warmed HBSS medium  (pH 7.4) supplemented with 1µM of the analyzed drug for  
30 sec, 1 min, 5 min, 15min or 30 min.  
Drug-drug interaction at the OCT1 transporter were measured as follows: the cells were 
exposed to 5 ml pre-warmed HBSS medium  (pH 7.4)  supplemented with 1 µM of the 
analyzed drug in combination with increasing concentrations of inhibitors (from 100 to 
200 µM) and incubated for 1 min and the experiment was followed as described 
previously in this chapter.  
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To measure the activity of CYP2D6 enzyme using microsome, 500µg of extracted 
microsome was treated with increasing concentration of debrisoquine (1, 10 and 100 
µM). For this reason, a 96 well plate with black walls and clear bottom was used. Then 
100 µl of the enzyme/substrate mix (mixture of CYP2D6-containing microsome and 
varied concentration of debrisoquine) was added to each well and incubated for 5 min at 
37°C. The reaction was started by adding 100µl of the cofactor mix (a mixture 
delivering and assuring the regeneration of NADPH, see section 2.2.5.2) and incubated 
for 60 min at 37
o
C. After this incubation time, the reaction was stopped by adding 75 µl 
stop solution (see section 2.2.5.2) and the amount of 4-OH debrisoquine was measured 
using HPLC. 
For measurement of drug-drug interaction at the OCT1 transporter and CYP2D6 
enzyme, the cells were exposed to 5 ml pre-warmed HBSS medium (pH 7.4) 
supplemented with 10 µM of the debrisoquine in combination with increasing 
concentrations of paroxetine as a inhibitor for OCT1transporter or CYP2D6 enzyme (0, 
0.1, 0.2, 0.5, 1, 5, 10 and 50 µM) and incubated for 3 min and the experiment was 
followed as described previously in this chapter. 
 
 
2.2.10 Measurements of CYP2D6 activity 
2.2.10.1 Microsome Preparation 
 
 
 
 
 
 
 
Microsome Buffer  
(TES without inhibitor and EDTA)  
Volume 
Tris-HCl (pH 7.4) 20 mM 
Sucrose 254 mM 
 
 
Homogenization buffer (TES) Volume 
Tris-HCl (pH 7.4) 20 mM 
Na-EDTA 5 mM 
Sucrose 254 mM 
Pefablock SC (Roche) 0.2 mM 
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Human liver microsomes (HLM) are used widely to characterize the role of cytochrome 
P450s (P450) and other enzymes in drug metabolism. Typically, liver samples are 
homogenized and centrifuged at a lower force to form a crude pellet of cell debris, 
nuclei, peroxisomes, lysosomes, and mitochondria (premicrosomal pellet). The resulting 
supernatant is then centrifuged at a higher force to precipitate the microsomes. The 
microsomal pellet is resuspended in a final suspension buffer and is then ready for use 
in incubation studies (Nelson et al., 2001). In this study we modified the techniques 
which usually used to extract the microsome from the tissue in order to isolate 
microsome from mammalian cell lines like the CYP2D6 and POR overexpressing HEK 
cells. 
20 x 10
6
 cells were cultured for 3 days in 75 cm
2
 culture flask. The medium of the 
culture flask was discarded; the cells were resuspended in 5 ml of homogenization 
buffer and transfered to a Teflon-glass homogenizer (15 ml volume, Sartorius, 
Goettingen, Germany). The collected cells were homogenized with 5-10 strokes at 1000 
rpm using Potter S homogenizer (Sartorius, Goettingen, Germany). Strokes were even 
and steady which lasted approximately 15 sec for passage. The glass tube was 
submersed in a small bucket of ice and water during the homogenization. This cell lysis 
was confirmed analyzing a mixture of 20µl trypan blue and 20 µl of homogenized cells. 
The majority of the cells (90%) should be lysed and tryptan blue positive. 
Then the samples were transferred to centrifugation tubes (50 ml falcon tubes) and 
centrifugated (3000 g, 30 min at room temperature; Eppendorf 5810R). The supernatant 
was transferred into the 13ml screw cap tubes and centrifuged at higher force (17000 g, 
30 min at room temperature; JA20, 12000 rpm, in Beckman J2-21 M/E). Afterwards, 
the supernatant was transferred in centrifugation tube (Ti 50.2) and balanced by 
weighing and ultra-centrifugated (100000 g, 60 min at room temperature; Ti 50.2, 
29000 rpm, rmax 107,9mm in Beckman L8-70 M-Ultracentrifuge). After that supernatant 
(representing cytosolic proteins) was transferred in a falcon tube and aliqouted in 2 ml 
Eppendorf reaction tube and stored at -80
o
C and. The pellet (containing the 
microsomes) was resuspended in 3 ml microsome buffer, aliqouted in 70 µl fractions 
and stored at -20
o
C for measuring the protein concentration and functional assay. 
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2.2.10.2 AMMC assay 
 
AMMC (10mM) Volume 
AMMC 25 mg 
Acetonitrile 5.8 ml 
                      aliquoted to 250 µl in 1.5 ml tubes and stored at -20
o
C. 
 
Phosphate buffer (pH7.4) Volume 
NaH2PO4 100mM 
Na2HPO4 100mM 
 
Stop solution Volume 
Acetonitrile 40 ml 
0.5M Tris (base) 10 ml 
 
20x (1/20) cofactors solution Volume 
Glucose 6-Phosphate (Sigma #G7879) 282 mg 
MgCl2(Sigma #M8266) 47.6 mg 
NADP
+
 (Sigma #N5755) 3.72 mg 
ddH2O Up to 5ml 
                   The solution was aliquoted at 200µl and stored at -20
o
C. 
 
100x G6PDH solution Volume 
Glucose 6-phosphate dehydrogenase  
(G6PDH, Sigma #g6378) 
30 U 
5mM Na-Citrate Up to 1ml 
                   The solution was aliquoted at 100µl and stored at -20
o
C. 
 
2 ml 2X Cofactor Mix Volume 
“1/20” the cofactor solution 200µl 
G6PDH solution 40 µl 
Phosphate buffer (pH7.4) Up to 2mL 
        This mix was incubated at 37°C in a water bath. 
 
2 ml 2X Enzyme/Substrate Mix Volume 
Microsome protein 0.8 mg 
1/100 diluted AMMC stock solution 10 µl 
0.1M Phosphate buffer (pH 7.4)  Up to 2 ml 
               (pre-warmed to 37oC in a water bath) 
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The activity of CYP2D6 enzyme in produced microsomes was measured using an 
AMMC probe (3-[2-(N,N-diethyl-N-methylammonium)- ethyl]-7- ethoxy-4-
methylcoumarin; Gentest, BD Biosciences). If active CYP2D6 is present, the 
nonflurescent AMMC probe will be transformed into its fluorescent metabolite AMHC 
(3-[2-N,N-diethyl-Nmethylammonium) ethyl]-7-hydroxy-4-methylcoumarin). The 
produced AMMC fluorescence was measured photometricaly and used to quantify the 
CYP2D6 activity.  
In this procedure, a 96 well plate with black walls and clear bottom was used. Then 100 
µl of the enzyme/substrate mix (mixture of CYP2D6-containing microsome and 
AMMC substrate) was added to each well and incubated for 5 min at 37°C.  
The reaction was started by adding 100µl of the cofactor mix (a mixture delivering and 
assuring the regeneration of NADPH) and incubated for 30 min at 37
o
C. After this in-
cubation time, the reaction was stopped by adding 75 µl stop solution. The amount of 
fluorescent AMHC as a subsequent metabolite was measured at excitation 340 nm and 
emission 465 nm wavelengths using 96 wells plate readers (TECAN-ULTRA,  
Männedorf, Switzerland). 
 
2.2.11 High-Performance Liquid Chromatography (HPLC) 
High-Performance Liquid Chromatography (HPLC) is a chromatographic technique 
used to separate single components of a complex mixture with the purpose of 
identifying, quantifying and purifying the individual components of the mixture. HPLC 
uses high pressure to force eluent through a chromatographic column density packed 
with micron-size particles. The high number of small size particle used leads to more 
precise separations. The principle of HPLC is that the solvent competes with the solute 
for the available adsorption sites on the stationary phase. Elution with a single solvent 
or a constant solvent mixture is called isocratic elution. If one solvent does not 
discriminate adequately between the components of a mixture or if the solvent does not 
provide sufficiently rapid elution of all components, the gradient elution can be used. In 
this case with increasing acetonitrile fraction in a water-acetonitrile mixture, solutes 
which were initially strongly retained by stationary phase (silica column) are eluted.  
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2.2.11.1 Quantification of intracellular tramadol and O-desmethyl-
tramadol by HPLC 
 
Stock solutions for Tramadol and O-Desmethyl-Tramadol: 
1) Tramadol   (C16H25NO2, MW 263.4 g/mol) 
10 mM stock solution: 10 mg of tramadol (Sigma) was solved in 4.012 ml ddH2O and 
thereof 1 ml aliquots were prepared and stored at -20
o
C. 
1 mg/ml (3.7mM): 379 µl of 10mM tramadol was mixed with 621 µl ddH2O and stored 
at 4
o
C.  
  
4 ng/µl: 1 mg/ml solution was diluted (1:10) with ddH2O to get 100 ng/µl. Then 40µl of 
the 100ng/µl solution was diluted with 960 µl ddH2O and stored at 4
o
C.  
 
0.4 ng/µl: 4 ng/µl solution was diluted (1:10) with ddH2O to prepare 1 ml solution 
 
0.04 ng/µl: 0.4 ng/µl solution was diluted (1:10) with ddH2O to prepare 1 ml solution 
 
1 ng/µl: 1 mg/ml solution was diluted (1:10) with ddH2O to get 100 ng/µl. Then 10µl of 
the 100ng/µl solution was diluted with 990 µl ddH2O and stored at 4
o
C. 
 
Standard test 100ng Tramadol with 25ng O-desmethyl-tramadol as internal standard: 
100µl of 4ng/µl tramadol stock solution was mixed with 100µl of 1ng/µl O-desmethyl-
tramadol stock solution (see below) and 50µl from this solution was injected by HPLC 
apparatus. 
 
Standard test 10ng Tramadol with 25ng O-desmethyl-tramadol as internal standard: 
100µl of 0.4ng/µl tramadol stock solution was mixed with 100µl of 1ng/µl O-
desmethyl-tramadol stock solution (see below) and 50µl from this solution was injected 
by HPLC apparatus. 
 
Standard test 1ng Tramadol with 25ng O-desmethyl-tramadol as internal standard: 
100µl of 0.04ng/µl tramadol stock solution was mixed with 100µl of 1ng/µl O-
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desmethyl-tramadol stock solution (see below) and 50µl from this solution was injected 
by HPLC apparatus. 
 
 
2) O-Desmethyl-Tramadol   (C15H23NO2, MW 249.349 g/mol) 
5 mM stock solution: 5 mg of O-desmethyl-tramadol (Sigma) was solved in 4.012 ml 
ddH2O. 1 ml aliquots were prepared and stored at -20
o
C.  
 
1 mg/ml (4 mM): 802 µl of 5mM O-desmethyl-tramadol was mixed with 198 µl ddH2O 
and stored at 4
o
C.   
 
4 ng/µl: 1 mg/ml solution was diluted (1:10) with ddH2O to get 100 ng/µl. Then 40µl of 
the 100ng/µl solution was diluted with 960 µl ddH2O and stored at 4
o
C.  
 
0.4 ng/µl: 4 ng/µl solution was diluted (1:10) with ddH2O to prepare 1 ml solution and 
then was stored at 4
o
C. 
 
0.04 ng/µl: 0.4 ng/µl solution was diluted (1:10) with ddH2O to prepare 1 ml solution 
and stored at 4
o
C. 
 
1 ng/µl: 1 mg/ml solution was diluted (1:10) with ddH2O to get 100 ng/µl. Then 10µl of 
the 100ng/µl solution was diluted with 990 µl ddH2O to get 1 ng/µl and stored at 4
o
C. 
 
Standard test 100ng O-desmethyl-tramadol with 25ng tramadol as internal standard: 
100µl of 4ng/µl O-desmethyl-tramadol stock solution was mixed with 100µl of 1ng/µl 
tramadol stock solution and 50µl from this solution was injected by HPLC apparatus. 
 
Standard test 10ng O-desmethyl-tramadol with 25ng tramadol as internal standard: 
100µl of 0.4ng/µl O-desmethyl-tramadol stock solution was mixed with 100µl of 1ng/µl 
tramadol stock solution and 50µl from this solution was injected by HPLC apparatus. 
 
Standard test 1ng O-desmethyl-tramadol with 25ng tramadol as internal standard:  
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100µl of 0.04ng/µl O-desmethyl-tramadol stock solution was mixed with 100µl of 
1ng/µl tramadol stock solution and 50µl from this solution was injected by HPLC appa-
ratus. 
 
 
Reagents  Manufacturer 
Methanol Merck, Germany 
Acetonitrile Merck, Germany 
 
 
Buffer A (pH 5.7) Volume 
NaH2PO4*H2O (50 mM) 6.9 g 
Na2HPO4 *2H2O   (2.5 mM) 0.45 g 
H2O   1L 
 
 
Buffer B Volume 
Acetonitrile 50% (v/v) 
Buffer A 50% (v/v) 
                      Buffer A and B were degassed with vacuum water jet pomp before running 
 
 
The concentrations of tramadol and O-desmethyl-tramadol were analyzed by HPLC 
using a LaChrom system (Merck Hitachi, Darmstadt, Germany) consisting of an inter-
face  (D-7000,Merck Hitachi), a pump (L-7100, Merck Hitachi), an automatic sampler 
(L-7200, Merck Hitachi), a Fluorescence detector (L-7485, Merck Hitachi) and a 
degasser (L-7614,Merck Hitachi). Separation was carried out on a LiChrospher 100 RP-
18e (5 μm, 4 × 150 mm) column with a LiChrospher100CN guard column (5 μm, both 
from Merck). The peaks were detected by fluorescence monitoring with excitation and 
emission wavelengths of 230 nm and 296 nm, respectively. Gradient elution was 
performed with an initial mobile phase of 77% (v) buffer A and 23% (v) buffer B and 
then the concentration of acetonitrile was increased to reach to 5% (v) buffer A and 
95% (v) buffer B during 13 min and after that declined to the initial concentration (77% 
(v) buffer A and 23% (v) buffer B) at a flow-rate of 1.5 ml/min at room temperature. 
The peaks of tramadol and O-desmethyl-tramadol were detected with retention times of 
3.8 min and 10.8 min, respectively, and were quantified using peak area with external 
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standardization. The amount of intracellular tramadol and O-desmethyl-tramadol 
indicated as area under curve (AUC) was normalized to the total amount of protein 
measured by BCA assay (section 2.2.3.1). 
 
2.2.11.2 Quantification of intracellular debrisoquine and 4-hydroxy 
debrisoquine by HPLC  
The concentrations of debrisoquine were analysed by HPLC using a LaChrom system 
(Merck Hitachi, Darmstadt, Germany) consisting of an interface  (D-7000,Merck Hita-
chi), a pump (L-7485, Merck Hitachi), an automatic sampler (L-7200, Merck Hitachi), a 
fluorescence detector (L-7400, Merck Hitachi) and a degasser (L-7614,Merck Hitachi). 
Separation was carried out on a LiChrospher 100 CN (5 μm, 4 × 150 mm) column with 
a LiChrospher 4-4,100CN guard column (5 μm, both from Merck). The peaks were 
detected by fluorescence monitoring with excitation and emission wavelengths of 210 
nm and 290 nm, respectively according to the previous report (Cerqueira et al., 2000). 
Isocratic elution was performed with a mobile phase of 5% (v) acetonitrile and 95% (v) 
0.05 mol/l sodium acetate buffer (pH 5.0) at a flow-rate of 0.7 ml/min at room 
temperature. Venlafaxine was used as internal standard, and the peaks of debrisoquine 
and venlafaxine were detected with retention times of 9 min and 16 min, respectively, 
and were quantified using peak area with external standardization. The amount of 
intracellular debrisoquine indicated as AUC was normalized to the total amount of 
protein measured by BCA assay (See section 2.2.3.1). 
Individual stock solutions of debrisoquine and venlafaxine as internal standard (IS) 
were prepared at concentrations of 100 µg ml
-1 
in water. The procedure for preparation 
of standard solutions was similar to those described for Tramadol and O-desmethyl tra-
madol (see section 2.2.11.1). To do this, aliquots of the stock solutions of debrisoquine 
were diluted with mobile phase to prepare a series of standard solutions containing 4, 
0.4 and 0.04 µg ml
-1
 of the drug. The initial stock solution of the internal standard 
(venlafaxine) was diluted with mobile phase to yield a 1 µg ml
-1
  and  then aliquots of 
the standard solutions and internal solution were mixed together in same volume and 
then 50 µl of these final solution was injected in column. 
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2.2.11.3 Quantification of intracellular tropisetron and ondansetron by 
HPLC  
Tropisetron and ondansetron quantifications were performed using a modification of a 
previously described HPLC method (BAUER et al. 2002). Briefly, tropisetron and 
ondansetron were quantified using a LaChrom HPLC system (Merck Hitachi, Darm-
stadt, Germany) consisting of an interface (D-7000, Merck Hitachi), a pump (L-7100, 
Merck Hitachi), an automatic sampler (L-7200, Merck Hitachi), an ultraviolet detector 
(L-7400, Merck Hitachi) and a degasser (L-7614, Merck Hitachi). The compounds were 
separated at room temperature on a LiChrospher 100 reverse phase-18e (5 mm, 
4_150mm) column with a LiChrospher 100CN guard column (5 mm, both from Merck) 
and quantified by ultraviolet detection at 284nm for tropisetron and 305nm for 
ondansetron. The mobile phase consisted of 20% acetonitrile and 80% 0.05M sodium 
acetate buffer (pH 5.0) and was delivered at a flow rate of 1.5 ml min
–1
. Tropisetron and 
ondansetron were detected as peaks with retention time of 5.7 and 4.3 min, respectively, 
and quantified using peak area with external standardization. The amount of 
intracellular tropisetron and ondansetron indicated as AUC was normalized to the total 
amount of protein measured by BCA assay (See section 2.2.3.1). 
The procedure for preparation of standard solutions was like those described for tra-
madol and O-desmethyl tramadol (see section 2.2.11.1). 
 
2.2.12 PAMPA assay 
Parallel Artificial Membrane Permeability Assay (PAMPA) is a useful screening tool 
for carrier-independent membrane permeability and has become a very useful tool for 
predicting in vivo drug permeability and is well-suited as a ranking tool for the assess-
ment of compounds with passive transport mechanisms. In this work PAMPAs were 
performed using precoated PAMPA 96-well plates in accordance with the 
manufacturer’s instructions (BD Biosciences, Heidelberg, Germany). Prior to use, the 
pre-coated PAMPA plate system should be warmed to room temperature for at least 30 
minutes. While the plate system is warming, the compound solutions were prepared by 
diluting stock solutions into a buffer (PBS). Then 300 μl of phosphate-buffered saline 
(PBS, pH 7.4) containing increasing concentrations of the drug (0, 1, 10, 50 and 100 
µM) were pipetted into the donor wells and 200 μl of PBS (pH 7.4) into the acceptor 
wells. The acceptor plate was then coupled with the donor plate and the resulting plate 
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assembly was incubated at room temperature without agitation for 5 hours. During the 
incubation, compounds in the donor solution permeate through the artificial membrane 
into the acceptor solution. At the end of the incubation, the plates were separated and 
150 μL solution from each well were used to measure the final concentrations of 
compounds in both donor wells and acceptor wells by means of HPLC (see section 
2.2.11). Membrane permeability (Pe) was calculated using the following equation: 
 
Pe = −ln [1 − CA × (VD + VA) / (CD × VD + CA × VA)] / [A × (1/VD + 1/VA) × t], 
 
Where CD and CA are the end concentrations in the donor and the acceptor wells, re-
spectively. VD and VA are the volumes of the liquids in the donor and the acceptor 
wells, respectively. A is the membrane surface area, and t is the incubation time. VD, 
VA, A, and t were constant in all experiments, with values of 0.3 ml, 0.2 ml, 0.3 cm
2
, 
and 18,000 s, respectively. 
 
2.2.13 Statistical analyses 
Statistical analyses were performed using PASW Statistics, version 18.0 (SPSS, 
Chicago, IL). P values < 0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS1 Statistics version 19 (SPSS Inc., IBM, 
Chicago, USA). Analyses of variance (ANOVA) were applied for multi-group 
comparisons. If two groups among the multiple groups were compared this was done 
using ANOVA followed by post hoc analyses applying Tukey’s Honestly Significant 
Difference (HSD) test. P-values <0.05 were regarded as significant.
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3 Results 
3.1 Generation of OCT1 and CYP2D6 expression plasmid 
constructs 
3.1.1 Generation of the pcDNA5.1::OCT1 plasmid 
In order to generate pcDNA5.1::OCT1 plasmid, an OCT1 expression plasmid 
pcDNA3::OCT1 (kindly supplied by Herman Koepsell and Valentin Gorboulev, 
University of Wuerzburg, Germany) was used. For this purpose, the wild-type OCT1 
was re-cloned into the expression vector pcDNA5.1 plasmid according to following 
procedure. Both pcDNA3::OCT1 and pcDNA 5.1 plasmids were cut with HindIII and 
EcoRV restriction enzymes (Fermentas, St. Leon-Roth). After running on the 1% 
agarose gel electrophoresis and purified from the gel, the OCT1 fragment was ligated 
into the linearized pcDNA 5.1 plasmid using Ligate-IT
TM
 Rapid Ligation Kit (USB, 
Staufen) and then ligation mixture was used to transform in E.coli strain top ten. The 
resulting construct pcDNA5.1:OCT1 carries the OCT1wild-type (Fig.3.1). 
In this study also five variant cDNA clones of OCT1 that represent the five loss-of-
function amino acid substitutions in OCT1 were constructed by site-directed 
mutagenesis (see section 2.2.1.8). The five substitutions are most common genetic 
polymorphisms in Caucasians. The substitutions were introduced either as a single 
amino acid substitutions, i.e. Arg61Cys (rs12208357), Gly401Ser (rs34130495), and a 
single deletion of Met420 (rs72552763), or combination of two substitutions as they 
were observed in the Caucasians, i.e. Met420 deletion with Cys88Arg (rs55918055) and 
Met420 deletion with Gly465Arg (rs34130495).  
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Fig.3. 1 Scheme of cloning of OCT1 into the expression vector pcDNA5.1. The pcDNA3 
containing OCT1 fragment was cut out with HindIII and EcoRV and the OCT1-containing 
fragment was cloned in the pcDNA5.1 plasmid opened with the same restriction enzymes.  
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3.1.2 Generation of the pcDNA5.1::CYP2D6::IRES::POR construct 
Cytochrome P450 reductase (POR) is a helper enzyme essential for CYP activity. The-
refor to generate cells actively expressing CYP2D6 both CYP2D6 and POR genes 
should be overexpressed. In this work we used a bicistronic CYP2D6-POR construct to 
overexpress simultaneously both genes.  
To assure both cytochrome P450 isoform CYP2D6 and cytochrome P450 reductase 
(POR) sufficient protein expression, an internal ribosome entry site (IRES) fragment 
originated from encephalomyocarditis virus (EMCV) was introduced upstream of  POR 
gene according to DNA assembling procedure described in chapter 2.2.1.10. The 
IRES::POR fragment was generated using pIRES (Invitrogen, Karlsruhe) and the 
pCMV-SPORT6 (Invitrogen, Karlsruhe) that contain the complete open reading frame 
of the human POR. Then POR gene and IRES fragment were amplified by PCR using 
primers which designed to have homologous for both POR and IRES (Table.3.1). More 
precisely the reverse primer of the IRES fragment shared a 30 bp homology fragment 
with the forward primer of the POR gene (underlined in table 3.1). This caused POR to 
tag in the downstream of IRES fragment (Fig.3.2). 
 
 
Table 3. 1 The lists of primers used for amplification of IRES and POR. (appropriate 
restriction sites are shown in italic) 
Amino acid  variant                         Primer sequence 
IRES_NotI_f          5’-GAATTCTGCGGCCGCGACGGTACCGCGGGCCCGGGATC-3’ 
IRES_r                   5’-TCCCATGTTGATCATATTATCATCGTCTTTTTCAAAGG-3’ 
POR_f   5’-AAACACGATGATAATATGATCAACATGGGAGACTCCCACGT-3’ 
POR_XhoI_r          5’-GGGGCAGGCTCGAGGCCCCTAGCTCCACACGTCCAG-3’ 
 
 
Results 
91 
 
 
Fig.3. 2 Scheme of assembling of POR with IRES fragment. POR complementary DNA was 
tagged to the downstream of IRES fragment according to DNA assembling method. For this 
reason, pIRES plasmid containing IRES and pCMV-SPORT6 plasmid containing POR were used 
as templates in amplification by PCR. Then two amplified products fused to each other and then 
the whole fragment was amplified by PCR using a pair of primers involved restriction sites for 
NotI and XhoI. 
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Then the assembled product IRES::POR was amplified with a pair of primer, 
IRES_NotI_f and POR_XhoI_r, designed to carry appropriate restriction sites (NotI and 
XhoI) in each flank (Fermentas, St. Leon-Roth). Afterwards this product was cut with 
the two restriction enzymes NotI and XhoI and inserted to the pcDNA5.1 plasmid which 
was linearized with the same restriction enzymes. 
The plasmid pcDNA5.1::CYP2D6::IRES::POR was obtained from Nadia Ayyad. This 
construct was made by tagging CYP2D6 gene in the upstream of IRES::POR fragment. 
The CYP2D6 fragment was amplified from the pCR-XL-TOPO plasmid with the 
forward primer CYP2D6_NheI_f and the reverse primer CYP2D6_NotI_r (Table 3.2) 
and cut with NheI and NotI and cloned into the pcDNA5.1::IRES::POR plasmid which 
was  linearized with the same enzymes (Fig.3.3).  
 
 
    Table 3. 2 Primers used to amplify CYP2D6 contain appropriate restriction sites (shown in 
italic) 
Primer Sequence 
CYP2D6_NheI_f         5’-TAGTGGCTAGCAGGTATGGGGCTAGCAAGCACTGGT-3’ 
 
CYP2D6_NotI_r              5’-TGGGGACGCGGCCGCATTCTAGCGGGGCACAGCACAA-3’ 
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Fig.3. 3 Scheme of assembling of CYP2D6 with IRES::POR. CYP2D6 complementary DNA 
was tagged to the upstream of IRES::POR fragment in the pcDNA5.1 plasmid. For this reason, 
CYP2D6 was amplified and inserted in the upstream of IRES::POR using NheI and NotI.  
The plasmid pcDNA 5.1 puro was obtained after replacement of the hygromycin 
resistance gene and the FRT locus by puromycine resistant one. The puromycine 
resistance cassette was obtained from pSilencer plasmid (Invitrogen, Karlsruhe) by PCR 
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amplification using the primers listed in table 3.3. The PCR product was cut with the 
artificially introduced NaeI sites and cloned into the pcDNA5.1 plasmid open with the 
same restriction sites. 
 
Table 3. 3 Primers used to amplify purpmycine resistance region contain appropriate 
restriction   sites (shown in italic) 
Primer                                                Sequence 
Puro_casete_f         5’-GAAAGTCGCCGGCTCCCCAGCAGGCAGAAGTATGC-3’ 
Puro_casete_r         5’-ATAAAAGCCGGCGTATCACGAGATTGCAGTGAAAA-3’ 
 
The CYP2D6::IRES::POR cassette is then recloned from the pcDNA5.1 into the 
pcDNA5.1puro plasmid using the BglII and XhoI restriction sites (Fig.3.4). 
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Fig.3. 4 Scheme for the generation of pcDNA5.1puro vector and recloning the 
CYP2D6::IRES::POR  from pcDNA5.1 into pcDNA5.1puro vector. The pcDNA5.1 plasmid 
containing whole fragment of CYP2D6::IRES::POR was digested with XhoI and BglII. The 
manipulated pcDNA5.1::puro also opened with the same restriction enzyme and then whole 
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fragment of CYP2D6::IRES::POR ligated to make the final construct 
pcDNA5puro::CYP2D6::IRES::POR.  
 
3.2 Generation and characterization of the transgenic cells 
models 
3.2.1 Generation and characterization of OCT1 overexpressing cell 
lines  
3.2.1.1 Generation of stably transfected HEK293 cell lines 
overexpressing OCT1 
To generate cells overexpressing OCT1 and its polymorphic naturally occurring 
variants, pcDNA5.1::OCT1 wild- type and variant constructs were stably transfected to 
HEK293 T-Rex cells using the Flp-In system. (section 2.2.5.4.2), and screened using 
DMEM medium containing 10% FBS serum, 1% Penicillin/Streptomycin and 300 
µg/ml concentrations of hygromycin B. After 10-14 days single colonies of cells 
resistant to hygromycine B were selected and transferred and grown in 12-well and later 
in 6-well plates in DMEM medium supplemented with reduced concentration of 
hygromycine B to 100 mg/ml. Then successful genomic integration of the 
pcDNA5.1::OCT1 constructs was confirmed by integration-specific PCR (see section 
2.2.1.9).  
Correct plasmid integration was confirmed by PCR and resequencing. Overexpression 
of the wild type and variant OCT1 genes was confirmed on RNA, protein and activity 
levels as will be illustrated in the following chapters in more detail. 
 
3.2.1.2 Confirming the chromosomal integration of the OCT1 con-
structs in the genome of HEK293-TRex cells 
Successful genomic integration was confirmed by integration-specific PCR. For this 
reason, two PCR reactions were performed. The first PCR amplified the region contains 
the downstream part of Psv40 promotor and the upstream part of the Hygromycin 
resistance region. A PCR signal of 614 bp length was observed confirming the correct 
integration of the pcDNA5 constructs (Fig.3.5).  
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A second PCR was performed to confirm the correct sequence of the chromosomally in-
tegrated gene of interest (in this case OCT1). The second PCR amplified the region 
between the downstream part of PCMV promoter and the upstream part of lacZ-Zeocin 
resistance region which contains OCT1 complementary DNA and the length of this 
amplified fragment is 2532 bp.  
And then the correctness of the obtained OCT1 wild type and variants was validated by 
sequencing using the primers mentioned in section 2.2.1.11. 
                                                                                
          
 
Fig.3. 5 Integration-specific PCRs confirming the correct integration of the plasmid 
constructs in the genome of OCT1 overexpressing HEK cells. A) Two regions of the genome of 
HEK cells which amplified by PCR1 and PCR2. B) a 614 bp fragment was amplified for 
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hygromycin resistance region in OCT1 overexpressing HEK cells of wild type and SNPs in 
compare to control HEK TRex cells that did not have this integrated fragment in the genome. C) A 
2532 bp fragment was amplified for the region contains gene of interest in OCT1 overexpressing 
HEK cells of wild type and SNPs in compare to control HEK TRex untransfected cells. This PCR 
product was used for full length sequencing of OCT1 complementary DNA in wild type and SNPs 
samples. 
 
3.2.1.3 Confirming OCT1 overexpression by qRT-PCR  
OCT1 overexpression was first confirmed using quantitative reverse transcription PCR 
(qRT-PCR). The results obtained by real-time reverse transcriptase-PCR indicate the 
clones stably transfected with the wild-type or the loss-of-function OCT1 variants 
showed 15-fold higher OCT1 mRNA expression compared with the control clone 
carrying genomic integration of the pcDNA5.1 vector alone. No significant differences 
were detected in the OCT1 mRNA expression between the wild-type and the loss-of-
function variants (Fig.3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. 6 Expression rate of OCT1 in the stably transfected HEK cells. The graphic shows 
mRNA levels of HEK cells overexpressing OCT1 wild type and five common variants in relation 
to the HEK cell containing pcDNA5 empty vector as control. The mRNA levels were normalized 
to the housekeeping gene TPB.  Mean values and standard errors from three repetitions are shown.          
.           
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3.2.1.4 Confirming OCT1 overexpression on protein level  
Following the confirmation of OCT1 mRNA overexpression, the OCT1 protein levels 
were analyzed. OCT1 protein overexpression was confirmed by means of western blot, 
FACS and immunocyto staining. Western blot analysis confirmed expression of OCT1 
protein in the wild type and variants of the transfected cells. Using a monoclonal 
SLC22A1 antibody (2c5) (Novus Biologicals, Cambridge, UK), two protein signals 
with 75 and 60 kDa weight were detected for all the samples containing wild type or 
polymorphisms of OCT1, but not in the control cells (Fig.3.7).  
 
        
 
Fig.3. 7 Western blot for the OCT1 protein in the OCT1 overexpressing HEK cells. The 
OCT1 protein with 75 and 60 kDa weights were detected for clones containing OCT1 wild type 
and variants. The housekeeping protein GAPDH was used to normalize the signal intensity of the 
samples. A mouse anti-(human) primary antibody SLC22A1 (2c5, Novus Biologicals, Cambridge, 
UK) was used for specific detection of the OCT1 protein and a GAPDH mouse monoclonal 
antibody (ZG003, Invitrogen) was used to detect GAPDH. The images were visualized by 
VersaDoc imaging system. 
 
3.2.1.5 Flow cytometry analysis for OCT1 overexpressing HEK cells  
Flow cytometry is a convenient tool for quantifying the OCT1 transporter in the cells. 
For this purpose, the OCT1 overexpressing HEK cells as well as the control cells 
transfected with pcDNA5 empty vector were fixed and permeabilized as described 
previously (section 2.2.6). The The 2.5 x 10
5
 cells were stained by indirect 
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immunofluorescence using primary antibody SLC22A1 (2c5, Novus Biologicals, 
Cambridge, UK) and flourochrome conjugated secondary antibody (Goat anti mouse 
Alexa 488, Invitrogen) and were analyzed by flow cytometry on a FACScan instrument 
BD LSR II (BD Bioscience) and the data were analyzed using BD FACSDiva software. 
Electronic gating of FSC (forward scatter) versus SSC (side scatter) was used to 
eliminate cellular fragments and debris from the population of cells to be analyzed for 
the presence of OCT1. The histogram showed that 97.9% of the HEK cells 
overexpressing OCT1 stained positively above the control HEK cells transfected with 
pcDNA5 vector (Fig. 3.8). 
 
 
 
Fig.3. 8 Characterization of OCT1 expression protein in OCT1 overexpressing HEK cells (A) 
and HEK cells transfected with pcDNA empty vector (B) by flow cytometry. A) The results show 
maximum amount of the OCT1 overexpressing cells can bind to antibody conjugated to FITC and 
emit the fluorescence after threshold line (P6 region). B) The control HEK cells show no emitted 
fluorescence after threshold line which means no antibody bind to these cells. 
 
3.2.1.6 Immunocytochemical staining 
The OCT1 overexpressing HEK cells as well as the control cells transfected with 
pcDNA5 empty vector were fixed and permeabilized as described before (section 2.2.7). 
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After reaching the cells to 80% confluency, the cells were stained by indirect 
immunofluorescence using primary antibody SLC22A1 (2c5, Novus Biologicals, 
Cambridge, UK) and flourochrome conjugated secondary antibody (Goat anti mouse 
Alexa 488, Invitrogen) and then visualized by confocal microscopy (Carl Zeiss, Jena). 
The results showed that the OCT1 protein localized in the cytoplasmic membrane of the 
HEK cells overexpressing OCT1 (Fig. 3.9). 
 
        
Fig.3. 9 Confocal image of the HEK cells overexpressing OCT1. The cells were treated with 
mouse anti-(human) primary antibody SLC22A1 (2c5, Novus Biologicals, Cambridge, UK) for 
OCT1 and visualized using goat anti-mouse conjugated to fluorochrome Alexa 488 secondary 
antibody (Invitrogen). The green particles depict localization of OCT1 protein mostly in the 
cytoplasmic membrane. 
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3.2.1.7 Confirming functional OCT1 overexpression by measuring  
OCT1 activity 
ASP
+
 was used as a model substrate for hOCT1 to confirm functionally active 
expression of the OCT1 transporter. The overexpression of functional OCT1 was 
confirmed using both fluorescence microscopy and photometric concentration analysis. 
Using ASP
+
 it was shown that wild type OCT1 can mediate the cellular uptake of ASP
+
. 
Furthermore as expected, despite similar OCT1 mRNA and protein levels, all loss of 
function polymorphisms exhibit reduced activity for ASP
+
 uptake in comparison to wild 
type (Fig.3.10).     
 
 
 
Fig.3. 10 OCT1 genetic variants are associated with different accumulation rates and 
responses to ASP
+
 in stably transfected HEK293 cells. A)  Phase contrast micrograph of 
HEK293 cells overexpressing wild type OCT1 and the empty vector (top) and the corresponding 
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fluorescent micrograph  B) Fluorescent micrographs competing the ASP
+
 uptake between the HEK 
cells overexpressing wild type (WT) and five common variant of OCT1 visualized by fluorescence 
microscopy. The pictures show that the five OCT1 variants exhibited reduced ASP
+
 uptake as 
compared with OCT1(WT). All images were obtained with 40 objective lens. 
 
Next the ability of the wild type OCT1 overexperssing cell lines to transport ASP
+
 was 
quantified and compared to the cells overexpressing the variant OCT1s. 
In this assay, the OCT1 overexpressing HEK cells were incubated for 3 min with 0.5 ml 
pre-warmed HBSS medium (pH 7.4) containing increasing concentrations of ASP
+
 (0, 
1, 5, 10, 20, 50, 100 and 200 µM). With increasing concentration of extracellular ASP
+
, 
the ASP
+
 uptake in OCT1 wild type overexpressing cells was considerably higher than 
in the OCT1 variants overexpressing cells and control cells with empty vector 
(Fig.3.11). 
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Fig.3. 11 ASP+ uptake by the wild-type OCT1 and the OCT1 variants carrying the common 
loss-of-function polymorphisms of OCT1. A)The cellular uptake of ASP
+
 was measured using 
TECAN Ultra plate photometer and the results were normalized to the total protein amount of the 
cells. B) The OCT1 mediated uptake of ASP
+
 calculated by subtracting the uptake in the control 
cells from the uptake in the OCT1- overexpressing cells using the dataset shown in (A). The graph 
shows mean values and standards errors from three independent experiments. 
 
 
Using regression to a Michaelis-Menten equation, the Vmax and Km of the ASP
+
 by the 
wild-type and variant OCT1 were determined and the intrinsic clearance of ASP
+ 
was 
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calculated (Table.3.4).  OCT1 wild type exhibited maximum clearance rate compared to 
SNPs variants, whereas between the OCT1 variants studied here, the 420del variant had 
the highest clearance rate from the variant-carrying OCT1s (71.1% of the wild type). 
The decrease in the intrinsic clearances was based on the decrease in the Vmax. The 
ASP
+
 uptake of the OCT1 variants 420del-88R and 420del-465R did not differ from the 
uptake in the control cells. The observed significant decrease or the lack of uptake in the 
variant expression cells is in concordance with previously published data about the 
effect of loss-of-function variants (SHU et al. 2003). 
 
 
Table 3. 4 Effects of the common functional amino acid substitutions in OCT1 on the kinetics 
of  ASP
+
 uptake. 
 
SNP 
Vmax Km [µM]  
CLint 
(Vmax/Km) 
 
CLint 
(%  wt) 
Mean SEM Mean SEM 
WT 15845.8 2877.1 11.42 1.79 1387.34 100.0 
61C 3951.42* 1013.15 9.25 1.13 427.11* 30.7 
401S 3698.2* 1784.76 47.88* 6.5 77.22* 5.5 
420del 10312 1787.89 11.22 1.9 918.77 66.2 
420del88R na na na na na na 
420del465R na na na na na na 
na., not applicable. * P < 0.01 compared to the WT reference in a Tukey’s HSD post hoc analysis 
following one-way ANOVA (P < 10
-4
). 
 
  
Based on the analyses of the DNA, RNA, protein and activity, it could be concluded 
that the constructed OCT1 overexpressing cell lines represent a functional model for 
analyzing OCT1 activity and the effects of OCT1 polymorphisms. 
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3.2.2 Generation and characterization of cell lines co-overexpressing 
CYP2D6 and POR   
3.2.2.1 Generation of stably transfected HEK293 cell lines co-
overexpressing CYP2D6 and POR 
The pcDNA5puro::CYP2D6::IRES::POR construct was chromosomally integrated in  
HEK293-TRex cells by random integration. For this purpose, this construct was 
extracted from the bacteria by midi prep method and transfected to the HEK293-TRex 
cells using FuGene 6 transfection reagent (Roche, Mannheim) and after adding 
screening medium containing 5ng/µl puromycine, positive clones were selected.  
The chromosomal integration of the construct was confirmed by PCR and resequencing. 
Overexpression of the CYP2D6 and POR genes was confirmed on RNA, protein and 
activity levels. 
 
3.2.2.2 Confirming the chromosomal integration of the 
pcDNA5puro::CYP2D6::IRES::POR constructs in the genome of the 
HEK293-TRex cells 
The integration of the CYP2D6::IRES::POR into the genome of the HEK293-TRex 
cells was confirmed by two PCR reactions. The PCR reactions were designed to 
amplify separately the CYP2D6 and the POR gene using the primers listed in table 3.5 
using cells genomic DNA as template. 
 
Table 3. 5 Primers used for amplification of the CYP2D6 and POR genes.    
Primer Primer sequence 
CYP2D6(f) 5’-ACACGATGATAATATGGGGCTAGAAGCACTGGTGCCCCTG-3’ 
CYP2D6 (r)    5’-TGGGGACGCGGCCGCATTCTAGCGGGGCACAGCACAA-3’ 
POR_ f 5’-AAACACGATGATAATATGATCAACATGGGAGACTCCCACGT-3’ 
POR_XhoI_r  5’-GGGGCAGGCTCGAGGCCCCTAGCTCCACACGTCCAG-3’ 
 
PCR signals of 1450 bp and 2075 bp were obtained for the CYP2D6 and POR genes 
respectively (Fig.3.12 A and B). The signals were presented in the 
pcDNA5puro::CYP2D6::IRES::POR transfected cells and were lacking in the control 
cells transfected with the empty pcDNA5puro plasmid. The signals were obtained from 
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cells resistant to puromycine in their 10 passage after transfection suggesting 
chromosomal integration of the plasmid.  The correctness of the integrated construct 
was validated by SNaPshot (see section 2.2.1.12).  
 
 
Fig.3. 12 Amplification of CYP2D6 (A) and POR (B) genes  from the genome of  HEK293-
TRex cells stably transfected with bicistronic CYP2D6::IRES::POR construct.  Total DNA 
from three clones of CYP2D6 and POR co-overexpressing HEK cells were isolated and PCR was 
done to amplify the CYP2D6 and POR cDNA fragments. HEK cell transfected with empty vector 
(pcDNA5 puro) was used as a control. 
                                                    
 
3.2.2.3 Confirming CYP2D6 and POR overexpression by qRT PCR  
The mRNA levels of CYP2D6 and POR genes were quantified by quantitative RT-PCR. 
For this purpose, total RNA which extracted from the 
pcDNA5puro::CYP2D6::IRES::POR transfected HEK cells were reverse transcribed 
and used as templates for real-time quantitative PCR, and then normalized to TATA- 
box binding protein (TBP) as a housekeeping gene. The CYP2D6 mRNA was 30587 
-fold stronger expressed in the stably transfected as in the control cells. The POR 
mRNA was 60-fold stronger expressed in the stably transfected as in the control cells 
(Fig.3.13).  
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Fig.3. 13 qRT-PCR analyses of the CYP2D6 and POR co-overexpression in the 
pcDNA5puro::CYP2D6::IRES::POR. The graph  shows mRNA levels of CYP2D6 (A) and 
POR (B) in HEK cells overexpressing CYP2D6_IRES_POR in compare with HEK cells 
overexpressing OCT1 (wt) wild type  or HEK cells transfected with empty vector (pcDNA 5) as 
controls. The mRNA expression of the genes of interest was normalized to the expression of the 
house-keeping gene TBP. The graph shows mean values and standard errors from three 
independent experiments.  
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3.2.2.4 Confirming CYP2D6 overexpression by western blot  
Expression of CYP2D6 protein in HEK cell transfected with 
pcDNA5puro::CYP2D6::IRES::POR was determined by western blot. Three clones of 
the stably transfected cells were selected and total protein of these samples were 
extracted for western blot analysis. Using the CYP2D6-specific monoclonal antibody 
MAB-2D6 (BD Gentest
TM
) a signal of 50 kDa in all three transfected clones was shown, 
whereas this signal was missing in the control-transfected cells (Fig.3.14).                                                                             
                      
 
Fig.3. 14 Western blot detection of CYP2D6 protein in pcDNA5puro::CYP2D6::IRES::POR 
transfected HEK cells. A monoclonal anti-CYP2D6 primary antibody MAB-2D6 was used for 
specific detection of the 50 kDa CYP2D6 protein. A goat anti-mouse-HRP secondary antibody with 
chemiluminescence detection was used. The housekeeping protein GAPDH was used to control for 
equal loading of the gel. The images were visualized by VersaDoc imaging system. 
 
3.2.2.5 Flow cytometry analysis for CYP2D6 overexpressing HEK cells 
In this experiment the CYP2D6 overexpressing HEK cells as well as the control cells 
transfected with pcDNA5 empty vector were fixed and permeabilized as described 
previously (section 2.2.6). The 2.5 x 10
5
 cells were then stained by indirect 
immunofluorescence using monoclonal anti-CYP2D6 antibody (MAB-2D6, BD 
Gentest) and flourochrome conjugated anti-mouse antibody (Goat anti mouse Alexa 
488, Invitrogen) and were analyzed by flow cytometry on a FACScan instrument BD 
LSR II (BD Bioscience) and the data were analyzed using BD FACSDiva software. 
Electronic gating of FSC (forward scatter) versus SSC (side scatter) was used to 
eliminate cellular fragments and debris from the population of cells to be analyzed for 
the presence of CYP2D6.The histogram showed that 90.6% of the HEK cells 
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overexpressing CYP2D6 stained positively above the control HEK cells transfected 
with pcDNA5 vector (Fig. 3.15). 
 
 
Fig.3. 15 Characterization of CYP2D6 expression protein in CYP2D6 overexpressing HEK 
cells (A) and HEK cells transfected with pcDNA empty vector (B) by flow cytometry. A) The 
results show that the maximum amount of the CYP2D6 overexpressing HEK cells bind to 
antibody conjugated to FITC and emit the fluorescence after threshold line (P6 region). B) The 
control HEK cells show no emitted fluorescence after threshold line which means no antibody 
bind to these cells. 
 
3.2.2.6 Immunocytochemical staining  
The CYP2D6 overexpressing HEK cells as well as the control cells transfected with 
pcDNA5 empty vector were fixed and permeabilized as described before (section 2.2.7). 
After reaching the cells to 80% confluency, the cells were treated by monoclonal anti-
CYP2D6 antibody (MAB-2D6, BD Gentest) and stained by flourochrome conjugated 
anti-mouse antibody (Goat anti mouse Alexa 488, Invitrogen) and then visualized by 
confocal microscopy (Carl Zeiss, Jena). The results showed that the CYP2D6 protein 
localized mostly in the cytosol of the HEK cells overexpressing CYP2D6 (Fig. 3.16). 
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Fig.3. 16 Confocal immunofluorescent analysis of HEK cells overexpressing CYP2D6.  The 
cells were treated using monoclonal anti-CYP2D6 primary antibody (MAB-2D6, BD Gentest) and 
visualized using Alexa Fluor 488-conjugated goat anti-mouse lgG (Invitrogen). The green particles 
depict localization of CYP2D6 protein mostly in the cytosol of the cells. 
 
 
3.2.2.7 Confirming the expression of functionally active CYP2D6  
To confirm functional CYP2D6 expression, microsomes were extracted from three 
clones of HEK293-TRex cells stable transfected with 
pcDNA5puro::CYP2D6::IRES::POR. The CYP2D6 enzyme activity was assessed using 
the AMMC kit. As it can be seen, the maximum amount of AHMC, the product of 
CYP2D6 catalyzed oxidation of AMMC, was detected for microsome of kit (used as a 
positive control), however no significant activity was detected for extracted microsome 
from the stably transfected cells (Fig.3.17) indicating that the amount of enzyme 
expressed may only be very low or enzyme was lost during preparation of the 
microsomes. 
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Fig.3. 17 Measurement the activity of CYP2D6 enzyme using AMMC kit.  Microsomes 
extracted from HEK293 cells transfected with pcDNA5puro::CYP2D6::IRES::POR were treated 
with AMMC substance and incubated for 30 min as described in section 2.2.10.2 The amount of 
AHMC, the fluorescent metabolite of AMMC, was measured by TECAN Ultra plate photometer at 
excitation 340 nm and emission 465 nm wavelengths. The data was normalized to the total protein 
amounts in the microsomes. Quinidine was used as inhibitor of CYP2D6 enzyme. The graph 
shows mean values and standard errors from two independent experiments. Rfu is an abbreviation 
for relative fluorescence units. 
  
Therefore, we continued characterization of the single and double transfected clones 
using debrisoquine instead of AMMC as a model substrate for CYP2D6 enzyme. In this 
case we detected 4-OH debrisoquine as the main product of CYP2D6 catalyzed 
oxidation by HPLC. For this reason, microsomes extracted from HEK cells transfected 
with pcDNA5puro::CYP2D6::IRES::POR exposed to three different concentrations of 
debrisoquine (1, 10 and 100 µM) for 1 hour using the same cofactors, buffers and stop 
solution from the AMMC kit, and then the amount of 4-OH debrisoquine was measured 
by HPLC. HEK293-TRex cells overexpressing OCT1were used as a negative control. In 
this experiment the samples were divided to two parts treated with and without 100 µM 
paroxetine as a well known inhibitor of the CYP2D6 enzyme (Fig. 3.18).  The amount 
of 4-OH debrisoquine produced by microsomes from the two clones of 
CYP2D6::IRES::POR (No. 1 and 2) was significantly higher than those obtained from 
the control cells. Furthermore paroxetine inhibited the production of 4-OH debrisoquine 
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in all samples except for the HEK cells overexpressing OCT1 (wt) which no change 
was seen.      
 
      
Fig.3. 18 Measurement the activity of CYP2D6 enzyme using the model substrate 
debrisoquine. Microsomes extracted from HEK293-TRex cells transfected with 
pcDNA5puro::CYP2D6::IRES::POR were incubated for 1 hour with different concentration of 
debrisoquine (1, 10 and 100 µM) in the absence (simple bars) or present of 100µM paroxetine as 
an inhibitor for CYP2D6 enzyme (hatched bars). As a control, microsomes extracted from 
HEK293-TRex cells transfected with OCT1 wild type were used. The amount of 4OH-
debrisoquine produced by CYP2D6 was measured by means of high-performance liquid 
chromatography and normalized to the total protein amounts in the microsomes. The graph shows 
mean values and standard errors from three independent experiments. 
 
3.2.2.8 Time dependence of CYP2D6-mediated tramadol metabolism 
This experiment was performed to measure the activity of CYP2D6 enzyme in the 
HEK293-TRex cells stably transfected with pcDNA5puro:: CYP2D6::IRES::POR. For 
this purpose, we modified the AMMC assay using tramadol as a substrate for CYP2D6 
enzyme and detecting O-desmethyltramadol as a produced metabolite by HPLC. 
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Microsomes obtained from the transfected cells were exposed to 1µM tramadol for 
different incubation times (0, 15, 30, 60 and 90 min) using the cofactor mix, buffers and 
stop solution used for AMMC assay (see section 2.2.10.2). After the reaction was 
stopped, the amount of the CYP2D6 product O-desmethyltramadol was measured by 
HPLC. The observed time-dependent increase in the O-desmethyltramadol production 
confirmed the presence of active CYP2D6 in the cells (Fig.3.19).   
 
       
              
Fig.3. 19 Measuring time dependence activity of CYP2D6 enzyme using tramadol.  
Microsome produced from HEK293-TRex cells stably transfected with 
pcDNA5puro::CYP2D6::RES::POR were incubated with the same concentration of tramadol 
(1µM) for different  incubation times (0, 15, 30, 60 and 90 min). The O-desmethyltramadol 
produced by microsomes was measured by means of high-performance liquid chromatography and 
normalized to the total protein amounts in the microsomes. The graph shows mean values and 
standard errors from two independent experiments. 
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3.2.3 Generation and characterization of the OCT1, CYP2D6 and POR 
co-overexpressing cell lines  
 
3.2.3.1 Generation of stably double-transfected HEK293 cell lines co-
overexpressing OCT1, CYP2D6 and POR 
After generation of CYP2D6::POR co-overexpressing HEK cells, the constructs 
including pcDNA5::OCT1 wild type and OCT1 variant 420del88R were used to 
transfect these cells using Flp-In system (see section 2.2.5.4.2). The positive clones 
were selected using DMEM medium containing 10% FBS serum, 1% 
penicillin/streptomycin and 10 µg/ml hygromycin B. After 10-14 days the single 
colonies of double-transfected cells (OCT1 and CYP2D6::IRES::POR) resistant to 
hygromycin B were selected and transferred and grown in 12-well and later in 6-well 
plates and culture flask. 
Correct plasmid integration was confirmed by PCR. Overexpression of the OCT1 gene 
was confirmed on RNA and protein levels.  
 
3.2.3.2 Confirming the chromosomal integration of the OCT1 con-
structs in CYP2D6::IRES::POR overexpressing HEK cells 
Successful genomic integration of these constructs was confirmed by integration-
specific PCR as described in section 2.2.1.9 (Fig. 3.20).  
                                                
Fig.3. 20 Integration-specific PCR for the hygromycin resistance region to check integration 
of the OCT1 plasmid constructs in the genome.  A 614 bp fragment was amplified for 
hygromycin resistance region in OCT1::CYP2D6::IRES::POR overexpressing HEK cells for 
OCT1 wild type  and 420del88R variant in compare to HEK cells overexpressing 
CYP2D6:.IRES:.POR as control.  
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3.2.3.3 Confirming OCT1, CYP2D6 and POR overexpression by qRT- 
PCR  
The expression of the mRNA transcripts of OCT1, CYP2D6 and POR genes were clear-
ly much higher in OCT1, CYP2D6 and POR double-transfected cells compared with 
control cells transfected with empty vector (Fig.3.21). The results showed that mRNA 
levels of OCT1, CYP2D6 and POR significantly increased in the cells which double-
transfected with pcDNA5::OCT1 and pcDNA5puro::CYP2D6::IRES::POR constructs 
in compared to HEK cells transfected with pcDNA5 empty vector as control.  
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Fig.3. 21 qPCR analyses of the CYP2D6 and POR co-overexpression in the 
pcDNApuro::CYP2D6::IRES::POR. The graphs show normalized mRNA levels of OCT1, 
CYP2D6 and POR in HEK cells overexpressing OCT1::CYP2D6::IRES::POR in compare with 
HEK cells overexpressing CYP2D6::IRES::POR or OCT1 wild type or HEK cells containing 
empty vector as control. A) The expression rate for OCT1 mRNA in OCT1::CYP2D6::IRES::POR 
transfected cells compared to those cells overexpressed OCT1 alone showed no differences, 
whereas the huge differences was seen compared to the cells transfected with 
CYP2D6::IRES::POR or empty vector. B) The expression rate of CYP2D6 mRNA in 
OCT1_CYP2D6_IRES_POR transfected cells compared to CYP2D6::IRES::POR transfected cells 
and cells transfected with OCT1wild type (wt) or HEK cells transfected with empty vector as 
control. C) The expression rate of POR mRNA in OCT1::CYP2D6::IRES::POR transfected cells 
compared to CYP2D6::IRES::POR transfected cells and cells transfected with OCT1 (wt) or 
empty vector. The graphs show mean values and standard errors from three repetitions.     
 
 
3.2.3.4 Confirming OCT1 and CYP2D6 co-overexpression by protein 
analyses  
Expression of OCT1 and CYP2D6 proteins in the double-transfected HEK293-TRex 
cell was determined by western blot analysis. The results showed an obtained signal 
with 75 and 61 kDa for OCT1 and a signal with 50 kDa for CYP2D6 on SDS-PAGE gel 
(Fig.3.22).   
Results 
118 
 
                     
 
Fig.3. 22 Western blot analyses for OCT1 and CYP2D6 in pcDNA5::OCT1 and 
pcDNA5puro::CYP2D6::IRES::POR double transfected HEK293-TRex cells. A) A monoclonal 
anti-(human) OCT1 primary antibody was used for specific detection of the 75 and 61 kDa  
proteins corresponding to OCT1. A goat anti-mouse-HRP secondary antibody with 
chemiluminescence detection was used. B) A monoclonal anti-(human) CYP2D6 primary antibody 
was used for specific detection of the 50 kDa CYP2D6 protein. A goat anti-mouse-HRP secondary 
antibody with chemiluminescence detection was used. The images were visualized by VersaDoc 
imaging system. 
 
3.2.3.5 Flow cytometry analysis for OCT1 and CYP2D6 overexpressing 
HEK cells 
In this experiment the OCT1::CYP2D6::POR overexpressing HEK cells as well as the 
control cells transfected with pcDNA5 empty vector were fixed and permeabilized as 
described previously (section 2.2.6). The 2.5 x 10
5
 cells were then stained by indirect 
immunofluorescence using primary antibody SLC22A1 (2c5, Novus Biologicals, 
Cambridge, UK) and fluorochrome conjugated anti-mouse antibody (Goat anti mouse 
Alexa 488, Invitrogen) and were analyzed by flow cytometry on a FACScan instrument 
BD LSR II (BD Bioscience) and the data were analyzed using BD FACSDiva software. 
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Electronic gating of FSC (forward scatter) versus SSC (side scatter) was used to 
eliminate cellular fragments and debris from the population of cells to be analyzed for 
the presence of OCT1.The histogram showed that 96.4% of the HEK cells 
overexpressing OCT1 and CYP2D6 stained positively above the control HEK cells 
transfected with pcDNA5 vector (Fig. 3.23). 
 
 
 
Fig.3. 23 Characterization of the expressed protein OCT1 in OCT1 and CYP2D6 
overexpressing HEK cells (A) and HEK cells transfected with pcDNA empty vector (B) by flow 
cytometry. A) The results show maximum amount of the OCT1 and CYP2D6 overexpressing 
HEK cells can bind to antibody conjugated to FITC and emit the fluorescence after threshold line 
(P6 region). B) The control HEK cells show no emitted fluorescence above the threshold line 
which means no antibody bind to these cells. 
 
3.2.3.6 Immunocytochemical staining  
The OCT1 and CYP2D6 overexpressing HEK cells as well as the control cells 
transfected with pcDNA5 empty vector were fixed and permeabilized as described 
before (section 2.2.7). After reaching the cells to 80% confluency, the cells were treated 
with primary antibody SLC22A1 (2c5, Novus Biologicals, Cambridge, UK) for OCT1 
protein or monoclonal anti-CYP2D6 antibody (MAB-2D6, BD Gentest) for CYP2D6 
protein and stained with flourochrome conjugated anti-mouse antibody (Goat anti 
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mouse Alexa 488, Invitrogen) and then visualized by confocal microscopy (Carl Zeiss, 
Jena). The results showed that the OCT1 protein localized on the membrane, whereas 
the CYP2D6 protein localized mostly in the cytosol (Fig. 3.24 A and B). 
 
Fig.3. 24 Confocal immunofluorescent analysis of HEK293TRex cells cooverexpressing 
OCT1 and CYP2D6. The cells were treated with mouse anti-(human) primary antibody SLC22A1 
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(2c5, Novus Biologicals, Cambridge, UK) for detecting OCT1 (A) or with the monoclonal anti-
CYP2D6 primary antibody (MAB-2D6, BD Gentest) for detecting CYP2D6 (B) and visualized 
using Alexa Fluor 488-conjugated goat anti-mouse lgG (Invitrogen). The green particles depict 
localization of OCT1 protein on the membrane (A) and CYP2D6 protein mostly in the cytoplasm 
of the cells (B). 
 
Based on the analyses of the DNA, RNA, protein and activity, it could be concluded 
that the constructed OCT1, CYP2D6 and POR co-overexpressing cell lines represent a 
functional model for analyzing OCT1-CYP2D6 interactions in drug metabolism and the 
effects of OCT1 polymorphisms on it. 
  
3.3 OCT1 as a cellular uptake transporter of antiemetic drugs 
3.3.1 Inhibition of OCT1-mediated ASP+ uptake by tropisetron, 
ondansetron and palonosetron 
We analyzed whether OCT1 mediates the cellular uptake of the antiemetic drugs 
tropisetron, ondansetron or palonosetron. First, we analyzed if these three drugs may 
inhibit the uptake of ASP
+
, which is a model substrate of OCT1. For this reason, 
HEK293-TRex cells overexpressing the wild type OCT1 were incubated with 1 µM 
ASP
+
 for 3 min in the presence of increasing concentrations of either tropisetron, 
ondansetron or palonosetron. The inhibition caused by the three antiemetic drugs was 
compared with the inhibition caused by the weak OCT1 inhibitor tetraethylammonium 
(TEA
+
) and the strong OCT1 inhibitor quinine. All these three antiemetic compounds 
examined in this experiment effectively inhibited the ASP
+ 
uptake (Fig.3.25). 
Tropisetron decreased the ASP
+
 uptake with an IC50 value of 8.5±1.4 µM, whereas the 
corresponding IC50 values for ondansetron and palonosetrone were 63±15.6 µM and 
22.9 ± 11.6 µM, respectively. The inhibition constants were comparable (ondansetron) 
or even tenfold (tropisetron) and fourfold (palonosetron) lower than the inhibition 
constant of quinine, a well-known OCT1 substrate. These results correspond to 
previously reported data (AHLIN et al. 2008; KOEPSELL et al. 2007), but still did not 
clarify whether these drugs are substrates that are actively transported by OCT1, or act 
only as inhibitors of OCT1. 
 
Results 
122 
 
                                             
 
Fig.3. 25 Inhibition of OCT1 uptake by tropisetron, ondansetron and palonosetron. The 
inhibition of 1 µM ASP
+
 uptake in OCT1 overexpressing cell lines was compared between the 
three antiemetic drugs and quinine and TEA as two model substrates of OCT1 on the OCT1-
mediated ASP
+
 uptake. All three antiemetic drugs, tropisetron, ondansetron and palonosetron were 
stronger inhibitors of the ASP
+
 uptake than the model substrates quinine and TEA. The graph 
shows mean values and standard errors of three independent experiments. 
 
3.3.2 pH-dependance of the inhibitory effect of tropisetron and 
ondansetron 
Tropisetron and ondansetron are weak organic bases. Thay are protonated and positively 
charged depending on the pH of the media. The change in the pH will automatically 
lead to change in the fraction of the drug that is protonated and thus positively charged. 
This experiment was performed in order to investigate whether any changes in 
ectracellular pH affect the affinity of tropisetron and ondansetron to react with OCT1 
measured as change in their ability to inhibit ASP
+
 uptake. For this purpose, the uptake 
of ASP
+
 in HEK293-TRex cells that overexpress OCT1 was measured in the presence 
and in the absence of 100µM tropisetron or ondansetron at four different pH values (5.4, 
6.4, 7.4 and 9). As expected, the highest ASP
+
 uptake was observed at physiological pH, 
as measured cells treated with ASP
+
 only (Fig.3.26). The inhibitory assay using 
tropisetron and ondansetron showed tropisetron significantly inhibited the ASP
+
 uptake 
in all four different pH. On contrary the inhibitory effect of ondansetron declined by 
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increasing of the pH medium with 100 µM ondansetron showing almost no inhibition at 
pH of 9. 
    
Fig.3. 26 pH dependence of the OCT1 inhibition of tropisetron and ondansetron. ASP
+
 uptake 
was measured after incubating the OCT1-overexpressing HEK293-TRex in the presence and in the 
absence of tropisetron or ondansetron. The intracellulary accumulated ASP
+ 
was measured using 
TECAN ultra plate photometer and normalized to the total protein amounts in the cells.The graph 
shows mean value of three independent experiments. 
 
3.3.3 Direct measurements of tropisetron and ondansetron cellular 
uptake by OCT1. Effects of the genetic polymorphisms in OCT1. 
To identify whether tropisetron and ondansetron are substrates and not only inhibitors 
of OCT1, the intracellular uptake of both drugs was measured in cells overexpressing 
the wild type OCT1 and compared to the control cells transfected with pcDNA5.1 
empty vector. The cells were exposed to the drugs for 1 min and then the cells were 
lysed, and to the intracellular concentrations of tropisetron and ondansetron were 
measured using HPLC. Compared with cells transfected with empty vector, the OCT1-
overexpressing HEK293-TRex cells (wild type) showed a 2.3-fold increase in the 
intracellular accumulation of tropisetron (P<0.001, Student’s t-test; Fig 3.27 A). This 
increase was completely reversible by MPP
+
 (1-methyl-4-phenylpyridinium), a specific 
model substrate and competitive inhibitor of OCT1. This experiment demonstrated that 
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tropisetron is a substrate for OCT1. In the same transport assay for ondansetron, the 
control cells showed high uptake of ondansetron and the overexpression of OCT1 led 
only to a marginal 28% increase in the ondansetron uptake that was not significant 
(P=0.59, Mann-Whitney-U test; Fig.3.27 B).  
Next we analyzed how common polymorphisms in the OCT1 gene may influence 
tropisetron uptake. The uptake of tropisetron was measured in the HEK293-TRex cells 
overexpressing variant OCT1 isoforms carrying the five common polymorphisms. In all 
variants, the uptake of tropisetron was reduced to the levels of the OCT1 non-
expressing cells (P<0.001, one-way ANO-VA; Fig.3.27 A).        
                                                                           
 
             
Fig.3. 27 Direct measurements for cellular uptake of tropisetron (A) and ondansetron (B) in 
OCT1 overexpressing HEK293-TRex cells. A) Control cells (pcDNA5.1, black bar) and cells 
overexpressing OCT1 wild-type (WT, green bar) or polymorphic OCT1 forms (red bars) were 
incubated with 1 µM tropisetron for 3min. The intracellular accumulation of tropisetron was 
measured by high-performance liquid chromatography (HPLC). The cellular uptake of tropisetron 
was blocked in the cells expressing OCT1 wild-type using 100 µM MPP
+ 
(green hatched bars). B) 
The cellular uptake of ondansetron in control cell (pcDNA5.1, black bar) and cells overexpressing 
OCT1 wild-type (OCT1, green bar). As it indicated there is no significant difference between the 
cells overexpressing OCT1wild type and control. The graphs show mean value and standard errors 
of three independent experiments. 
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It could be concluded that tropisetron is transported by OCT1 and that the common 
loss-of function polymorphisms in OCT1 abolished tropisetron transport. Although 
ondansetron inhibited the OCT1 transport (see section 3.3.1), a direct OCT1-mediated 
uptake of ondansetron did not show any significant difference between OCT1-
transfected cells compared to control cells. 
 
 
3.4 OCT1 as a cellular uptake transporter of the analgesic drugs 
tramadol and O-desmethyltramadol 
 
3.4.1 PAMPA assay for tramadol and O-desmethyltramadol 
The ability of tramadol and O-desmethyltramadol to penetrate cell membranes by 
carrier-independent diffusion was evaluated using a parallel artificial membrane 
permeability assay (PAMPA) as described in section 2.2.12. Tramadol showed high 
carrier-independent membrane permeability (Pe of 12.6 × 10
−6
 ± 0.12 × 10
−6
 cm/s), 
whereas O-desmethyltramadol showed low permeability (Pe of 1.46 ×10
−6
 ± 0.08 × 10
−6
 
cm/s). These findings suggest that tramadol, but not O-desmethyltramadol, may 
penetrate cell membranes by means of carrier-independent diffusion (Fig.3.28).   
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Fig.3. 28 Carrier-independent membrane permeability of tramadol and O-
desmethyltramadol as measured using the parallel artificial membrane permeability assay 
(PAMPA). Mean permeability (Pe) values of all five different concentrations (0, 1, 10, 50 and 100 
µM) are given. The graph shows mean values and standard errors of three independent 
experiments performed in duplicate. 
 
3.4.2 Inhibition of OCT1-mediated ASP+ uptake by tramadol and O-
desmethyltramadol 
To determine if tramadol and O-desmethyltramadol are the substrates for OCT1, the 
ability of these two drugs to inhibit the OCT1-mediated uptake was measured. Both 
tramadol and O-desmethyltramadol inhibited with ASP
+
 uptake in HEK293-TRex cells 
overexpressing OCT1 (Fig. 3.29). Tramadol strongly inhibited ASP
+ 
uptake, with a half-
maximal inhibitory concentration (IC50) of 30.3 ± 3.1 μM, whereas O-
desmethyltramadol inhibited the uptake less strongly, with an IC50 of 172 ± 73 μmol/l. 
This data indicated that both tramadol and O-desmethyltramadol may be substrates of 
OCT1. 
            
Fig.3. 29 Inhibition of the cellular uptake of the OCT1 substrate ASP
+
 by tramadol and O-
desmethyltramadol. OCT1-overexpressing HEK293 cells were incubated with 1 μM ASP+ for 3 
min in the presence of increasing concentrations of tramadol and O-desmethyltramadol. The graph 
shows mean values and standard errors of three independent experiments and illustrates that both 
substances do inhibit OCT1. However, tramadol inhibits OCT1 more strongly than O-
desmethyltramadol. 
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3.4.3 Tramadol and O-desmethyltramadol cellular uptake by OCT1 
and effects of the OCT1 polymorphisms. 
To determine whether tramadol and O-desmethyltramadol are substrates and not only 
inhibitors of OCT1, direct measurements of the cellular uptake of the both drugs by 
OCT1 were performed. The measurement of intracellular uptake by HPLC showed no 
differences in the uptake of tramadol between the OCT1 overexpressing cells and the 
control cells transfected with an empty plasmid (Fig. 3.30 A). In contrast, the cellular 
uptake of O-desmethyltramadol was 2.4-fold higher in the OCT1-overexpressing cells 
than in the control cells (P < 0.001, Student’s t-test; Fig. 3.30 B). This increase in the O-
desmethyltramadol uptake was completely reversible by the addition of 100 μmol/l 
MPP
+
 and was reversed to an extent of >85% by the addition of 100 μmol/l ASP+ (Fig. 
3.30 B).  
Next the effect of OCT1 polymorphisms on the uptake of O-desmethyltramadol was 
analyzed. The uptake of O-desmethyltramadol was significantly lower as compared 
with uptake by wild-type OCT1 (P < 0.05, Student’s t-test; Fig. 3.30 B). The uptake in 
the cells overexpressing OCT1 variants did not differ significantly from the uptake in 
control cells transfected with the empty plasmid (one-way analysis of variance with 
Tukey’s honestly significant difference post hoc comparison). 
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Fig.3. 30 The cellular uptake of (A) tramadol and (B) O-desmethyltramadol in OCT1 
overexpressing HEK293 cells. The OCT1 overexpressing HEK cells and the control cells 
transfected with pcDNA5.1 empty vector were incubated with 1 µM tramadol or 1 μM O-
desmethyltramadol for 1 min, and the intracellular concentrations of both substances were 
measured. A) No differences were detected for tramadol uptake in OCT1 overexpressing OCT1 
wild-type (WT) (green bar) compared to the control cells (pcDNA5.1, black bar). B) 
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Overexpression of the wild type OCT1 increased the O-desmethyltramadol uptake by 2.5-fold 
(WT) (green bar), but not the overexpression of the loss-of-function OCT1 variants (red bars). The 
cellular uptake of O-desmethyltramadol was blocked by 100 μM MPP+ in the cells that expressed 
wild-type OCT1 (green hatched bar). The graph shows mean values and standard errors from three 
independent experiments. 
 
 
Based on the artificial membrane permeability assays, on the inhibition and direct 
uptake assays, it could be concluded that O-desmethylramadol is a substrate of OCT1 
and O-desmethyltramadol uptake depends on OCT1 polymorphisms. In contrast 
tramadol have high carrier-independent membrane permeability and do not depend on 
OCT1 for its cellular uptake.   
 
 
3.5. OCT1 as a cellular uptake transporter of the model drug 
debrisoquine 
 
3.5.1 PAMPA assay for debrisoquine 
In order to assess the ability of debrisoquine to penetrate cellular membranes in a 
carrier-independent manner, we measured debrisoquine diffusion through artificial 
PAMPA membranes after 5 hours incubation at room temperature as described 
previously (See section 2.2.12). Debrisoquine displayed very low artificial membrane 
permeability (Pe 0.01 x 10
-6
 cm/s), suggesting that debrisoquine is not able to penetrate 
cellular membranes in a carrier-independent manner (Fig.3.31). This observation is in 
concordance with the low calculated lipophilicity value for debrisoquine (octanol/water 
distribution coefficients as log D7.4 of 1.0; calculated using ADMED PredictorTM 
Software Version 5.0, Simulations Plus Inc., Lancaster, CA, USA). 
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Fig.3. 31Carrier-independent membrane permeability of debrisoquine measured by 
PAMPA. The mean permeability (Pe) value of all five different concentrations of debrisoquine (0, 
1, 10, 50 and 100 µM) are given. The graph shows mean values and standard errors of three 
independent experiments. 
 
3.5.2 Inhibition of OCT1-mediated MPP+ uptake by debrisoquine 
First we investigate whether debrisoquine may inhibit OCT1- mediated uptake. For that 
purpose, OCT1 overexpressing HEK293-TRex cells as well as control cells transfected 
with an empty pcDNA5.1 vector were used. The cells were incubated with MPP
+
 (1-
methyl-4-phenyl- pyridinium), a model substrate of OCT1, in the presence of increasing 
concentrations of debrisoquine. Without inhibition, MPP
+
 uptake was 13.6-fold higher 
in the cells overexpressing OCT1 compared to the control cells (Fig. 3.32). 
Debrisoquine strongly inhibited the MPP
+
 uptake. The difference in the MPP
+
 uptake 
between the OCT1 overexpressing and the control cells was completely reversed at 500 
µM debrisoquine and half-maximal inhibitory concentration (IC50) of debrisoquine was 
6.2 ± 0.8 µM (Fig. 3.32). 
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Fig.3. 32 Debrisoquine inhibits the uptake of the OCT1 model substrate MPP
+.
 The cellular 
accumulation of 1 μM MPP+ for 3 min in the presence of increasing concentration of debrisoquine 
was measured in cells overexpressing OCT1 and in control cells transfected with the empty 
plasmid pcDNA5.1. The graph shows mean values and standard errors from three independent 
experiments. 
 
 
3.5.3 Direct measurements of debrisoquine cellular uptake by OCT1.  
First we measured time dependence of the OCT1-mediated debrisoquine uptake. 
Thereto we incubated the cells overexpressing OCT1 wild type and control cells with a 
constant concentration of 1 µM debrisoquine and different incubation time (30 sec, 1 
min, 5 min, 15 min and 30 min). Intracellular concentration increased in a time 
dependent manner in the wild-type, whereas no similar effect was observed in the 
control cells (Fig.3.33). 
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Fig.3. 33 Time dependence of debrisoquine accumulation. HEK cells overexpressing OCT1 
(green line) and control cells (transfected with the empty pcDNA5.1 vector, black line) were 
incubated with 1 µM debrisoquine for 30 sec, 1, 5, 15, or 30 min and the amount of intracellular 
debrisoquine was determined by means of HPLC. The graphs show mean values and standard 
errors from three independent experiments. 
 
 
 
Next, the OCT1-mediated uptake of debrisoquine was measured by comparing the in-
tracellular accumulation of debrisoquine between the OCT1-overexpressing and control 
cells at different concentrations of debrisoquine (0, 1, 5, 10, 20, and 40 µM). OCT1-
overexpressing cells showed strong concentration-dependent uptake of debrisoquine 
that was absent in the control cells (Fig. 3.34 A). To distinguish between the OCT1-
specific and carrier-independent uptake of debrisoquine, the uptake of the control cells 
was subtracted from the uptake of the OCT1-overexpressing cells. The OCT1-specific 
debrisoquine uptake showed typical Michaelis–Menten kinetics with a KM of 5.9 ± 1.5 
µM and Vmax of 41.9 ± 4.5 pmol/min/mg of protein (Fig. 3.34 B). From this data, we 
can conclude that debrisoquine is a high affinity substrate of OCT1. 
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A) 
                         
B) 
                          
Fig.3. 34 Concentration dependence of the OCT1-mediated cellular uptake of debrisoquine. 
(A) Concentration dependence of debrisoquine uptake. OCT1-overexpressing (OCT1) and control 
cells (pcDNA5.1) were incubated for 1 min with increasing concentrations of debrisoquine. (B) 
The OCT1 specific debrisoquine uptake calculated by subtracting the uptake in the control cells 
from the uptake in the OCT1-overexpressing cells using the dataset shown in (A). Intracellular 
accumulation of debrisoquine was measured by means of high-performance liquid 
chromatography and normalized to the total protein amounts in the cells. The graphs show mean 
values and standard errors from three independent experiments. 
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3.5.4 Effects of OCT1 genetic polymorphisms on debrisoquine 
uptake 
We analyzed how common coding polymorphisms in OCT1 affect debrisoquine uptake. 
For this reason, we compared the intracellular accumulation of debrisoquine in 
HEK293-TRex cells overexpressing the wild type or the five variant OCT1s as well as 
control cells transfected with pcDNA5.1 empty vector. In the presence of 1 µM extra-
cellular debrisoquine, all OCT1 variants tested showed lower debrisoquine uptake 
compared to the wild-type OCT1 (Fig. 3.35). However, the observed reduction in the 
uptake varied among the isoforms carrying different polymorphisms. We were unable to 
demonstrate a significant decrease in debrisoquine uptake when the Met420 deletion 
variant was present. In contrast, the Cys88Arg and Gly465Arg substitutions led to 
complete lack of OCT1-mediated uptake.    
   
             
Fig.3. 35 Effects of common loss-of-function polymorphism on the debrisoquine cellular 
uptake. The OCT1 wild type (green bar) carrying OCT1 variants (red bars) and the control 
HEK293 cells transfected with the empty pcDNA5.1 plasmid (black bar) were incubated with 1 
µM debrisoquine for 1 min. The graphs show mean values and standard errors from three 
independent experiments 
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Analyses of the concentration dependence of the debrisoquine uptake showed that the 
Vmax of OCT1 was affected by all of the polymorphisms tested (P < 0.003, ANOVA 
with Tukey-HSD post hoc test, Fig.3.36). In contrast, the KM values were not signifi-
cantly affected by any of the polymorphisms (P = 0.73, ANOVA; Table.3.6). 
 
                        
               
 
Fig.3. 36 Concentration dependence of OCT1-mediated debrisoquine uptake in the wild-type 
and loss-of-function OCT1 isoforms after incubation with increasing concentrations of 
debrisoquine (0, 1, 5, 10, 20 and 40 μmol/l). The cellular uptake of debrisoquine was measured by 
means of high-performance liquid chromatography and normalized to the total protein amount of 
the cells. The graphs show mean values and standard errors from three independent experiments.  
 
 
 
 
 
 
 
 
 
Results 
136 
 
Table 3. 6 Effects of the common loss-of-function amino acid substitutions in OCT1 on the 
kinetic of debrisoquine.  
SNP 
Vmax Km Clint 
Mean SEM Mean SEM Mean 
Reference (WT) 41.9 4.5 5.9 1.5 7.1 
61Cys 15.6* 0.5 6.2 3.5 2.5 
401Ser 3.6* 2.1 2.6 2.5 1.4 
420del 21.7* 1.1 4.8 1.5 4.5 
420del/88Arg na na na na na 
420del/465Arg na na na na na 
na., not applicable. * P < 0.01 compared to the WT reference in a Tukey’s HSD post hoc analysis 
following one-way ANOVA (P < 10
-4
). 
 
 
3.5.5 Effects of drug–drug interactions on the OCT1-mediated 
debrisoquine uptake  
In this experiment we analyzed whether known model OCT1 substrates or clinically 
relevant drugs may inhibit the OCT1-mediated cellular uptake of debrisoquine 
(Fig.3.37). For this reason, we used the well known OCT1 model substrates MPP
+
 and 
ASP
+
, the inhibitor TBA
+
 (tetra-N-butylammonium) and the clinically relevant drugs 
tropisetron, ondansetron, tramadol and paroxetine (all known as OCT1 substrates or 
inhibitors from earlier data). All substances tested led to significant inhibition of the 
OCT1-mediated uptake (P < 0.003, ANOVA with Tukey-HSD post hoc test). Of all the 
tested substances, the least inhibition was observed with tramadol (66% reduction of the 
OCT1-mediated uptake, P = 0.003). This result was expected given that tramadol has a 
higher IC50 value for OCT1 than do tropisetron and ondansetron (Tzvetkov et al., 2010; 
2011). Paroxetine had higher inhibitory effect on debrisoquine uptake among the 
clinically relevant drugs. The highest inhibitory effect of all tested compounds was 
observed for ASP
+
 (Fig.3.37).  
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It could be concluded that debrisoquine is a low membrane permeability drug and de-
pends for its cellular uptake on OCT1-mediated uptake. Furthermore, known OCT1 
inhibitors reduced or completely abolished the ability of OCT1 to mediate debrisoquine 
uptake. 
 
              
Fig.3. 37 Inhibition of the OCT1-mediated uptake debrisoquine by OCT1 inhibitors and 
weakly basic drugs. HEK293-TRex cells overexpressing OCT1 were incubated for 1 min with 1 
µM debrisoquine in the absence of any inhibitors (green bar) or in the presence of 200 µM model 
OCT1 substrates or drugs known to be substrates or inhibitors of OCT1 (hatched green bars). As a 
control, HEK293-TRex cells transfected with the empty pcDNA5.1 plasmid were incubated with 
debrisoquine in the absence of inhibitors (black bar). The cellular uptake of debrisoquine was 
measured by means of high-performance liquid chromatography and normalized to the total 
protein amounts in the cells. The graph shows mean values and standard errors from three 
independent experiments. 
 
3.5.6 Interaction between OCT1 and CYP2D6 during metabolism of 
debrisoquine 
To analyze the interactions between cellular uptake and intracellular metabolism of 
debrisoquine, cells overexpressing OCT1 alone, CYP2D6 alone and a combination of 
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OCT1 and CYP2D6 were used. The cells were incubated with the same concentration of 
debrisoquine (10 µM) for different incubation time (1, 3, 20, 60, 90 and 120 min). The 
intracellular amount of debrisoquine and 4-OH debrisoquine was measured by HPLC 
(Fig. 3.38).  
The debrisoquine uptake was increased by increasing incubation time for OCT1 
overexpressing cells, whereas the maximum uptake was obtained in 1 hour incubation 
for HEK cells overexpressing OCT1::CYP2D6::IRES::POR. No clear trend was 
observed for HEK cells overexpressing CYP2D6::IRES::POR or control cells (Fig. 
3.38A). On the other hand, the maximum amount of 4-hydroxy debrisoquine was 
reached after 1 hour incubation for the cells overexpressing only CYP2D6, whereas the 
maximum amount of 4-hydroxy debrisoquine was reached already after 3 minutes 
incubation for the cells overexpressing OCT1 and CYP2D6 (Fig. 3.38B). As expected 
no 4-hydroxy debrisoquine was detected in the cells overexpressing OCT1 only or in 
the control cells. 
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Fig.3. 38 Time dependence of debrisoquine uptake (A) and 4- hydroxy debrisoquine production 
(B) in the cells overexpressing OCT1 (single hatched bars), CYP2D6 (yellow bars) and 
combination of OCT1 and CYP2D6 (double hatched bars). The control cells transfected with the 
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empty pcDNA5.1 vector are depicted as black bars. The cells were incubated with 10 µM 
debrisoquine, washed, lysed and the intracellular accumulation of debrisoquine and 4-hydroxy 
debrisoquine was quantified by HPLC The graphs show mean values and standard errors from 
three independent experiments.  
 
3.5.7 Effects of loss of function polymorphisms in OCT1 on uptake 
and metabolism of debrisoquine  
In this experiment to evaluate the interactive effect of polymorphisms in OCT1 with 
CYP2D6 enzyme on production of 4-OH debrisoquine, the cells overexpressing 
OCT1::CYP2D6::IRES::POR wild type and the variant of OCT1 420del88R as well as 
the HEK cells transfected with empty vector pcDNA5 as control were treated with the 
same concentration of debrisoquine (10 µM) and incubated for 3 min. Then the 
intracellular amount of debrisoquine and 4-OH debrisoquine was measured by HPLC 
(Fig.3.39 A and B). As illustrated in the graphs, the amount of debrisoquine uptake and 
consequently intracellular production of 4-OH debrisoquine was significantly higher in 
wild type compared to loss of function 420del88R variant or control cells. 
 
 
Fig.3. 39 Interactive effects of polymorphisms in the OCT1 transporter with CYP2D6 
metabolizing enzyme on debrisoquine uptake (A) and 4-OH debrisoquine production (B) in 
the HEK cells overexpressing OCT1::CYP2D6::POR wild type (green bar) and 420del88R variant 
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of OCT1 (red bar) in compare with the HEK cells transfected with empty vector pcDNA5.1 as 
control (black bar).  The graphs show mean values and standard errors from three independent 
experiments. 
 
3.5.8 Effects of CYP2D6 inhibitors on debrisoquine metabolism in 
the triple transfected system 
In this experiment we analyzed whether paroxetine known as an inhibitor of CYP2D6 
may inhibit the OCT1-mediated debrisoquine uptake and subsequently CYP2D6-
mediated metabolism of debrisoquine to 4-hydroxy debrisoquine at the same fashion 
(Fig.3.40 A and B). For this reason, we used increasing concentration of paroxetine (0, 
0.1, 0.2, 0.5, 1, 5, 10 and 50 µM) with the same concentration of debrisoquine (10 µM). 
The results showed that the amount of intracellular debrisoquine declined deramatically 
after using paroxetine, however this trend was different for 4-hydroxy debrisoquine. As 
we can see, at low concentrations, paroxetine acted predominantly as an inhibitor of 
OCT1, whereas at higher concentrations, the inhibitory effects of paroxetine on 
metabolism of 4-hydroxy debrisoquine predominated. The highest concentrations of 
paroxetine (50 µM) can completely blocked activity of CYP2D6 enzyme. This 
experiment impressively demonstrates that paroxetine at the low concentrations is 
predominantly an inhibitor of OCT1 and not of CYP2D6. 
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Fig.3. 40 Inhibitory effect of paroxetine on debrisoquine uptake (A) and 4- hydroxy 
debrisoquine production (B) in the HEK cells overexpressing OCT1 and CYP2D6. The HEK 
cells overexpressing OCT1 and CYP2D6 were treated with 10 µM debrisoquine and increasing 
concentration of paroxetine (0, 0.1, 0.2, 0.5, 1, 5, 10 and 50 µM) for 3 min and consequently 
intracellular accumulation of debrisoquine and 4-hydroxy debrisoquine in the cells was quantified 
by HPLC. The graphs show mean values and standard error from three independent experiments.  
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3.6 OCT1 as a possible uptake transporter of the cytotoxic 
drugs irinotecan and doxorubicin 
 
3.6.1 Inhibition of OCT1-mediated uptake by irinotecan and its active 
metabolite SN38 
Irinotecan and its active metabolite SN38 were tested as potential substrates of OCT1. 
Thereto first we measured the ability of irinotecan and SN38 to inhibit OCT1-mediated 
ASP
+
 uptake. HEK293-TRex cells overexpressing wild type OCT1 were incubated with 
1μM ASP+ for 3 min in the presence of increasing concentrations of irinotecan or SN38 
(0, 1, 10, 100 and 500 µM). Only irinotecan, but not SN38, inhibited the OCT1-
mediated ASP
+
 uptake (Fig.3.41). The half-maximal inhibitory concentration (IC50) of 
irinotecan was 3 ± 0.54 µM. 
 
 
                 
Fig.3. 41 Inhibition of the OCT1 by irinotecan and SN38. OCT1-overexpressing HEK293-
TRex cells were incubated with 1 μM ASP+ for 3 min in the presence of increasing concentrations 
of irinotecan or SN38 (0, 1, 10, 100 and 500 µM). The graph shows mean values and standard 
errors of three independent experiments. 
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3.6.2 pH-dependance of the inhibitory effect of irinotecan and its 
metabolite SN38  
Next we investigate whether the changes in pH medium affect the inhibitory effect of 
irinotecan and SN38 on OCT1-mediated ASP
+
 uptake. Thereto HEK293-TRex cells 
overexpressing wild type OCT1 was incubated with 1µM ASP
+
 for 3 min in the 
presence or in the absence of 100µM irinotecan or SN38 in HBSS medium adjusted at 
different pH. Four different pH were analyzed (pH of 5.4, 6.4, 7.4 and 9). Similary as 
shown before (section 3.3.2), the highest ASP
+
 uptake was observed at pH of 7,4 . 
Irinotecan significantly inhibited the ASP
+
 uptake at all pH tested except pH 9 which no 
significant suppression was seen (Fig.3.42). In contrast, SN38 inhibited the ASP
+
 
uptake only at pH 9.  
 
        
Fig.3. 42 pH-dependant effects of irinotecan and SN38 on the OCT1-mediated cellular 
uptake of ASP
+
. HEK293-TRex cells overexpressing OCT1 were incubated for 3 min with 1µM 
ASP
+
 in the presence and in the absence of irinotecan or SN38. The intracellulary accumulated 
ASP
+ 
was measured using TECAN ultra plate photometer and normalized to the total protein 
amounts in the cells. The graph shows mean values and standard errors of three independent 
experiments. 
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3.6.3. Effects of OCT1 overexpression on irinotecan cytotoxicity 
Irniotecan is not a fluorescent substrate and we did not had access to radiolabeled 
irinotecan. Therefore, instead of going the tedious way of developing an HPLC method 
for intracellular drug and metabolite concentrations, we analyzed  the differences in the 
amount of cellular irinotecan indirectly by differences in its cytotoxicity. In this 
experiment irinotecan was used as a cytotoxic drug to measure and compare the cell 
viability between control cells and cells overexpressing wild type and variant OCT1s. 
To exclude cell line specific differences in the irinotecan cytotoxicity the experiment 
was done both in HEK and CHO cell lines. The number of vital cells after the treatment 
was assessed using MTT cell proliferation assay. Incubation of the control cells with 
irinotecan resulted in 14 % decrease in the vitality of the HEK293 cells (Fig.3.43A) or 
even 8% increase in the vitality of the CHO cells (Fig.3.43B). The OCT1 
overexpression did not result in an increase of irinotecan cytotoxicity and there were no 
significant differences between the variant and wild-type OCT1. 
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Fig.3. 43 Effects of OCT1 on irinotecan cytotoxicity in HEK (A) and CHO cells (B). The cells 
were treated with 100µM concentration of irinotecan for 15 min and then after overnight 
incubation the cell viability was determined by adding 1 ml  750 µg/ml MTT to each well and 
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incubated for 2 hours at 37
o
C. The absorbance of the produced formazan was measured at 570 nm. 
The graph shows mean values and standard errors of three independent experiments. 
 
As can be seen from both cell constructs, there was no relevant modification of cell 
toxicity depending on the expression of active or mutant OCT1. Thus, OCT1 may not 
be a relevant transporter for irinotecan or its active metabolite SN38.  
 
3.6.4. OCT1-mediated cellular uptake of doxorubicin  
In another experiment we analyzed whether OCT1 may transport doxorubicin. 
Doxorubicin has endogenous fluorescence that enabled us to measure doxorubicin 
uptake fluorometricaly. The OCT1 overexpressing HEK293-TRex cells as well as the 
control cells transfected with empty pcDNA5.1 plasmid were treated with increasing 
concentrations of doxorubicin (0, 1, 10, 100 and 500 µM) for 3 min. The intracellular 
accumulated doxorubicin was measured by TECAN ultra plate photometer. There were 
no significant differences in doxorubicin uptake between the OCT1 overexpressing and 
the control cells (Fig. 3.44), suggesting that OCT1 is not involved in the cellular uptake 
of doxorubicin. 
 
 
Fig.3. 44 Doxorubicin uptake is not dependent on OCT1 transporter. OCT1-overexpressing 
HEK cells as well as HEK cells transfected with empty vector pcDNA5 were exposed with 
increasing concentrations of doxorubicin (0, 1, 10, 100 and 500 µM) for 3 min. Doxorubicin has a 
native fluorescence that was used to determine the intracellular doxorubicin accumulation. 
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Doxorubicin fluorescence was measured at an excitation wave length of 485 nm and an emission 
wave length of 612 nm using a TECAN Ultra plate
TM
 photometer and normalized to the total 
protein amounts in the cells. The graphs show mean values and standard errors from three 
independent experiments. 
 
3.7 Analyzing potential dominant negative effect of the OCT1 
protein variants 
3.7.1 Generation of pcDNA5.1::OCT1_GFP construct 
We generated a fusion construct between OCT1 and GFP in order to monitor the 
subcellular localization of OCT1 more precisely as compared with 
immuno¬histochemistry. Therefore we fused EGFR to the C-terminus of the OCT1 
protein. The pcDNA5.1 plasmid containing OCT1 wild type or two variants A61C and 
420del-C88A, and also the pIRES2-EGFP plasmid (Addgene, Cambridge, MA) 
containing a 719 bp fragment of green flourescence protein (GFP). To amplify OCT1 
and GFP by PCR, the primers were designed to have homologous for both genes 
(Table3.7). For this reason, the reverse primer of OCT1 had a homology with the 
forward primer of GFP which in turn caused GFP to tag in the downstream of OCT1 
open reading frame and then the experiment was performed according to DNA 
assembling procedure as described previously (see section 2.2.1.10). 
 
Table 3. 7 The lists of primers used for amplification of OCT1 and GFP. 
Primer Primer sequence 
Fussion_OCT1_f       5’-GTTTAAACTTAAGCTTGCATGCTGAG-3’ 
Fussion_OCT1_r       5’-CAGCTCCTCGCCCTTGCTCACCATGGTGCCCGAGGGTTGTGAGGT-3’ 
Fussion_eGFP_f     5’-AACCTCAGAACCCTCGGGCACCATGGTGAGCAAGGGCGAGGAGCT-3’ 
Fussion_eGFP_r          5’-ATCGCTCTAGAGCGGCCGCTTTACTT-3’ 
 
 
Then the assembled product (OCT1_GFP) was amplified with the forward primer, 
Fussion_OCT1_f   and the reverse primer. Fussion_OCT1_f and Fussion_eGFP_r primers 
introduced the restriction sites for HindIII and NotI respectively (Fig.3.45).  
 
Results 
149 
 
 
Fig.3. 45 Scheme of assembling of the OCT1_GFP fusion construct. GFP fragment was used to 
the C-terminal end of OCT1 cDNA according to DNA assembling method.  
 
The PCR product was cloned into pCR-XL-TOPO plasmid and sequenced. The 
OCT1_GFP fragments was digested with HindIII and NotI restriction enzymes from 
pCR-XL-TOPO, purified from a 1% agarose gel and cloned into pcDNA 5.1 plasmid 
that was linearized with the same restriction enzymes and purified from agarose gel 
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(Fig.3.46). The resulting construct pcDNA5.1::OCT1_GFP carries the OCT1wild-type 
and two variants A61C and 420del- C88A fused to EGFP. 
 
Fig.3. 46 Scheme of cloning of the OCT1-GFP fusion construct into the expression vector 
pcDNA5.1.  
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3.7.2 Generation of HEK293 cell lines transiently expressing OCT1-
GFP 
This cell line was produced in order to investigate localization of OCT1 transporter in 
the cell. For this purpose, after generation of pcDNA5.1::OCT1-GFP constructs for 
OCT1 wild type and two variants (61C and 420del88R), these constructs were 
transiently transfected to HEK293T-Rex cells as described before for transient 
transfection (see section 2.2.5.4.1) and then the transfected cells were analyzed by ASP
+
 
uptake measurement.  
 
 
3.7.3 Quantitative measurement of OCT1 activity  
Recent report suggested that OCT1 protein exist as oligomers and that disulfide bridges 
in the N-terminal extracellular loop are essential for the oligomerization and the correct 
cellular localization of OCT1 (KOEPSELL, 2011). Two of the common polymorphisms in 
the OCT1, which were also analyzed in this work, result in either a gain (R61C) or a 
loss of cysteine amino acid (C88R). Both cysteine amino acids are located in the N-
termina extracellular loop and may change the ability of oligomerization and correct 
cellular localization of OCT1. Incorrect cellular localization of the 61C variant has been 
shown previously (SHU et al., 2009). In this experiment we analyzed whether the 
presence of one polymorphic allele carrying either 61C or 88R may lead to incorrect 
oligomerization and cellular localization not only of the polymorphic, but also of the 
wild-type allele; to lead to so called dominant negative effect.  
To do this, we transiently transfected HEK293-TRex cells with an equimolar mixture of 
pcDNA5.1 plasmid carrying OCT1 wild type and carrying one of the variants allele  
61C or 420del-88R. The resulting OCT1 activity was compared to the OCT1 activity in 
cells transfected with wild type only and with the variant only (simulating the 
homozygous carriers of this variants). To measure OCT1 activity, the transfected cells 
were incubated with four different concentrations of ASP
+
 (5, 20, 50 and 150 µM) for 3 
min. The maximal activity Vmax  of cells transfected with the combination of the wild 
type and variant allels (heterozygous) exhibited exactly average Vmax activity between 
the wild type alone (homozygous wild type) or OCT1 variants alone (homozygous 
variant carrier) (Fig.3.47, Table 3.8). Identical effects were observed when the 61C 
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variant and the 420del-88R variants were analyzed.  This result suggested that there are 
no dominant negative effects of the 61C and 88R polymorphisms on the OCT1 activity. 
 
             
 
Fig.3. 47 ASP
+ 
kinetics in HEK cells overexpressing  OCT1 wild type alone (homozygous) or 
in combination of wild type and a loss of function variants (heterozygous). The ASP
+
 uptake at 
four different concentrations of ASP
+
 were measured by means of TECAN ultra plate photometer 
and normalized to the total protein amounts in the cells. The graph shows mean values of three 
independent experiments. 
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               Table 3. 8 Effects of the combined allels in OCT1 on the kinetics of ASP
+
 uptake. 
 
 
SNP 
 
Vmax* 
 
Km [µM] 
Mean SEM Mean SEM 
OCT1(wt) /OCT1 (wt) 
2015.9 31.94 13.69 0.8 
wt /61C 1317,09 19.18 11,06 0.65 
61C/61C 601,51 42.45 19,34 4.62 
     
OCT1(wt) /OCT1 (wt) 
2015.9 31.94 13.69 0.8 
wt /420del88R 942.83 53.94 7.57 1.98 
420del88R/420del88R 387.36 47.93 163.45 34.04 
       * P < 0.05 in Jonckheere-Terpstra trend test. 
 
 
3.7.4 Analysis of the subcellular localization 
Next, we analyzed whether the presence of OCT1 variant alleles carrying 61C or 
420del88R affect the correct cellular localization of the transporter in the membrane. 
For this reason, the HEK cells overexpressing OCT1 wild type and 61C or 420del88R 
variants were used to investigate the subcellular localization of OCT1 using 
immunocytochemical staining (see section 2.2.7). After reaching the cells to 80% 
confluency, the cells were stained by indirect immunofluorescence using primary antibody 
SLC22A1 (2c5, Novus Biologicals, Cambridge, UK) and flourochrome conjugated 
secondary antibody (Goat anti mouse Alexa 488, Invitrogen) and then visualized by 
confocal microscopy (Carl Zeiss, Jena). The results showed while the OCT1wild type was 
localized on the membrane, the mentioned variants showed a notorious change where 
most of the OCT1 protein was intracellular (Fig.3.48). These observations were 
validated by ASP
+
 uptake studies as described previously (see section 3.7.3).   
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Fig.3. 48 Subcellular localization of OCT1 wild type and two genetic variants. The HEK293 
cells overexpressing OCT1-wild type and 61C or 420del88R variants were treated with mouse 
anti-(human) primary antibody SLC22A1 (2c5, Novus Biologicals, Cambridge, UK) for OCT1 
and visualized using goat anti-mouse conjugated to fluorochrome Alexa 488 secondary antibody 
(Invitrogen). The green particles depict localization of OCT1 protein, while the blue spots are 
nucleus stained by DAPI.  A) The HEK293 cells overexpressing OCT1 wild type show membrane 
localization. B) The HEK293 cells overexpressing OCT1 variants exhibit reduced membrane and 
enhanced cytoplasmic localization. 
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4 Discussion 
4.1 Effects of loss of function polymorphisms of OCT1 
transporter on the uptake and kinetics of ASP+ 
In the current study, we generated HEK293 cells overexpressing OCT1 as wild-type or 
five of its common SNPs. These loss-of-function OCT1 forms carrying the single amino 
acid substitutions Arg61Cys, Gly401Ser, and Met420del, or the combinations 
Met420del-with-Cys88Arg and Met420del with Gly465Arg, represent all the common 
and functionally relevant OCT1 alleles in Caucasians (TZVETKOV et al. 2009; SHU et al. 
2003; KUHNE et al. 2009). Our data showed that the OCT1 variants and wild type have 
similar levels of mRNA transcripts in the OCT1 stably transfected HEK cell lines (Fig. 
3.6), suggesting that posttranscriptional changes account for the reduced function of the 
OCT1variants observed for ASP
+
 uptake (Fig. 3.11). Regarding the effects of wild-type 
and common loss-of-function polymorphisms in OCT1 on the uptake and kinetics of 
ASP
+
, our data showed significant differences in ASP
+
 uptake activity and kinetic 
between OCT1 wild type and variants (Table 3.4). All variants had lower maximal 
transport rates (Vmax) than the wild type OCT1, while Km value did not show any 
significant differences between OCT1 wild type and variants, except for variant 401Ser 
that the Km value was significantly higher. With respect to intrinsic CL value, maximum 
clearance rate of ASP
+
 was seen for the HEK cells overexpressing OCT1 wild type 
compared to all variants. Taken together these data suggested that ASP
+
 uptake activity 
and kinetic in the HEK cells overexpressing OCT1 wild type was significantly higher 
than those in variants. These results were confirmed by comparison the amount of ASP
+
 
uptake visualized by fluorescence microscopy which showed OCT1 wild type can 
uptake higher amount of ASP
+
 than the  variants (Fig.3.10). The OCT1 only contain one 
substrate binding region that changes between an outwardly directed and an inwardly 
directed orientation during the transport cycle. The change in orientation of the substrate 
binding region during transport is supposed to be accompanied by structural changes 
that alter the affinity for substrates or inhibitors. Therefore it may conclude that 
different structural changes between OCT1 wild type and these variants lead to 
changing in affinity for ASP
+
 or other cationic drugs.  
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4.2 Effects of loss of function polymorphisms of OCT1 
transporter on the uptake of tropisetron and ondansetron 
Although previous studies showed the impact of polymorphisms in cytochrome P450 
enzymes on the pharmacokinetics and clinical effects of many drugs (BROCKMOLLER et 
al. 2000; INGELMAN-SUNDBERG 2004; LYNCH and PRICE 2007). However, before a drug 
can be metabolized, it must enter the cell, therefore polymorphisms in a transporter 
mediating the cellular uptake of a drug may modify pharmacokinetics and clinical 
effects. Indeed genetic polymorphisms in drug transporter genes have been increasingly 
recognized as an additional mechanism accounting for the pharmacokinetic variability 
of many drugs (HO and KIM 2005; KOEPSELL et al. 2007; SEITHEL et al. 2008; 
VORMFELDE et al. 2008).  
The human organic cation transporter 1 (hOCT1, SLC22A1) is a multispecific 
transporter of organic cations, including many clinically used drugs. It has been 
identified that organic cation transporters are not only critical for the intestinal 
absorption, distribution and hepatic and renal excretion of endogenous compounds and 
a wide array of drugs, but also play important roles for the function of various 
physiological systems and various diseases (JONKER and SCHINKEL 2004; KOEPSELL et 
al. 2007). In this study, we investigated the activity of the wild type and five 
nonsynonymous variants of OCT1 in uptake of tropisetron, ondansetron and 
palonosetron. 
According to our data, HEK cells overexpressing OCT1 wild type resulted in an 
increased uptake of tropisetron that was completely blocked by addition of the typical 
OCT1 substrate MPP
+
 acting as a competitive inhibitor of tropisetron transport 
(Fig.3.27 A). Also regarding to the impact of polymorphisms in OCT1 gene on 
tropisetron uptake, our data showed the HEK cells overexpressing all these five 
polymorphisms of OCT1 reduced tropisetron uptake compared to the cells 
overexpressing wild type (Fig. 3.27 A). These data were confirmed by clinically data 
which suggested that patients lacking fully active OCT1 have impaired cellular uptake, 
reduced inactivation and consequently a prolonged residence of the drug in the 
circulation, resulting in better efficacy (TZVETKOV et al. 2010). On the other hand, 
carriers of three and more active CYP2D6 alleles, are at higher risk of antiemetic 
therapy failure (CANDIOTTI et al. 2005; JANICKI et al. 2006; KAISER et al. 2002). These 
carriers may indeed be particularly prone to antiemetic treatment failure if they carry in 
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addition two fully active OCT1 alleles. This rare group of patients may profit from both 
OCT1 and CYP2D6 genotyping. In this rare group, a combined genotyping of OCT1 
and CYP2D6 may have clinical consequences like dose escalation or selection of other 
5-HT3 antagonists that are not dependent on polymorphic CYP2D6. 
The results for ondansetron showed although ondansetron inhibited the OCT1 transport 
(Fig.3.25), no significant difference in the ondansetron uptake is present between HEK 
cells overexpressing OCT1wild type and the control cells transfected with empty vector 
(Fig.3.27 B). This results is in contrast with the clinical data which showed the patients 
lacking any fully active OCT1 allele had a significant decrease in vomiting incidence in 
compare to patients with one or two fully active OCT1 alleles (TZVETKOV et al. 2010). 
This variability in OCT1-mediated uptake of tropisetron and ondansetron can be due to 
differences in physiochemical properties of these two drugs that may affect the 
membrane permeability of tropisetron and ondansetron. As it can be seen in table 4.1, 
ondansetron has lower pKa value that causes lower protonated fraction in blood in 
compare to tropisetron which protonates about 96.6 percent in physiological pH 
condition. In addition, ondansetron is more lypophilic with log D of 2.28 in compared to 
1.36 for tropisetron which means ondansetron can penetrate to the cells by passive 
diffusion in contrast to tropisetron which needs transporter to enter the cells (Table 4.1). 
Taken together, these data suggest that ondansetron may be more prone to enter cells by 
passive diffusion than tropisetron, and may be less dependent on OCT1.
 
              Table 4. 1  Comparison of physicochemical properties for tropisetron and ondansetron 
Drug pKa 
% charged 
at pH 7.4 
% un charged 
at pH 7.4 
Lipophilicity 
logD at pH 7.4 
Tropisetron 8.9 96.6 3.4 1.36 
Ondasetron 7.4 50.0 50.0 2.28 
The pKa value of ondansetron is according to Mashru et al., 2005. All other physiochemical 
properties were calculated using ADMET Predictor Software 4.0 (Simulations Plus, Lancaster, 
CA, USA). 
Discussion 
 
158 
 
4.3 Effects of loss of function polymorphisms of OCT1 
transporter on the uptake of tramadol and O-
desmethyltramadol 
Tramadol is a prodrug that requires bioactivation to O-desmethyltramadol for its 
analgesic activity. This bioactivation is catalyzed almost exclusively by the genetically 
polymorphic enzyme CYP2D6, and poor metabolizers of CYP2D6 substrates 
experience little, if any, analgesic effect from tramadol (PAAR et al. 1997; PEDERSEN et 
al. 2005; POULSEN et al. 1996; WANG et al. 2006). After bioactivation, O-
desmethyltramadol is released into systemic circulation to reach its target sites and exert 
its influence and then to eliminate as glucuronide from body it needs to reuptake into 
the hepatocytes via OCT1-mediated manner (TZVETKOV et al. 2011).  
Our data showed both tramadol and its metabolite O-desmethyltramadol can inhibit 
ASP
+
 uptake in the HEK cells overexpressing OCT1 (Fig.3.29). Although this inhibition 
experiment indicated that both tramadol and O-desmethyltramadol may be substrates of 
OCT1, it did not prove that the cellular uptake of tramadol and O-desmethyltramadol 
depends on OCT1. For this reason, we measured the cellular uptake of tramadol and O-
desmethyltramadol by HPLC. As has been shown in figure 3.30A, direct measurements 
of intracellular uptake of tramadol by HPLC showed no increasing in the OCT1 
overexpressing HEK293 cells in compared to the control cells that were transfected with 
empty vector. However the uptake of O-desmethyltramadol was 2.5-fold higher in the 
OCT1 overexpressing cells than in the control cells (Fig.3.30 B). To explain these 
results, both tramadol and desmethyltramadol are organic bases with nearly identical 
pKa values of 9.13 and 9.12, respectively and have similar structures. However, 
tramadol has a fivefold higher octanol/water solubility coefficient than O-
desmethyltramadol (logD7.4 of 1.13 and 0.4, respectively). This may explain the higher 
permeability of tramadol through artificial membranes (Fig. 3.28) and its higher uptake 
rates in mock-transfected HEK293 cells. In contrast, O-desmethyltramadol is highly 
dependent on OCT1 for its cellular uptake. 
We also analyzed how OCT1 polymorphisms influence the uptake of O-
desmethyltramadol. We induced overexpression of OCT1 variants carrying the five 
most common functional amino acid substitutions in Caucasians (Arg61Cys, Cys88Arg, 
Gly401Ser, Met420del, and Gly465Arg) and compared their activity with the activity of 
the wild-type OCT1. In all variants, the uptake of O-desmethyltramadol was 
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significantly lower as compared with uptake by wild-type OCT1 (Fig.3.30 B). However, 
no significant difference was found for the O-desmethyltramadol uptake in the cells 
overexpressing OCT1 variants in comparison to the control cells transfected with the 
empty plasmid.  
In a clinical study performed by our group, volunteers carrying variant OCT1 alleles 
had higher plasma concentration of O-desmethyltramadol than patients carrying the 
wild type OCT1 (TZVETKOV et al. 2011). The same patients had also stronger and 
prolonged miosis. It can be also due to high concentration of tramadol in the central 
nervous system and higher stimulation of the μ-opioid receptor in OCT1-deficient 
volunteers.  
The apparent dependence of O-desmethyltramadol on carrier-mediated membrane 
transport may have two additional consequences beyond the pharmacokinetically 
relevant hepatic uptake. First, the release of O-desmethyltramadol after formation by 
CYP2D6 in the liver back into the blood may be critically dependent on specific 
membrane transporters (TZVETKOV et al. 2011). However, the efflux transporter(s) 
involved remain to be identified. Second, O-desmethyltramadol may require carrier-
mediated transport to cross the blood–brain barrier. Recently, it was suggested that 
OCT1 and OCT2 are expressed on the luminal side of the brain capillaries and may 
thereby mediate the passage of O-desmethyltramadol across the blood–brain barrier 
(LIN et al. 2010). In another experiment, a high correlation between the plasma 
concentration of O-desmethyltramadol and opioidergic activity was observed, 
suggesting that the absence of OCT1 does not limit the transport across the blood–brain 
barrier and that OCT2 or other transporters may supplement it.  The requirement for 
carrier-mediated transport of the more hydrophilic metabolite, but not of the parent 
drug, may be relevant for numerous other drugs as well. In drug development, active 
substances are often selected for their high lipophilicity to increase their bioavailability. 
However, drug metabolizing reactions lead to a decrease in the lipophilicity of the 
parent drug, potentially decreasing its ability to diffuse through biological membranes. 
If the metabolite is biologically active, membrane transporters that enable it to re-enter 
systemic circulation, to reach its target, or to be biotransformed may be of therapeutic 
relevance (TZVETKOV et al. 2011).  
Individual response to tramadol is apparently not dependent on a single factor, but 
rather on multiple clinical and genetic factors (STAMER et al. 2010). Combined 
CYP2D6–OCT1 pharmacogenetic analyses may be added to other methods of therapy 
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individualization in order to help optimize tramadol dosing. Carriers of two or more 
active CYP2D6 alleles who also lack or have reduced OCT1 activity may require lower 
dosages of tramadol and therefore be at risk of overdosing (TZVETKOV et al. 2011). One 
may also speculate that slow-intermediate metabolizers (carriers of only one low-
activity CYP2D6 allele) who have full OCT1 activity will be at high risk of receiving 
sub therapeutic doses.  
Our findings that tramadol is a relevant inhibitor of OCT1 and that OCT1 is an 
important transporter of O-desmethyltramadol may also help us understand and predict 
some drug–drug interactions. For instance, interaction at OCT1 sites may be another 
explanation (in addition to synergistic serotoninergic effects) for the severe adverse 
effects observed in a patient receiving a tramadol–citalopram drug combination 
(MAHLBERG et al. 2004). Also, some effects of prototypical CYP2D6 inhibitors used in 
human pharmacology studies, such as quinine or quinidine, may be mediated not only 
by CYP2D6 enzyme inhibition but also by inhibition of OCT1-mediated liver uptake of 
O-desmethyltramadol. 
 
 
4.4 Effects of loss of function polymorphisms in OCT1 
transporter on the uptake of debrisoquine 
Although debrisoquine has been extensively described in the literature as a marker drug 
of the oxidative phenotype of patients to investigate drug pharmacokinetics and 
elimination depending on the polymorphic isoform CYP2D6, there were no previous 
studies on the dependence of debrisoquine uptake on carrier-mediated membrane 
transport. According to the results taken from inhibitory experiment, debrisoquine can 
function as an inhibitor of OCT1-mediated transporter with half maximal inhibitory 
concentration (IC50) of 6.2 µM (Fig. 3.32). One hypothesis could be because 
debrisoquine has positively charge structure and can compete with ASP
+
 to bind to 
OCT1. We have also shown such competition between tropisetrone, ondansetrone, 
tramadol and O-desmethyltramadol with ASP
+ 
to bind to this transporter in previous 
chapters. Such inhibition could be clinically relevant to drug–drug interactions and 
would be an indication that debrisoquine may also be transported through OCT1. In this 
study we showed that debrisoquine has very low carrier-independent membrane 
permeability (Pe 0.01 x 10
-6
 cm/s, Fig. 3.31), which means it needs transporter to enter 
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the cells. Debrisoquine is a high affinity substrate of OCT1, this could be explained by 
the presence of a highly hydrophobic aromatic tetrahydroisoquinoline ring in the 
debrisoquine molecule. As all available pharmacophores for OCT1 substrates or 
inhibitors contain at least one hydrophobic moiety of the molecule next to a positive 
charge (AHLIN et al. 2008; BEDNARCZYK et al. 2003; MOADDEL et al. 2007), 
debrisoquine fits much better in the structural requirements for OCT1 substrates. Taken 
together, our data suggests that OCT1 may mediate the cellular uptake of debrisoquine 
in the liver and thus may modulate the hepatic metabolism of debrisoquine.  
Genetic polymorphisms in drug transporters have been increasingly recognized as 
possible sources of variation in drug disposition and response (GIACOMINI et al. 2007). 
In previous studies has been shown that functional amino acid substitutions in the OCT1 
gene which leading to a reduction in OCT1 activity may reduce hepatic uptake of 
metformin and consequently decrease the efficacy of metformin (SHU et al. 2007; 
TZVETKOV et al. 2009). Our data illustrated that the cellular uptake of debrisoquine 
depends on genetic variants in OCT1. As has been shown in figure 3.35, maximum 
intracellular uptake was obtained for the HEK cells overexpressing OCT1 wild type 
compared to cells overexpressing variants. However, no similar pattern in uptake was 
seen between variants (Fig.3.35). For example, the high amount of absorption was 
detected for Met420del and Arg61Cys variants in comparison to other variants or 
control, implying that these two variants might have substrate selectivity to bind to 
debrisoquine. Further examination of the functional effects of the variants on 
debrisoquine transport will raise our understanding regarding the amino acid residues 
which determine OCT1 activity. Also kinetic studies indicated that OCT1 is a high 
affinity transporter of debrisoquine (KM 5.9 µM, Table 3.6), while all OCT1 variants 
have an increased Km or reduced Vmax values in compare with wild-type. These 
fluctuations in Km or Vmax values could be caused by a structural change in OCT1 and 
might suggest that these residues involved the substrate binding affinity. This finding 
supported the idea that all these OCT1-variants have low activity than the wild-type to 
uptake debrisoquine into the cells. These results are consistent with previous results 
taken for tropisetron and O-desmethyltramadol. 
On the other hand, drug-drug interaction at OCT1 has also been shown that inhibited 
debrisoquine uptake (Fig.3.37). A number of factors beyond the known loss-of-function 
amino acid polymorphisms may affect the OCT1 ability to take up drugs on the liver, 
i.e. unknown amino acid substitutions, drug– drug interactions and suggested high 
Discussion 
 
162 
 
variable expression of OCT1 (NIES et al. 2009). OCT1 is genetically highly 
polymorphic and in this study we presented evidence that common genetic 
polymorphisms and commonly used drugs affect the OCT1-mediated cellular uptake of 
debrisoquine. These findings have at least two direct consequences. First, OCT1 
polymorphisms and drug–drug interactions at OCT1 may contribute to the high and thus 
far unexplained inter-individual variability in debrisoquine hydroxylation. In addition, 
next to CYP2D6 phenotyping, debrisoquine may have the potential to be developed as 
probe drug for phenotyping OCT1 activity in vivo. In vivo phenotyping in humans using 
model drugs will be a powerful tool to study these effects. A number of in vitro model 
OCT1 substrates like MPP
+
, TEA
+
 and ASP
+
 exist. However, all these model substrates 
are highly toxic and cannot be given directly to humans (MARKEY et al. 1984). In 
contrast, small amounts of debrisoquine are safe to be administered to humans, and 
debrisoquine is a well established in vivo probe drug (TANAKA et al. 2003; ZGHEIB et 
al. 2006; FUHR et al. 2007). However, clinical studies are required to evaluate to what 
extent the dependence of debrisoquine cellular uptake on OCT1, which was 
demonstrated here in vitro, will manifest as inter-individual variations in vivo. 
 
 
 
4.5 Interactions between OCT1-mediated transporter and 
CYP2D6-mediated metabolism on debrisoquine metabolism 
Debrisoquine is a unique drug as a substrate that we can use to investigate interaction 
between polymorphisms in OCT1 and metabolizing enzyme CYP2D6. Debrisoquine 
metabolism is highly variable and debrisoquine has been extensively studied as a probe 
drug for the variable CYP2D6 oxidative phenotype in humans. To investigate the 
interactive effects between OCT1 drug transporter and CYP2D6 metabolizing enzyme 
on the metabolism of drugs, we established HEK cells which overexpressed both the 
genes of OCT1 transporter and CYP2D6 drug metabolizing enzyme. For this purpose, 
to have the correct evaluation of CYP2D6 activity, this cell lines were modified to 
overexpress cytochrome P450 reductase (POR enzyme) which supply electron for 
CYP2D6 enzyme function, and we used debrisoquine which is a well-known substrate 
for CYP2D6 (GONZALEZ et al. 1988; KIMURA et al. 1989)  and recently reported by us 
as a model substrate for OCT1 transporter (SAADATMAND et al. 2012). Overexpression 
of OCT1 in combination with CYP2D6 and POR in HEK cells significantly increased 
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the production of 4-OH debrisoquine, the metabolite of debrisoquine, in comparison 
with the HEK cells overexpressed CYP2D6::POR alone (Fig.3.38). These data illustrate 
that the OCT1 may be a rate limiting factor for the metabolism of organic cationic drugs 
and may help for more rapid metabolism. 
Our data suggest that debrisoquine may have the potential to be used as a probe drug for 
in vivo phenotyping of OCT1 activity in humans.  
 
 
4.6 Effects of loss of function polymorphisms of OCT1 
transporter on the metabolism of debrisoquine 
Interindividual variations in the pharmacokinetics of drugs may be caused by genetic 
variations in biotransformation and transmembrane transport (HO and KIM 2005; 
KOEPSELL et al. 2007; VORMFELDE et al. 2008). In previous studies, haplotype analysis 
has been explored the independently impact of CYP2C9 metabolizing enzyme and 
polymorphisms in OATP1B1 transporter on the pharmacokinetics of torsemide 
(VORMFELDE et al. 2008). To evaluate the effects of polymorphisms in drug transporter 
on the metabolism of organic cationic drugs, we generated the HEK cells which 
overexpressed OCT1 wild type and 420del88R variant in combination with CYP2D6 
drug metabolizing enzyme and then after treating the cells with debrisoquine the 
produced metabolite of debrisoquine was measured by HPLC.  As has been shown in 
the results, the amount of debrisoquine uptake and consequent produced metabolite in 
420del88R variant were reduced to the level of control cells. According to our data, the 
metabolism of debrisoquine to 4-OH debrisoquine depends on genetic variants in 
OCT1. As has been shown, maximum debrisoquine hydroxylation occurred in the HEK 
cell overexpressing OCT1::CYP2D6::POR wild type compared to the tested variant 
(Fig.3.39).  From these data we can conclude that polymorphisms in OCT1 gene can 
modulate the entrance and access of debrisoquine to its target sites (CYP2D6 enzyme) 
in the liver cell. Therefore low amounts of intracellular debrisoquine leads to low 
amount of its metabolite by CYP2D6. These results are in concordance with the 
previous results corresponding to the effects of genetic polymorphisms in OATP1B1 on 
the metabolism of some organic anionic drugs (ROMAINE et al. 2010; VORMFELDE et al. 
2008). 
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The debrisoquine hydroxylation capacity, measured as the ratio of debrisoquine over its 
major metabolite 4-hydroxydebrisoquine in urine, varies by more than 100-fold among 
individuals (EVANS et al. 1980; LLERENA et al. 2009; SACHSE et al. 1997). This high 
inter-individual variation in debrisoquine hydroxylation capacity may represent 
variation not only in CYP2D6, but also in OCT1 activity. Our data suggest that beyond 
the previously suggested effects of environmental factors (LLERENA et al. 1996) or 
downstream metabolism reactions  (ZHEN et al. 2006), the variations in debrisoquine 
hydroxylation may also be due to variations OCT1-mediated hepatocellular uptake. The 
existence of genetic polymorphisms of OCT1 with different function in cellular assays 
suggests that the combination of genetic polymorphism in OCT1 in relation to genetic 
variability in CYP2D6 metabolizing enzyme may contribute to interindividual 
variability in drug metabolism.  
 
4.7 Drug–drug interactions on the CYP2D6-madiated 
debrisoquine metabolism 
In our study we evaluated the effect of drug-drug interaction on OCT1 transporter alone, 
on CYP2D6 enzyme alone or combination of OCT1with CYP2D6 enzyme. As our 
results showed all known OCT1 inhibitors in this study inhibited OCT1-mediated 
debrisoquine uptake (Fig. 3.37). 
To evaluate drug-drug interaction exclusively on CYP2D6 enzyme, we extracted 
microsome from the HEK cells overexpressing CYP2D6::POR. First to examine the 
microsome activity, we used AMMC kit which no difference was detected between the 
microsomes extracted from HEK cells overexpressing CYP2D6::IRES::POR, while 
microsome from the commercial kit showed more activity compared to those extracted 
from the cells (Fig. 3.17). One possible explanation might be that the amount of 
CYP2D6 enzyme in the microsomes originated from human liver may differ from those 
extracted from HEK cells. This difference may be due to different processing in 
extraction and/or purification of the microsomes.  In our experiment, the procedure used 
to extract the microsome from the cells was similar to those usually utilize for 
extraction from tissues. Analyzing the data by western blot also showed very intensive 
signal detected for CYP2D6 in the human liver microsome from the commercial kit in 
compare to faint signal taken for the microsome extracted from the cells. Another 
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possibility for these results may correspond to the substrate (AMMC) that we used or 
detection of the produced metabolite (AHMC) measured by TECAN photometer. 
Therefore, we used debrisoquine which is also a model substrate for CYP2D6 enzyme 
and detected 4-OH debrisoquine, a metabolite compound of debrisoquine, by HPLC. 
The amount of 4-OH debrisoquine depends on debrisoquine concentration and 
hydroxylation of debrisoquine was inhibited significantly in the presence of a CYP2D6 
inhibitory drug, paroxetine (Fig. 3.18). The production of 4-OH debrisoquine was 
specific for the HEK cells overexpressing CYP2D6::POR and was not present in the 
HEK cells overexpressing OCT1 or control cells transfected with empty plasmid. Our 
results imply that debrisoquine can be a good substrate to measure microsome activity 
and interaction between debrisoquine and paroxetine can inhibit metabolism of 
debrisoquine mediated by CYP2D6 enzyme. 
Regarding to the effect of drug-drug interaction on the CYP2D6-mediated debrisoquine 
metabolism, we used HEK cells overexpressing OCT1::CYP2D6::POR as a model cell 
and we used paroxetine as an inhibitor on the levels of drug uptake and drug 
metabolism. The results showed that the inhibitory effect of paroxetine on the OCT1-
madiated debrisoquine uptake is stronger than those depicted for CYP2D6-madiated 
debrisoquine metabolism, because the OCT1 transporter was blocked using lowest 
amount of paroxetine, while in the range of 0.1-1 µM concentration of paroxetine the 
activity of enzyme slightly decreased (Fig.3.40). However, the potential clinical 
relevance of this result remains to be tested.    
Inhibition of CYP-mediated metabolism, often the mechanism for drug-drug 
interactions, can limit the use of a drug because of adverse clinical effects. For example, 
inhibition of CYP3A4 enzyme by coadministered drugs has been shown to result in 
adverse clinical drug-drug interactions, including fatalities (HONIG et al. 1993). 
Therefore, it is important to determine the inhibition potential of each new chemical 
drug for cytochrome P450 enzymes early in the discovery stage as to predict, anticipate, 
and ultimately manage potential drug-drug interactions.  
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4.8 Effects of OCT1 transporter on the uptake of cytotoxic 
drugs irinotecan and doxorubicin  
In this study cytostatic drugs, doxorubicin, irinotecan and SN38, the active metabolite 
of irinotecan, were tested to evaluate whether they are substrates or only inhibitors for 
OCT1. As demonstrated in the results, only irinotecan can act as an inhibitor for OCT1, 
whereas no inhibitory effect was seen for SN38 (Fig.3.41).  
Also regarding to the effects of polymorphisms in OCT1 on the cytotoxicity of 
irinotecan using MTT assay, our data showed small differences between the HEK or 
CHO cells overexpressing OCT1 wild type and five common polymorphisms treated 
with irrinotecan compared to untreated cells (Fig.3.43). This test is used to measure the 
activity and viability of cells, one explanation for this result can be, in these measured 
cells no reductase enzyme has been produced, because active reductase enzymes are 
needed for this reduction of MTT to formazan, so OCT1 and CYP2D6 overexpressing 
cells may be useful for this assay. For the therapy of cancers expressing OCT1, it might 
be useful to use a cytostatic, which is taken up by OCT1 at high rates and is not a 
prodrug. Future research might reveal a drug suitable for such a cause. However the 
recent data published by Gupt et al, 2012 showed OCT1 may contribute to the 
susceptibility of cancer cells to selected antineoplastic drugs. They showed that the 
OCT1-positive cell lines and transfectants exhibit significantly higher susceptibilities to 
the cytotoxic effects of irinotecan and paclitaxel compared with those of OCT1-negative 
controls (GUPTA et al. 2012).  
The cytostatic drug doxorubicin showed very high levels of fluorescence at the same 
wavelength where ASP
+
 fluorescence was measured, therefore this drug was exposed 
alone to the cells to check how much of the drug was taken up by the cells and then 
after lysing the cells the amount of drug absorption was measured. As has been shown, 
no significant difference was found in doxorubicin uptake by HEK cells overexpressing 
OCT1 wild type compared to control cells transfected with empty vector (Fig.3.44). 
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4.9 Effects of different pH on interaction of organic cations with 
OCT1 
In our study changes in the pH value from 5.4 to 9 had no significant effect on the 
inhibitory effect of tropisetron on ASP
+ 
uptake. The results showed tropisetron can 
inhibit OCT1-mediated ASP
+
 uptake in all these pH ranges, however the inhibitory 
effects of ondansetron on ASP
+
 uptake was decreased by increasing in pH (Fig.3.26). In 
other hand it can be concluded that only charged form of ondansetron interacts with 
OCT1. It may be related to pKa value of these drugs. Ondansetron has pKa value 7.4 
which means it is mostly charged in lower than pH 7.4. One explanation could be the 
decreasing in fractional protonation (positively charged form) of ondansetron at high pH 
which results in decreasing to bind to the OCT1 transporter and act as inhibitor for 
ASP
+
 uptake. Also regarding the effects of irinotecan and SN38 on OCT1-mediated 
cellular uptake of ASP
+
 in different environmental pH, our data showed that the 
inhibitory effect of irinotecan on ASP
+ 
uptake was decreased by increasing pH value 
from 5.4 to 9, while SN38 did not suppresse ASP
+ 
uptake in these pH ranges (Fig. 3.42). 
This might be relevant to pKa values of these two compounds. The pKa value for 
irrinotecan is 8.48 which is a weak basic in physiological pH. At pH values of 7.4 and 
below, irinotecan is protonated and this causes to bind to OCT1 and consequently 
inhibits ASP
+ 
uptake, while SN38 is a weak acid and is negatively charged under these 
examined pH and in turn could not bind to transporter and exert an inhibitory influence 
on ASP
+
 uptake. Other studies have also indicated that transport of organic cations via 
OCT2 is sensitive to environmental pH (FUJITA et al. 2006). They concluded that 
environmental pH may influence OCT2 activity by modulating the fractional 
protonation of OCT2 amino acid residues or of OCT2 substrates, although translocation 
of organic cations by OCT2 does not appear to be directly coupled to H
+
 influx or 
efflux. Urakami et al., 2002 indicated a decrease in the influx of TEA by OCT2 with 
lowering the extracellular pH from 8.4 to 5.4, demonstrating that the transport function 
of OCT2 is influenced by extracellular pH. In another study, changing the pH value 
from 7.0 to 8.0 had no effect on the rate of transport of TEA, whereas the interaction of 
the weak bases cimetidine and trimethoprim with OCT2 was decreased by changing the 
pH value from 7.0 to 8.0. It was concluded that the change in fractional protonation of 
the compounds is the basis for their decreased interaction with the transporter at higher 
pH (BARENDT and WRIGHT 2002).  
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4.10 Analysis of dominant negative effect between OCT1 
variants 
Examination of the functional effects of the OCT1 wild type and variants on drug 
transport has implications on our understanding of the amino acids that determine 
OCT1 activity and trafficking. Chen et al., 2010 demonstrated that in comparison to the 
OCT1 wild type, variant P117L exhibited a reduced uptake activity and Vmax for 
metformin with a similar localization to the plasma membrane. They concluded that the 
reduced Vmax of metformin in cells expressing P117L could be caused by a structural 
change in OCT1. However, the change in Km value of variant Q97K might suggest that 
this residue involved the substrate binding affinity (CHEN et al. 2010). According to the 
secondary structure of OCT1 transporter, both R61C and OCT1-420del88R variants are 
substitutions which are located in the large extracellular loop of OCT1, which is 
generally considered as containing substrate recognition domains (Jonker and Schinkel 
2004; Koepsell and Endou 2004) and to be important for the oligomerization and the 
correct cellular localization of OCT1. As has been shown in figure 3.48 visualized by 
confocal microscopy, the HEK cells transfected with OCT1 wild type construct showed 
the expression of OCT1 protein in membrane, while most of the OCT1 protein was 
localized in the cytoplasm for the HEK cells transfected with variants of OCT1, 61C 
and 420del88. These results showed these two variants resulted in a disruption of 
transporter subcellular localization. One experiment indicated that the reduced activity 
of the OCT1 variant R206C seemed to be explained by a much reduced surface 
expression level of the transporter (CHEN et al. 2010). The reduced total GFP-tagged 
signal in cells expressing GFP-R206C or GFP-R206E may be caused by accelerated 
protein degradation in the endoplasmic reticulum (ER) with the misfolded immature 
protein. R206C reduced the export of OCT1 from the endoplasmic reticulum to the 
plasma membrane. Therefore, we hypothesize that the OCT1 variants 61C or 
420del88R may have dominant negative effects by impairing the correct membrane 
localization of the wild type OCT1 in case on co-existence of both forms, i.e. in 
heterozygous carriers of this two polymorphisms. To determine whether there is a 
dominant negative effect between OCT1 wild type and variants, the HEK cells were 
transiently transfected with combination of plasmid constructs containing OCT1 wild 
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type and two common variants 61C and 420del88R. The results obtained for ASP
+
 
uptake showed that ASP
+
 uptake was reduced in the cells overexpressing OCT1 variants 
R61C and OCT1-420del88 compared to wild type (Fig. 3.47). It is noteworthy that the 
Vmax values for ASP
+
 uptake in the cells transfected with the combination of wild type 
and variants were almost exactly the half of the Vmax values in the cells transfected with 
OCT1 wild type alone. From this result, we can conclude that there is no dominant 
negative effect between wild type and variants in OCT1. However, analyses of the exact 
subcellular localization of wild type OCT1 in the presence and absence of both OCT1 
variants are still necessary to confirm these preliminary results.  
5 Summary and conclusion 
The major result and conclusion of this work may be summarized as follows: 
 In this work HEK293 cell lines were generated that overexpress wild type 
organic cation transporter 1 (OCT1) and the five common loss-of-function 
OCT1 polymorphic variants. The cell lines were generated by targeted 
chromosomal integration using the Flp-In system.   
We characterized these cell models using integration-specific polymerase chain 
reaction (PCR) to evaluate the correct genome integration, quantitative PCR to 
evaluate mRNA expression rate, western blot and flow cytometry to evaluate 
protein expression and immunocytochemistry staining to evaluate localization 
of the OCT1 proteins. OCT1 activity was measured using the model OCT1 
substrate 4-(-4-(dimethylamino) styryl-N-methylpyridinium (ASP+). 
 
 Using the cell line model we showed that the antiemetic drugs tropisetron and 
ondansetron inhibited OCT1-mediated ASP
+ 
uptake. Tropisetron uptake was 
2.3-fold higher in the cells overexpressing wild type OCT1 compared to the 
control cells. There was no increase in the tropisetron uptake in the cells 
overexpressing the common loss-of-function OCT1 variants. 
In conclusion, tropisetron was proven to be a substrate of OCT1 and common 
loss-of-function polymorphisms affect tropisetron uptake in cell culture. Studies 
of tropisetron pharmacokinetic and efficacy in humans (performed in our group 
but not part of this thesis) showed that OCT1 is a medically relevant transporter 
of tropisetron in vivo.    
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 Using the same model we showed that the opioid pro-drug tramadol and its 
active metabolite O-desmethyltramadol inhibited OCT1-mediated ASP
+ 
uptake. 
The cellular uptake of O-desmethyltramadol, but not that of tramadol, was 
increased in cells overexpressing wild type OCT1 compare to the control cells. 
There was no increase in the O-desmethyltramadol uptake in the cells 
overexpression the common loss-of-function variants of OCT1.  
In conclusion, O-desmethyltramadol, but not tramadol is a substrate of OCT1 
and common loss-of-function polymorphisms affect O-desmethyltramadol 
uptake. Studies of O-desmethyltramadol pharmacokinetic and efficacy in 
humans (performed in our group but not part of this thesis) showed that OCT1 
is a medically relevant transporter of O-desmethyltramadol in vivo.    
 
 Using the OCT1-overexpressing model we showed that the prototypic CYP2D6 
drug debrisoquine inhibited OCT1-mediated ASP
+ 
uptake. Debrisoquine uptake 
was significantly increased in HEK293 cells overexpressing OCT1 compared to 
control cells and followed Michaelis–Menten kinetics (KM of 5.9 ±1.5 mM and 
Vmax of 41.9± 4.5 pmol/min/mg protein). There was significant decrease in the 
debrisoquine uptake in the cells overexpression the common loss-of-function 
variants compared to cells overexpressing wild type OCT1. 
 
 An additional cell line model was generated co-overexpressing OCT1 
transporter and CYP2D6 metabolizing enzyme. Initially, the genes for CYP2D6 
and its helper enzyme POR were stably transfected in HEK293 cells using 
random chromosomal integration. In the next step, using Flp-In system wild 
type or the 420del/465R loss-of-function OCT1 variant was stably transfected. 
The chromosomal integration and co-overexpression of OCT1, CYP2D6 and 
POR were confirmed using integration-specific PCR, qPCR, western blot, flow 
cytometry and immunocytochemistry.  
 
 Using this second cell model we showed that the presence of OCT1 leads to 
higher production of 4-OH debrisoquine, the main CYP2D6 metabolite of 
debrisoquine. The effect was present when the wild-type OCT1, but not when 
variant OCT1 was co-expressed with CYP2D6 and POR.  
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Using the same model we analyzed drug-drug interaction. The well known 
CYP2D6 inhibitor paroxetine inhibited both OCT1-mediated uptake and 
CYP2D6-mediated metabolism. 
It could be concluded that OCT1 may limit debrisoquine metabolism and that 
OCT1 variants and drug-drug interactions at OCT1 can result in decreased 
metabolism providing a new view on the “old” CYP2D6 substrate debrisoquine 
and the “old” CYP2D6 inhibitor paroxetin.  
 
 The effects of OCT1 transporter on cytotoxic drugs were minor in this study. 
Irinotecan, but not its active metabolite SN38 can inhibit OCT1-mediated ASP
+
 
uptake, but more extensive experiments would have been required to fully rule 
out a role of OCT in this drug. No effects of OCT1 on doxorubicin could be 
measured.  
 
In general, it could be concluded that OCT1 play an important role in the cellular uptake 
of clinically relevant weak basic drugs as tropisetron and tramadol. Common loss-of-
function genetic variants lead to reduced hepatocellular uptake and thus limit the 
metabolism and modulate the efficacy of these drugs. The cell lines developed in this 
work are a valid model for evaluating the role of OCT1 in drug metabolism. This model 
may be used for identification of drugs beyond those described in this work, which 
metabolism may be affected by the common loss-of-function polymorphisms in OCT1 
gene or be subjected to drug-drug interaction at OCT1.  
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